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Foreword 
It is a truth universally acknowledged that general practice, subsidised at the point of 
delivery through Medicare, is at the epicentre of Australian healthcare. General practitioners 
manage most peoples’ immediate health concerns or refer patients to specialist or hospital 
care when deemed necessary.  
The magnitude of this primary care service is reflected in the singular statistic that from 
April 2010 to March 2011, Medicare paid rebates for about 118.1 million general practice 
services amounting to an average of 5.3 GP visits per head of population 
Undoubtedly, the question that most occupies users of this service is its quality and safety. 
International comparative surveys of general practice reveal that Australia consistently falls 
in the upper echelon of participating first world nations; but rigorous studies of its safety  
are sparse.  
Be that as it may, the overriding concern of most public health practitioners and funders of 
the service is what actually transpires in these numerous primary care consultations. The 
answer to this question is provided by a unique program—the BEACH—Bettering the 
Evaluation and Care of Health – program conducted by the Family Medicine Research 
Centre, of the University of Sydney.  
Since 1998 the BEACH program has conducted an ongoing national, cross-sectional study of 
Australian general practice. Every year about 1000 randomly selected general practitioners 
record details of 100 consecutive patient encounters on a structured questionnaire. Through 
this activity BEACH has accumulated and published a comprehensive and sequential record 
of general practice activities. The most recent significant movement in medicine is evidence-
based practice and this requires accurate and relevant data. No one could deny that the 
BEACH program is a jewel in the crown of evidence-based medicine for general practice—
other clinical disciplines do not have such a valuable asset.  
The latest addition in this series is Number 29: General practice activity in Australia 2010–11, 
which compiles, an array of data on: general practitioners, practice encounters, the patients, 
the clinical problems, management actions including medications and other interventions 
such as preventive counselling, referrals to hospitals and admissions, referrals to specialists 
and allied health professionals, tests and investigations, practice nurse activity and patient 
risk factors. Accompanying this publication is the 30th book in the General Practice Series A 
decade of Australian general practice activity 2001–02 to 2010 –11, which highlights the many 
changes that have occurred over the decade in GP clinical activity.  
All outcomes in General practice activity in Australia 2010–11 are succinctly outlined, accessible 
and prove to be interesting reading. Importantly, this report also suggests how BEACH data 
may be integrated and aligned with other national data such as from the Pharmaceuticals 
Benefits Scheme, pathology and imaging MBS data and the National Health Survey.  
However, in these times of evidence-based medicine, one thing that might frustrate attuned 
readers is that the availability of such a volume of data, necessary as it is, may well hinder 
attempts to draw meta-analyses effectively signposting possible future directions in primary 
healthcare delivery.  
  
iv 
Crucially, neither here nor from other sources, is there systematic or extensive analysis of 
what is appropriate in general practice, or identification of the leading health care cost 
centres. Answers to these questions are becoming more relevant as health expenditure 
swallows increasing proportions of the national gross domestic product. Perhaps the BEACH 
team might consider how these indices could be serially evaluated in future reports.  
Another future direction would be to focus on the activities of recent players in general 
practice, such as the autonomous nurse practitioner clinics. These are simply suggestions for 
consideration of future lines of enquiry.  
With these issues in mind, the Family Medicine Research Centre is actively planning the 
development of a longitudinal general practice patient cohort study to complement the 
current BEACH data collection. This program will provide data from a stratified random 
sample of patients, which is collected via GP desktop computer systems. This program will 
allow the tracking of patient outcomes over time and will enhance the capacity of the 
BEACH team to comprehensively describe the management of patients in both primary and 
secondary care.  
In the meantime, it must be categorically stated that this assiduous and painstaking 
assembling of the BEACH data is a credit to Australian medicine, providing the definitive 
snapshot of activities of general practice in Australia.  
 
Martin B Van Der Weyden MD 
Emeritus Editor  
Medical Journal of Australia  
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Summary 
This report describes clinical activity at, or associated with, general practitioner (GP) 
encounters, from April 2010 to March 2011, inclusive. It summarises results from the 13th 
year of the Bettering the Evaluation and Care of Health (BEACH) program, using a sample of 
95,800 patient encounters with 958 randomly selected GPs. After post-stratification 
weighting, 95,839 encounters were analysed in this report. 
BEACH is a continuous cross-sectional national study that began in April 1998. Every year 
each of about 1,000 randomly selected GPs records details of 100 consecutive encounters on 
structured paper recording forms, and provides information about themselves and their 
practice. BEACH is the only continuous randomised study of general practice activity in the 
world, and the only national program that provides direct linkage of management (such as 
prescriptions, referrals, investigations) to the problem under management.  
The BEACH database now includes information for almost 1.3 million encounters from 
12,831 participants representing about 8,700 individual GPs. Smaller studies are done with 
subsamples of the BEACH encounters. Results for patient body mass index, smoking status 
and alcohol consumption are reported and abstracts (with the research tools) for other 
substudies (from 2010–11) are provided.  
The companion report highlighting major change over the most recent 10 years of BEACH,  
A decade of Australian general practice activity 2001–02 to 2010–11,1 is available at 
<purl.library.usyd.edu.au/sup/9781920899875>.  
The general practitioners 
Of the 958 GP participants in 2010–11: 
• 62% were male, and 42% were aged 55 years and over 
• 69% had graduated in Australia and 27% conducted some consultations in a language 
other than English 
• 69% practised in ‘Major cities’ (classified using the Australian Standard Geographical 
Classification) 
• 26% bulk-billed Medicare for all patients and 73% for selected patients 
• 56% had provided care in a residential aged care facility in the previous month 
• 61% worked in a practice comprising fewer than five full-time equivalent GPs 
• 81% of the GPs worked in a practice that employed practice nursing staff  
• more than half (58%) had a co-located pathology laboratory or collection centre  
• 43% were in a practice that provided their own or cooperative after-hours care, and 52% 
in a practice that used a deputising service (multiple response allowed) 
• 62% worked in a practice teaching undergraduates, junior doctors or registrars.  
GPs spent an average 38 hours per week on direct patient care services.  
There were no significant differences in the characteristics of the final sample of BEACH 
participants and all GPs in the sample frame in terms of sex, age, place of graduation, state, 
or location by the Australian Standard Geographical Classification.  
Participating GPs were slightly less ‘busy’ than non-participants, rendering an average 5.5 
fewer GP service items per week claimed under Medicare than their counterparts. 
 xiv 
The encounters 
After weighting the data for GP activity and the age-sex of the GP participants, the age-sex 
distribution of patients at BEACH encounters had an excellent fit (precision ratios 0.91–1.06), 
with patients at all GP services claimed under the Medicare Benefits Schedule (MBS).  
• Direct encounters (patient seen) accounted for 99% of encounters, of which 97% were 
claimable through MBS or Department of Veterans’ Affairs (DVA).  
• Surgery consultations accounted for 93% of all MBS/DVA-claimable GP encounters, 
standard consultations being most common (83% of these). Home, institution and 
residential aged care visits were few (3%). About 1% were claimable as mental health 
care items, and 1% as chronic disease items. 
In a subsample of 32,257 BEACH encounters containing start and finish times for 
MBS/DVA-claimable encounters, mean consultation length was 15.0 minutes.  
Who were the patients?  
• In line with earlier years, females accounted for 57% of encounters.  
• Children (aged < 15 years) accounted for 12% of encounters; 15–24 years 9%;  
25–44 years 23%, 45–64 years 28%; 65–74 13%; and 75 years and over 16%. 
• The patient was new to the practice (not seen before) at only 7% of encounters and at 
45% of encounters the patient held a Commonwealth concession card  
• Indigenous people (self identified) accounted for 1.2% of encounters and at 11% the 
patient was from a non-English-speaking background. 
• For every 100 encounters, patients gave 156 reasons for encounter (RFEs): 67 described as 
symptoms/complaints; 31 as diagnoses/diseases; and 58 as requests for a service. The 
most common RFEs were requests for a check-up, prescriptions, and test results.  
What problems do GPs manage at patient encounters? 
Problems were managed at a rate of 153 per 100 encounters (n = 146,141). 
• The most common were classified as respiratory problems (20 per 100 encounters); 
problems of a general and unspecified nature (19); skin problems (17); cardiovascular 
(17); and musculoskeletal problems (17 per 100 encounters). 
• Individual problems managed often were hypertension (8.7 per 100 encounters), 
check-ups (6.4), immunisation/vaccination (5.5), upper respiratory tract infection (URTI) 
(5.4), and depression (4.2 per 100 encounters). 
• On average GPs managed 59 new problems per 100 encounters, the most common being 
URTI, immunisation/vaccination, and acute bronchitis.  
• At least one chronic problem was managed at 41% of encounters and 53 chronic 
problems were managed per 100 encounters. 
An example of the relationship between a problem managed and other data fields is 
provided for GP management of Type 2 diabetes in 2010–11 in Section 7.8. 
What management actions were recorded for problems managed? 
For an ‘average’ 100 problems managed, GPs recorded: 69 medications (81% prescribed); 23 
clinical treatments; 11 procedures; 6 specialist referrals; 3 referrals to allied health services; 
and ordered 30 pathology tests/batteries and 6 imaging tests. 
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Medications  
There were 100,817 medications, 105 per 100 encounters or 69 per 100 problems managed: 
81% prescribed, 10% supplied by the GP and 9% recommended for OTC purchase. 
When these results are extrapolated to the 118.1 million general practice Medicare-claimed 
encounters (April 2010 – March 2011), GPs in Australia: prescribed medications 100.5 million 
times; supplied 12.2 million medications directly to the patient; and recommended 
medications for OTC purchase 11.6 million times. 
• No prescription was given for 55% of problems managed: one for 36%, two for 6%, and 
more than two for 2%. Prescription rates increased with patient age. 
• Medications most often prescribed were: the antibiotics amoxycillin (4% of all 
prescriptions), cephalexin (3%) and amoxycillin with potassium clavulanate (2%); the 
analgesics paracetamol (3%) and paracetamol/codeine (2%); and the lipid modifying 
agent atorvastatin (2%), and the opioid oxycodone (2%). 
• Medications were GP-supplied at a rate of 7 per 100 problems managed and vaccines 
accounted for two-thirds of these. 
• Medications were advised for OTC purchase at a rate of 6 per 100 problems managed; 
paracetamol accounted for 27% of these.  
The pattern of GP prescription or supply of statins (to whom and for what) is presented as an 
example of pharmaco-epidemiological analysis of BEACH data in Section 9.5.  
Other treatments  
At least one other treatment was provided at 40% of encounters and 50,235 other treatments 
were recorded, 68% being clinical treatments.  
Clinical treatments: 34,019 clinical treatments were recorded, 36 per 100 encounters, or 23 
per 100 problems. General advice and education (17% of clinical treatments), and counselling 
about the problem being managed (15%) were most common. Common preventive 
counselling/advice about: nutrition and weight; exercise; smoking; lifestyle; prevention; and 
alcohol was also frequently provided by GPs (together at a rate of 7.5 per 100 encounters).  
Of all problems for which clinical treatments were provided, the top 10 accounted for 30%. 
The most common were depression (5.6% of problems with clinical treatments), URTI (5.2%), 
hypertension (3.4%) and diabetes (3.4%).  
Procedural treatments: 16,216 procedural treatments were recorded, 17 per 100 encounters, 
or 11 per 100 problems. The most common were: excisions (2.9 per 100 encounters), dressings 
(2.6 per 100), local injections (2.4) and rehabilitation (1.2). 
Referrals and admissions  
There were a total of 13,526 referrals, 14 per 100 encounters or 9 per 100 problems. The most 
frequent were to medical specialists (9 per 100 encounters, 6 per 100 problems managed), 
followed by referrals to allied health services (4 per 100 encounters, 3 per 100 problems). 
Very few patients were referred to hospitals or emergency departments (0.7 per 100 
encounters, 0.4 per 100 problems).  
Referrals to specialists were most often to surgeons (10% of specialist referrals), orthopaedic 
surgeons (8%) ophthalmologists (8%) and dermatologists (8%). Malignant skin neoplasms, 
pregnancy, diabetes and osteoarthritis were the problems most often referred to specialists. 
Referrals to allied health services were most often to physiotherapists (27% of allied health 
referrals), psychologists (21%), podiatrists (10%) and dentists (9%). Problems most likely to 
be referred to allied health services were depression, diabetes and back complaints.  
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Tests and investigations 
Pathology tests ordered: GPs recorded 43,313 orders for pathology tests/batteries, at a rate 
of 45 per 100 encounters (30 per 100 problems managed). At least one pathology test was 
recorded at 18% of encounters (for 13% of problems managed). 
• Chemistry tests accounted for 58% of pathology test orders, the most common being: 
lipid tests (2.6 per 100 problems managed); electrolytes, urea and creatinine (2.2); liver 
function (1.9); and thyroid function tests (1.7 per 100).  
• Haematology tests accounted for 18% of pathology and included full blood count, the 
most frequently ordered individual test (15% of all pathology), ordered at a rate of 4.1 
per 100 problems managed). 
• Microbiology accounted for 14% of pathology orders. Urine microscopy, culture and 
sensitivity was the most frequent test ordered within the group.  
• Almost 40% of all pathology tests were generated by orders for ten problems, led by 
diabetes, hypertension, general check-ups, and lipid disorders.  
Imaging ordered: There were 9,370 imaging test orders recorded, 10 per 100 encounters and 
6 per 100 problems managed. At least one imaging test was ordered at 8% of encounters (for 
6% of problems managed). Diagnostic radiology accounted for 47%, ultrasound 39%, and 
computerised tomography for 11% of all imaging orders.  
An example of the relationship of tests and other data elements is provided for lipid tests in 
Section 12.5. 
Practice nurse activity  
• Practice nurses were involved in 8% of encounters and 5% of problems managed. A 
practice nurse Medicare item number was recorded for 40% of those encounters 
involving a practice nurse, the most common claims being for immunisation (67%) and 
wound treatment (28%). 
• The majority of their activities were procedural (92%), and these procedures represented 
38% of all procedures recorded. Clinical treatments accounted for 8% of practice nurse 
activity, but only 2% of all recorded clinical treatments.  
• The most common procedures done by nurses were injections (40% of recorded 
procedures), dressings (19%), incisions (6%), check-ups (7%) and INR tests (7%).  
Patient risk factors 
Overweight and obesity in adults (18 years and over): Of 31,315 adults, 62% were 
overweight or obese: 35% being overweight and 27% obese.  
Overweight and obesity in children (2–17 years): Of 3,008 children, 28% were overweight 
(18%) or obese (11%).  
Smoking status (adults 18 years and over): Of 32,160 adults, 15% (18% of men and 13% of 
women) were daily smokers.  
Alcohol consumption (adults 18 years and over): Of 31,190 adult patients 25% (30% of men 
and 21% of women) reported drinking at-risk levels of alcohol.  
Adult risk profile: Of the 30,177 patients for whom all three risk factor data were available: 
25% had no risk factors 52% had one, 19% had two, and 4% had three.  
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1 Introduction 
This publication is the 13th annual report and the 29th book in the series from the BEACH 
(Bettering the Evaluation and Care of Health) program, a continuous national study of general 
practice activity in Australia. It provides the annual results for the period April 2010 to March 
2011 inclusive, using details of 95,800 encounters between general practitioners (GPs) and 
patients (almost a 0.1% sample of all general practice encounters) from a random sample of 
958 practising GPs across the country. 
Released in parallel with this report is a summary of results from the most recent 10 years of 
the BEACH program, A decade of Australian general practice activity 2001–02 to 2010–11,1 
available at <purl.library.usyd.edu.au/sup/9781920899875>. The BEACH program began in 
April 1998 and was the culmination of about 20 years research and development work at the 
University of Sydney. BEACH is currently supported financially by government and private 
industry (see ‘Acknowledgments’). 
The BEACH program 2010–11 was conducted by the Family Medicine Research Centre 
(FMRC), University of Sydney, in collaboration with the Australian Institute of Health and 
Welfare (AIHW), under the AIHW Act. The collaboration ceased in March 2011. Since then, 
the FMRC has continued to conduct the BEACH program. 
BEACH is the only continuous randomised study of general practice activity in the world, 
and the only national program that provides direct linkage of management actions (such as 
prescriptions, referrals, investigations) to the problem under management. The BEACH 
database now includes information for almost 1.3 million encounters from 12,831 
participants representing about 8,711 individual GPs, almost half the sample frame of 
actively practising GPs from which the samples are drawn. 
1.1 Background 
In December 2010, the population of Australia was estimated to be 22.48 million people.2  
Australia’s health expenditure in 2008–09 was $112.8 billion, an average $5,190 per 
Australian, and 9.0% of GDP in 2008–09. Governments funded 69.7%, with the remainder 
(31.1%) being paid by the non-government sector.3 Government expenditure on general 
practice services (including those of the practice nurses) was more than $5 billion dollars in 
the 2010–11 BEACH year.4 
GPs are usually the first port of call in the Australian health care system. Payment for GP 
visits is largely on a fee-for-service system, there being no compulsory patient lists or 
registration. People are free to see multiple practitioners and visit multiple practices of their 
choice. There is a universal medical insurance scheme (managed by Medicare Australia), 
which covers all or most of a person’s costs for a GP visit.  
In 2008 in Australia, there were 24,029 practising primary care practitioners (vocationally 
recognised GPs and other medical practitioners), making up 23,188 full-time equivalents 
(based on a 40 hour week), or 107.9 per 100,000 people.5  
From April 2010 to March 2011, Medicare paid rebates for about 118.1 million general 
practice services (excluding practice nurse items), 4 at an average of about 5.3 GP visits per 
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head of population or 6.3 visits per person who visited at least once. This equates to about 2.3 
million GP-patient encounters per week. 
While Medicare statistics provide information about frequencies and costs of visits claimed 
from Medicare for GP services, they cannot tell us about the content of these visits. The 
BEACH program fills this gap. 
1.2 The BEACH program 
In summary, the BEACH program is a continuous national study of general practice activity 
in Australia. Each year an ever changing random sample of about 1,000 practising GPs 
participate, each recording details of 100 patient encounters on structured paper based 
recording sheets. This provides details of about 100,000 GP-patient encounters per year. The 
BEACH methods are described in Chapter 2 of this report. 
A random sample of GPs who claimed at least 375 general practice Medicare items of service 
in the previous 3 months is regularly drawn from Medicare Australia data by DoHA. GPs 
are approached by letter and followed up by telephone recruitment. Each participating GP 
completes details for 100 consecutive GP–patient encounters on structured paper encounter 
forms (Appendix 1). They also provide information about themselves and their major 
practice (Appendix 2).  
Aims 
The three main aims of the BEACH program are to: 
• provide a reliable and valid data collection process for general practice that is responsive 
to the ever-changing needs of information users, and provides insight into the evolving 
character of GP–patient encounters in Australia 
• establish an ongoing database of GP–patient encounter information 
• assess patient risk factors and health states, and the relationship these factors have with 
health service activity. 
Current status of BEACH 
BEACH began in April 1998 and is now in its 14th year. The BEACH database now includes 
details of 1,283,100 GP–patient encounters from 12,831 participating GPs. Each year we 
publish an annual report of BEACH results. This publication reports results from the 
previous BEACH data year (April 2010 to March 2011) and provides an overview of general 
practice activity. 
A companion publication A decade of Australian general practice activity 2001–02 to 2010–11,1 
provides summaries of changes in the most frequent events that have occurred over the 
decade.  
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The strengths of the BEACH program 
• BEACH is the only national study of general practice activity in the world that is 
continuous, relying on a random ever-changing sample of GPs, and directly linking 
management actions to the morbidity under management.  
• The sheer size of the GP sample (1,000 per year) and the relatively small cluster of 
encounters around each GP provide more reliable estimates than a smaller number of 
GPs with large clusters of patients and/or encounters.6 Our access to a regular random 
sample of recognised GPs in active practice, through DoHA, ensures that the GP sample 
is drawn from a very reliable sample frame of currently active GPs. 
• There are sufficient details about the characteristics of all GPs in the sample frame to test 
the representativeness of the final sample, and to apply post-stratification weighting to 
correct for any under or over-representation in the sample when compared with the 
sample frame. The ever-changing nature of the sample (where each GP can participate 
only once per triennium) ensures reliable representation of what is happening in general 
practice across the country. The sampling methods ensure that new entrants to the 
profession are available for selection because the sample frame is based on the most 
recent Medicare data.  
• Where data collection programs use a fixed set of GPs over a long period, they are 
measuring what that group is doing at any one time, or how that group has changed 
over time, and there may well be a ‘training effect’ inherent in longer-term participation. 
Such measures cannot be generalised to the whole of general practice. Further, where 
GPs in the group have a particular characteristic in common (for example, all belong to a 
professional organisation to which not all GPs belong; all use a selected software system 
which is not used by all GPs), the group is biased and cannot represent all GPs. 
• Each GP records for a set number of encounters (100), but there is wide variance among 
them in the number of patient consultations they conduct in any one year. DoHA 
therefore provides an individual count of activity level (that is, number of Medicare GP 
service items claimed in the previous period) for all randomly sampled GPs, allowing us 
to give a weighting to each GP’s set of encounters commensurate with his or her 
contribution to total general practice encounters. This ensures that the final encounters 
represent encounters with all GPs. 
• The structured paper encounter form leads the GP through each step in the encounter, 
encouraging entry of data for each element (see Appendix 1), with instructions and an 
example of a completed form. In contrast, systems such as electronic health records rely 
on the GP to complete fields of interest without guidance. 
• Activities described in BEACH include all patient encounters, not just Medicare paid.  
• The medication data include all prescriptions, rather than being limited to those 
prescribed medications covered by the Pharmaceutical Benefits Scheme (PBS).  
• BEACH is the only source of information on medications supplied directly to the patient 
by the GP, and about the medications GPs advise for over-the-counter (OTC) purchase, 
the patients to whom they provide such advice and the problems managed in this way.  
• The inclusion of other (non-pharmacological) treatments such as clinical counselling and 
procedural treatments provides a broader view of the interventions used by GPs in the 
care of their patients than other data sources.  
• The link from all management actions (for example, prescribing, ordering tests) to the 
problem under management provides a measure of the ‘quality’ of care rather than just a 
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count of the number of times an action has occurred (for example, how often a specific 
drug has been prescribed). 
• The use of an internationally standard well-structured classification system (ICPC-2)7 
designed specifically for general practice, together with the use of an extended 
vocabulary of terms which facilitates reliable classification of the data by trained 
secondary coders, removes the guesswork often applied in word searches of available 
records (in free text format) and in classification of a concept.  
• The use of the World Health Organization’s (WHO) Anatomical Therapeutic Chemical 
Classification for pharmaceuticals at the generic level ensures reporting of medications 
data is in terms of the international standard. 
• The analytical techniques applied to the BEACH data ensure that the clustering inherent 
in the sampling methods is dealt with. Results are reported with 95% confidence 
intervals. Users are therefore aware of how reliable any estimate might be. 
• Reliability of the methods is demonstrated by the consistency of results over time where 
change is not expected, and by the measurement of change when it might be expected.  
1.3 Using BEACH data with other national data 
Users of the BEACH data might wish to integrate information from multiple national data 
sources, as this can provide a more comprehensive picture of the health and health care of 
the Australian community. It is therefore important that readers are aware of how the 
BEACH data differ from those drawn from others. This section summarises differences 
between BEACH and other national sources of data about general practice in Australia. 
The Pharmaceutical Benefits Scheme  
Prescribed medications paid for under the Pharmaceutical Benefits Scheme (PBS) are 
recorded by Medicare Australia. The PBS data: 
• count the prescription each time it crosses the pharmacist’s counter (so that one 
prescription written by the GP with five repeats in BEACH would be counted by the 
PBS six times if the patient filled all repeats) 
• count only those prescribed medications subsidised by the PBS and costing more than 
the minimum subsidy (and therefore covered by the PBS for all patients), or medications 
prescribed for those holding a Commonwealth concession card or for those who have 
reached the safety net threshold  
• will change with each change in the PBS copayment level for non-Commonwealth 
concession cardholders – when the copayment level increases, those medications  
that then fall under the new level will no longer be counted in the PBS for  
non-Commonwealth concession cardholders8 
• have no record of the problem being managed (with the exception of authority 
prescriptions, which require an indication and account for a small proportion of PBS 
data), and the morbidity cannot be reliably assumed on the basis of the prescription 
type.9 
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In BEACH: 
• total medications include those prescribed (whether covered by the PBS or not), those 
supplied to the patient directly by the GP, and those advised for OTC purchase 
• each prescription recorded reflects the GP’s intent that the patient receives the prescribed 
medication, and the specified number of repeats; the prescription, irrespective of the 
number of repeats ordered, is counted only once  
• the medication is directly linked to the problem being managed by the GP 
• there is no information on the number of patients who do not present their prescription 
to be filled (this also applies to the PBS). 
These differences have a major impact on the numbers of prescriptions counted and also 
affect their distribution. For example, the majority of broad spectrum antibiotics such as 
amoxycillin fall under the PBS minimum subsidy level and would not be counted in the 
PBS data, except where patients received the medication under the PBS because they are 
Commonwealth concession cardholders or had reached the annual safety net threshold.8 
Medicare Benefits Schedule 
Consultations with GPs that are paid for in part or in full under the Medicare Benefits 
Schedule (MBS) are recorded by Medicare Australia. 
• Publicly available MBS claims data do not include data about patients and encounters 
funded through the Department of Veterans’ Affairs (DVA).  
• The MBS data include GP services that have been billed to Medicare. BEACH includes 
all consultations, irrespective of whether a charge is made or who pays for them.  
• The MBS data reflect the item number charged to Medicare for a service and some 
patient demographics, but hold no information about the content of the consultation. 
• In 2010–11, BEACH participants were limited to recording three Medicare item numbers 
for each encounter. In contrast, MBS data include all Medicare item numbers claimed. In 
the BEACH data set this may result in a lower number of ‘other’ Medicare items than 
would be counted in the Medicare data.  
• In activities of relatively low frequency with a skewed distribution across individual 
GPs, the relative frequency of the event in the BEACH data may not reflect that reported 
in the MBS data. For example, a study of early uptake of some enhanced primary care 
items by GPs demonstrated in 2002 that almost half the enhanced primary care items 
claimed through the MBS came from about 6% of active GPs.10 Where activity is so 
skewed across the practising population, a national random sample will provide an 
underestimate of activity because the sample reflects the population rather than the 
minority. 
• One of the advantages of BEACH over the MBS is also the relative consistency over time 
of the data collection form. BEACH is relatively resilient to changes in MBS payment 
policies, such as the inclusion or removal of items from the MBS.  
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Pathology data from the MBS 
Pathology tests undertaken by pathologists that are charged to Medicare are recorded by 
Medicare Australia. However, these Medicare data are not comparable with BEACH data. 
• MBS pathology data reflect pathology orders made by medical specialists and GPs. 
About 70% of the volume of MBS pathology data are generated by GP orders.11 
• Each pathology company can respond differently to a specific test order label recorded 
by the GP. So the tests completed by a pathologist in response to a GP order for a full 
blood count may differ between companies. 
• The pathology companies can charge through the MBS only for the three most expensive 
items undertaken, even when more were actually done. This is called ‘coning’ and is part 
of DoHA pathology payment system. This means that the tests recorded in the MBS 
include only those charged for, not all those that were done. Coning applies only to GP 
pathology orders, not to those generated by medical specialists. 
• This means that the MBS pathology data reflect those tests billed to the MBS after 
interpretation of the order by the pathologist, and after selection of the three most 
expensive items.  
• Pathology MBS items contain pathology tests that have been grouped on the basis of cost 
(for example, ‘any two of the following … tests’). Therefore an MBS item often does not 
give a clear picture of the precise tests performed. 
In BEACH, the pathology data: 
• include details of pathology tests ordered by the participating GPs; however, the GP is 
limited to the recording of five tests or battery of tests at each encounter, and as the 
number of tests/batteries ordered on any single occasion is increasing,12 an increasing 
number of additional tests ordered will be lost 
• reflect the terms used by GPs in their orders to pathologists, and for reporting purposes 
these have been grouped by the MBS pathology groups for comparability.  
The distributions of the two data sets will therefore differ, reflecting on the one hand the GP 
order and on the other the MBS-billed services from the pathologist. 
Pathology ordering by GPs is described in Chapter 12 of this report. Those interested in 
pathology test ordering by GPs should also view the following publications: 
• Are rates of pathology test ordering higher in general practices co-located with pathology 
collection centres?13 This publication investigated the independent effect of general 
practice co-location with pathology collection centres on GP pathology test ordering in 
Sydney and Melbourne metropolitan areas.  
• Evidence-practice gap in GP pathology test ordering: a comparison of BEACH pathology data and 
recommended testing.14 
• Changes in pathology ordering by general practitioners in Australia 1998–2001.15  
Imaging data from the MBS 
Some of the issues discussed regarding pathology data also apply to imaging data. Although 
coning is not an issue for imaging, radiologists can decide whether the test ordered by the 
GP is the most suitable and whether to undertake other tests of their choosing. The MBS data 
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therefore reflect the tests that are actually undertaken by the radiologist, whereas the 
BEACH data reflect those ordered by the GP.  
The National Health Survey 
The National Health Survey, conducted by the Australian Bureau of Statistics, provides 
estimates of population prevalence of specific diseases, and a measure of the problems taken 
to the GP by people in the 2 weeks before the survey. 
• Prevalence estimates are based on self-reported morbidity from a representative sample 
of the Australian population, using a structured interview to elicit health-related 
information from participants.16  
• Community surveys such as the National Health Survey have the advantage of accessing 
people who do not go to a GP as well as those who do. They can therefore provide an 
estimate of population prevalence of disease and a point estimate of incidence of disease. 
• Self-report has been demonstrated to be susceptible to misclassification because of a lack 
of clinical corroboration of diagnoses.17 
Management rates of health problems in general practice represent GP workload for a health 
problem. BEACH can be used to estimate the period incidence of diagnosed disease 
presenting in general practice through the number of new cases of that disease. The 
management rates of individual health problems and management actions can be 
extrapolated to national management rates.  
The general practice patient population sits between the more clinical hospital-based 
population and the general population,18,19 with about 83% of Australians visiting a GP at 
least once in 2009–10 (personal communication DoHA, June 2010). Disease management 
rates are a product of both the prevalence of the disease/health problem in the population, 
and the frequency with which a patient visits a GP for the treatment of that problem. Those 
who are older and/or have more chronic disease are therefore likely to visit more often, and 
have a greater chance of being sampled in the encounter data.  
There was a substudy of disease prevalence among patients seen in general practice (using 
the Supplementary Analysis of Nominated Data method, see Section 2.6). Those interested in 
disease prevalence should refer to the following papers: Estimating prevalence of common 
chronic morbidities in Australia,20 and Prevalence and patterns of multimorbidity in Australia.21  
1.4 Access to BEACH data 
Different bundles of BEACH data are available to the general public, to 
BEACH-participating organisations, and to other organisations and researchers. 
Public domain 
This annual publication provides a comprehensive view of general practice activity in 
Australia. The BEACH program has generated many papers on a wide variety of topics in 
journals and professional magazines. All published material from BEACH is available at 
<www.fmrc.org.au/publications/>. 
Since April 1998, a section at the bottom of each encounter form has been used to investigate 
aspects of patient health or health care delivery not covered by general practice 
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consultation-based information. These additional substudies are referred to as SAND 
(Supplementary Analysis of Nominated Data). The SAND methods are described in 
Section 2.6. Abstracts of results and the research tools used in all SAND substudies from 
April 1998 to March 2011 have been published. Those from: 
• April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia22 
• April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts 
and research tools 1999–200623 
• August 2006 to March 2010 were published in the BEACH annual report for each  
year24-27 
• April 2010 to March 2011 are included in Chapter 15 of this report. 
Abstracts of results for all SAND substudies are also available on the FMRC website 
<www.fmrc.org.au/publications/SAND_abstracts.htm> where you can search by topic. 
Participating organisations 
Organisations providing funding for the BEACH program receive summary reports of the 
encounter data quarterly, and standard reports or specifically designed analyses about their 
subjects of interest. Participating organisations also have direct access to straightforward 
analyses on any selected problem, medication, pathology or imaging test through an 
interactive web server. All data made available to participating organisations have been 
further ‘de-identified’. Patients’ encounter data are not identifiable even from the original 
forms, but are further stripped of date of birth (replaced with age in years and months) and 
postcode of residence (replaced with state and area type). GP characteristics data are 
provided only in the form of grouped output (for example, GPs aged less than 35 years) to 
any external organisation. 
External purchasers of reports 
Non-contributing organisations may purchase standard reports or other ad hoc analyses. 
Charges are outlined at <www.fmrc.org.au/purchase.htm>. The FMRC should be contacted 
for specific quotations. Contact details are provided at the front of this publication. 
Analysis of the BEACH data is a complex task. The FMRC has designed standard reports 
that cover most aspects of a subject under investigation. Examples of a problem-based 
standard report (subject: ischaemic heart disease in patients aged 45 years and over), a group 
report (subject: female patients aged 15–24 years) and a pharmacological-based standard 
report (subject: allopurinol) for a single year’s data are available at 
<www.fmrc.org.au/purchase.htm>. 
Individual data analyses can be done where the specific research question is not adequately 
answered through standard reports.  
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2 Methods  
In summary: 
• each year, BEACH involves a new random sample of about 1,000 GPs 
• each GP records details about 100 doctor–patient encounters of all types  
• the GP sample is a rolling (ever-changing) sample, with about 20 GPs participating in 
any 1 week, 50 weeks a year 
• each GP can be selected only once per quality assurance (QA) triennium (that is, once 
every 3 years) 
• the encounter information is recorded by the GPs on structured paper encounter forms 
(Appendix 1) 
• GP participants also complete a questionnaire about themselves and their practice 
(Appendix 2). 
2.1 Sampling methods 
The source population includes all vocationally registered GPs and all general practice 
registrars who claimed a minimum of 375 general practice A1 Medicare items in the most 
recently available 3-month Medicare data period (which equates to 1,500 A1 Medicare claims 
a year). This ensures inclusion of the majority of part-time GPs, while excluding those who 
are not in private practice but claim for a few consultations a year. 
The Medicare Statistics section of the DoHA updates the sample frame from the Medicare 
records quarterly, leaving out of the sample frame any GPs already randomly sampled in the 
current triennium, and draws a new sample from those currently in the sample frame. This 
ensures the timely addition of new entries to the profession, and timely exclusion of those 
GPs who have stopped practising, or have already participated or been approached in the 
current triennium. 
2.2 Recruitment methods 
The randomly selected GPs are approached by letter, posted to the address provided by 
DoHA. 
• Over the following 10 days, the telephone numbers generated from the Medicare data 
are checked using the electronic white and yellow pages. This is necessary because many 
of the telephone numbers provided from the Medicare data are incorrect. 
• The GPs are then telephoned in the order they were approached and, referring to the 
approach letter, asked whether they will participate. 
• This initial telephone contact with the practice often indicates that the selected GP has 
moved elsewhere, but is still in practice. Where new address and/or telephone number 
can be obtained, these GPs are followed up at their new address. 
• GPs who agree to participate are set an agreed recording date several weeks ahead. 
• A research pack is sent to each participant before the planned start date. 
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• Each GP receives a telephone reminder early in the agreed recording period – this also 
provides the GP with an opportunity to ask questions about the recording process. 
• GPs can use a ‘freecall’ (1800) number to ring the research team with any questions 
during their recording period. 
• Non-returns are followed up by regular telephone calls for 3 months. 
• Participating GPs earn clinical audit points towards their QA requirements through the 
Royal Australian College of General Practitioners (RACGP) and/or the Australian 
College of Rural and Remote Medicine (ACRRM). As part of this QA process, each 
receives an analysis of his or her results compared with those of nine other de-identified 
GPs who recorded at about the same time. Comparisons with the national average and 
with targets relating to the National Health Priority Areas are also provided. In addition, 
GPs receive some educational material related to the identification and management of 
patients who smoke or consume alcohol at hazardous levels. Additional points can be 
earned if the participant chooses to do a follow-up audit of smoking and alcohol 
consumption among a sample of patients about 6 months later. 
2.3 Ethics approval and informed patient consent 
Ethics approval for this study was obtained from the Human Ethics Committee of the 
University of Sydney and from the Ethics Committee of the Australian Institute of Health 
and Welfare. 
Although the data collected by the GPs is not sufficient to identify an individual patient, 
informed consent for inclusion of the encounter details is required from each patient. GPs are 
instructed to ensure that all patients presenting during their recording period are provided 
with a Patient Information card (Appendix 3) and that they ask the patient if they are happy 
for their data to be included in the study. If the patient refuses, details of the encounter are 
not recorded. This is in accordance with the requirements for ethics approval for the BEACH 
program. 
2.4 Data elements 
BEACH includes three interrelated data collections: GP characteristics, encounter data and 
patient health status. An example of the form used to collect the encounter data and the data 
on patient health status is included in Appendix 1. The GP characteristics questionnaire is 
provided in Appendix 2. The GP characteristic and encounter data collected are summarised 
below. Patient health status data are described in Section 2.6. 
GP profile form (Appendix 2) 
• GP characteristics: age and sex, years in general practice, number of direct patient care 
hours worked per week, country of graduation, postgraduate general practice training 
status, Fellow of the RACGP status, Fellow of the Australian College of Rural and 
Remote Medicine status, usual bulk-billing behaviour, use of computers at work, work 
undertaken in other clinical settings. 
• Practice characteristics: postcode and GP Division of major practice, number of 
individual, and number of full-time equivalent GPs working in the practice, number of 
individual and number of full-time equivalent practice nurses working in the practice, 
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usual after-hours care arrangements, whether the practice is accredited, whether it is a 
teaching practice. 
Encounter recording form (Appendix 1) 
• Encounter data: date of consultation, type of consultation (direct/indirect) (tick box 
options), up to three MBS/DVA item numbers (where applicable), and other payment 
source (where applicable) (tick boxes). 
• Patient data: date of birth, sex and postcode of residence. Tick boxes (yes/no options) 
are provided for Commonwealth concession cardholder, holder of a Repatriation health 
card (from DVA), non-English-speaking background (patient self-report – a language 
other than English is the primary language at home), Aboriginal person (self-
identification), and Torres Strait Islander person (self-identification). Space is provided 
for up to three patient reasons for encounter (RFEs) (see ‘Glossary’). 
• The problems managed at encounter (at least one and up to four). Tick boxes are 
provided to denote the status of each problem as new or continuing for the patient and 
whether the problem is considered by the GP to be work-related. 
• Management of each problem, including: 
– medications prescribed, supplied by the GP and advised for over-the-counter 
purchase including brand name, form (where required), strength, regimen, status 
(whether new or continuing medication for this problem for this patient) and 
number of repeats 
– other treatments provided for each problem, including counselling, advice and 
education, and procedures undertaken, and whether the recorded other treatment 
was provided by practice nurse (tick box) 
– new referrals to medical specialists, allied health services, emergency departments, 
and hospital admissions 
– investigations, including pathology tests, imaging and other investigations ordered 
at the encounter. 
2.5 The BEACH relational database 
The BEACH relational database is described diagrammatically in Figure 2.1. Note that: all 
variables can be directly related to GP and patient characteristics, and to the encounter; RFEs 
have only an indirect relationship with problems managed, as a patient may describe one 
RFE (such as ‘repeat prescriptions’) that is related to multiple problems managed, or several 
RFEs (such as ‘runny nose’ and ‘cough’) that relate to a single problem (such as upper 
respiratory tract infection) managed at the encounter (see Section 6.3); all types of 
management are directly related to the problem being managed.  
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The encounter 
• date 
• direct (face to face) 
— Medicare/DVA item 
number(s) claimable 
— workers compensation 
— other paid 
— no charge 
• indirect (e.g. telephone) 
Patient substudies (SAND) 
• risk factors 
— body mass 
— smoking status 
— alcohol consumption  
• other topics 
Management of each problem 
Medications (up to four per problem) 
• prescribed 
• over-the-counter advised 
• provided by GP 
— drug class 
— drug group 
— generic 
— brand name 
— strength 
— regimen 
— number of repeats  
— drug status (new/continued) 
 
Other treatments (up to two per 
problem) 
• procedural treatments 
• clinical treatments (e.g. advice, 
counselling) 
• practice nurse involvement 
 
Other management 
• referrals (up to two) 
— to specialists 
— to allied health professionals 
— to emergency departments 
— hospital admissions 
• pathology tests ordered (up to five) 
• imaging ordered (up to three) 
GP characteristics 
• age and sex 
• years in general practice 
• country of graduation 
• direct patient care hours/week 
• usual bulk-billing practice 
• postgraduate GP qualifications 
• FRACGP status (yes/no) 
• FACRRM status (yes/no) 
• currently a registrar (yes/no) 
• clinical use of computers  
Practice characteristics 
• practice size (no. & FTE GPs) 
• practice nurse(s) (no. & FTE) 
• after-hours arrangements 
 postcode and GP Division 
• teaching practice (yes/no) 
Problems managed 
• diagnosis/problem label 
• problem status (new/old) 
• work-related problem status 
The patient 
• age and sex 
• practice status (new/old) 
• Commonwealth concession 
card status 
• DVA Status 
• postcode of residence 
• NESB/Indigenous status 
• reasons for encounter 
Note: FTE—full-time equivalent; FRACGP—Fellow of the Royal 
Australian College of General practitioners; FACRRM—Fellow 
of the Australian College of Rural and Remote Medicine; 
DVA—Department of Veterans’ Affairs; NESB—non-English-
speaking background; SAND—Supplementary Analysis of 
Nominated Data. 
Figure 2.1: The BEACH relational database 
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2.6 Supplementary Analysis of Nominated Data  
A section at the bottom of each recording form investigates aspects of patient health or 
health care delivery in general practice not covered by the consultation-based data. These 
additional substudies are referred to as SAND, Supplementary Analysis of Nominated Data. 
• Each year the 12 month data period is divided into 10 blocks, each of 5 weeks, with three 
substudies per block. The research team aims to include data from about 100 GPs in each 
block.  
• Each GP’s pack of 100 forms is made up of 40 forms that ask for the start and finish times 
of the encounter, and include questions about patient risk factors: patient height and 
weight (used to calculate body mass index, BMI), alcohol intake and smoking status 
(patient self-report). The methods and results of topics in the SAND substudies for 
alcohol consumption, smoking status and BMI are reported in Chapter 14. The start and 
finish times collected on these encounters are used to calculate the length of consultation. 
The length of consultation for Medicare-claimable encounters is reported in Section 5.3. 
• The remaining 60 forms in each pack are divided into two blocks of 30, so each SAND 
block includes about 3,000 records. Some topics are repeated to increase sample size. 
Different questions are asked of the patient in each block and these vary throughout the 
year. 
• The order of SAND sections is rotated in the GP recording pack, so that 40 patient risk 
factor forms may appear first, second or third in the pad. Rotation of ordering ensures 
there was no order effect on the quality of the information collected. 
Abstracts of results and the research tools used in all SAND substudies from April 1998 to 
March 2011 have been published. Those: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery 
in general practice in Australia22 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: 
abstracts and research tools 1999–200623 
• conducted between August 2006 and March 2010 have been published in each of the 
general practice activity annual reports24-27 
• conducted in the 2010–11 BEACH year are provided in Chapter 15 of this publication. 
Abstracts of results for all SAND substudies are also available on the FMRC’s website 
<www.fmrc.org.au/publications/SAND_abstracts.htm>. 
2.7 Statistical methods 
The analysis of the 2010–11 BEACH data was conducted with Statistical Analysis System 
(SAS) version 9.1.3,28 and the encounter is the primary unit of inference. Proportions are used 
only when describing the distribution of an event that can arise only once at a consultation 
(for example, patient or GP age and sex), or to describe the distribution of events within a 
class of events (for example, problem A as a percentage of total problems). Due to rounding, 
proportions may not always add to exactly 100%. 
Rates per 100 encounters are used when an event can occur more than once at the 
consultation (for example, RFEs, problems managed or medications). 
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Rates per 100 problems are also used when a management event can occur more than once 
per problem managed. In general, the results present the number of observations (n), the rate 
per 100 encounters, and (in the case of management actions) the rate per 100 problems 
managed, and the 95% confidence interval. 
BEACH is a single stage cluster sample study design, each 100 encounters forming a cluster 
around each GP participant. In cluster samples, variance needs to be adjusted to account for 
the correlation between observations within clusters. Procedures in SAS version 9.1.3 were 
used to calculate the intracluster correlation, and adjust the confidence intervals 
accordingly.28  
Post-stratification weighting of encounter data adjusts for: any difference in the age–sex 
distribution of the participating GPs and those GPs in the sample frame from which the 
samples were drawn; and for the varying activity level of each GP (measured by number of 
claims each has made in the previous 12 months from Medicare Australia) (see Chapter 3). 
2.8 Classification of data 
The following data elements are classified according to the International Classification of 
Primary Care – Version 2 (ICPC-2), a product of the World Organization of Family Doctors 
(Wonca):7 
• patient reasons for encounter (RFEs) 
• problems managed 
• clinical treatments (for example, counselling, advice) 
• procedural treatments 
• referrals 
• investigations ordered (including pathology, imaging and other investigations). 
The ICPC-2 is used in more than 45 countries as the standard for data classification in 
primary care. It is accepted by the World Health Organization (WHO) in the WHO Family of 
International Classifications,29 and is the declared national standard in Australia for 
reporting of health data from general practice and patient self-reported health information.30 
The ICPC-2 has a biaxial structure, with 17 chapters on one axis (each with an alphabetic 
code) and seven components on the other (numeric codes) (Figure 2.2). Chapters are based 
on body systems, with additional chapters for psychological and social problems. 
Component 1 includes symptoms and complaints. Component 7 covers diagnoses – it can 
also be expanded to provide data about infections, injuries, neoplasms, congenital anomalies 
and ‘other’ diagnoses.  
Component 2 (diagnostic, screening and prevention) is often applied in describing the 
problem managed (for example, check-up, immunisation). Components 3 to 6 cover other 
processes of care, including referrals, other (non-pharmacological) treatments and orders for 
pathology and imaging. The components are standard and independent throughout all 
chapters. The updated component groupings of ICPC-2 codes, released by the Wonca 
International Classification Committee in 200431 have been used in this report. 
The ICPC-2 is an excellent epidemiological tool. The diagnostic and symptom rubrics have 
been selected for inclusion on the basis of their relative frequency in primary care settings, or 
because of their relative importance in describing the health of the community. ICPC has 
about 1,370 rubrics and these are sufficient for meaningful analyses. However, reliability of 
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data entry, using ICPC-2 alone, requires a thorough knowledge of the classification for 
correct classification of a concept to be ensured. 
In 1995, recognising a need for a coding and classification system for general practice 
electronic health records, the Family Medicine Research Centre (FMRC) (then Unit) 
developed an extended clinical terminology classified according to the ICPC, now called 
ICPC-2 PLUS.32 This is an interface terminology, developed from all the terms used by GPs 
in studies such as the Australian Morbidity and Treatment Survey 1990–91 (113,468 
encounters),33 A comparison of country and metropolitan general practice 1990–91 
(51,277 encounters),34 the Morbidity and Therapeutic Index 1992–1998 (a clinical audit tool 
that was available to GPs) (approximately 400,000 encounters), and BEACH 1998–2011 
(about 1.3 million encounters), that together make up about 2.7 million encounter records, 
involving more than 4 million free text descriptions of problems managed and a further 4 
million for patient reasons for encounter. These terms are classified according to ICPC-2 to 
ensure international standards for reporting. Readers interested in seeing how coding works 
can download the ICPC-2 PLUS Demonstrator at 
<www.fmrc.org.au/icpc2plus/demonstrator.htm>. 
When the free-text data are received from the GPs, trained secondary coders (who are 
undergraduate students), code the data in more specific terms using ICPC-2 PLUS. This 
ensures high coder reliability and automatic classification of the concept, and provides the 
ability to ‘ungroup’ such ICPC-2 rubrics as ‘other diseases of the circulatory system’ and 
select a specific disease from the terms within it. 
 
                    
 Components A B D F H K L N P R S T U W X Y Z  
 1. Symptoms, complaints                    
 2. Diagnostic, screening, prevention                   
 3. Treatment, procedures, medication                   
 4. Test results                   
 5. Administrative                   
 6. Other                   
 7. Diagnoses, disease                   
 A General L Musculoskeletal U Urinary 
 B Blood, blood-forming N Neurological W Pregnancy, family planning 
 D Digestive P Psychological X Female genital  
 F Eye R Respiratory Y Male genital  
 H Ear S Skin Z Social  
 K Circulatory T Metabolic, endocrine, nutritional   
 
Figure 2.2: The structure of the International Classification of Primary Care – Version 2 (ICPC-2) 
Presentation of data classified in ICPC-2 
Statistical reporting is almost always at the level of the ICPC-2 classification (for example, 
acute otitis media/myringitis is ICPC-2 code H71). However, there are some exceptions 
where data are grouped either above the ICPC-2 level or across the ICPC-2 level. These 
grouped morbidity, pathology and imaging codes are defined in Appendix 4 available at: 
<purl.library.usyd.edu.au/sup/9781920899868>. 
 16 
Reporting morbidity with groups of ICPC-2 codes 
When recording problems managed, GPs may not always be very specific. For example, in 
recording the management of hypertension, they may simply record the problem as 
‘hypertension’. In ICPC-2, ‘hypertension, unspecified’ is classified as ‘uncomplicated 
hypertension’ (code K86). There is another code for ‘complicated hypertension’ (K87). In 
some cases the GP may simply have failed to specify that the patient had hypertension with 
complications. The research team therefore feels that for national data reporting, it is more 
reliable to group the codes K86 and K87 and label this ‘Hypertension*’ – the asterisk 
indicating that multiple ICPC-2 codes (as in this example) or ICPC-2 PLUS codes (see below) 
are included. Appendix 4, Table A4.1 lists the codes included in these groups.  
Reporting morbidity with groups of ICPC-2 PLUS codes 
In other cases, a concept can be classified within (but be only part of) multiple ICPC-2 codes. 
For example, osteoarthritis is classified in ICPC-2 in multiple broader codes according to site, 
such as L92 – shoulder syndrome (includes bursitis, frozen shoulder, osteoarthritis of 
shoulder, rotator cuff syndrome). When reporting osteoarthritis in this publication, all the 
more specific osteoarthritis ICPC-2 PLUS terms classified within all the appropriate ICPC-2 
codes are grouped. This group is labelled ‘Osteoarthritis*’ – the asterisk again indicating 
multiple codes, but in this case they are PLUS codes rather than ICPC-2 codes. Appendix 4, 
Table A4.1 lists the codes included in these groups. 
Reporting chronic morbidity 
Chronic conditions are medical conditions characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that affect an 
individual’s quality of life.  
To identify chronic conditions, a chronic condition list35 classified according to ICPC-2 was 
applied to the BEACH data set. In general reporting, both chronic and non-chronic 
conditions (for example, diabetes and gestational diabetes) may have been grouped together 
when reporting (for example, diabetes – all*). When reporting chronic morbidity, only 
problems regarded as chronic have been included in the analysis. Where the group used for 
the chronic analysis differs from that used in other analyses in this report, they are marked 
with a double asterisk. Codes included in the chronic groups are provided in Appendix 4, 
Table A4.2. 
Reporting pathology and imaging test orders 
All the pathology and imaging tests are coded very specifically in ICPC-2 PLUS, but ICPC-2 
classifies pathology and imaging tests very broadly (for example, a test of cardiac enzymes is 
classified in K34 – Blood test associated with the cardiovascular system; a CT scan of the 
lumbar spine is classified as L41 – Diagnostic radiology/imaging of the musculoskeletal 
system). In Australia, the MBS classifies pathology and imaging tests in groups that are 
relatively well recognised. The team therefore regrouped all pathology and imaging ICPC-2 
PLUS codes into MBS standard groups. This allows comparison of data between data 
sources. The groups are marked with an asterisk, and inclusions are provided in Appendix 4, 
Tables A4.8 and A4.9. 
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Classification of pharmaceuticals 
Pharmaceuticals that are prescribed, provided by the GP or advised for over-the-counter 
purchase are coded and classified according to an in-house classification, the Coding Atlas 
for Pharmaceutical Substances (CAPS). 
This is a hierarchical structure that facilitates analysis of data at a variety of levels, such as 
medication class, medication group, generic composition and brand name. 
When strength and regimen are combined with the CAPS code, we can derive prescribed 
daily dose for any prescribed medication or group of medications. 
CAPS is mapped to the Anatomical Therapeutic Chemical (ATC)36 classification, which is the 
Australian standard for classifying medications at the generic level.30 The ATC has a 
hierarchical structure with five levels. For example: 
• Level 1: C – Cardiovascular system 
• Level 2: C10 – Serum lipid reducing agents 
• Level 3: C10A – Cholesterol and triglyceride reducers 
• Level 4: C10AA – HMG CoA reductase inhibitors 
• Level 5: C10AA01 – Simvastatin (the generic drug). 
Use of the pharmaceutical classifications in reporting 
For pharmaceutical data, there is the choice of reporting in terms of the CAPS coding scheme 
or the ATC. They each have advantages in different circumstances. 
In the CAPS system, a new drug enters at the product and generic level, and is immediately 
allocated a generic code. Therefore, the CAPS classification uses a bottom-up approach. 
In the ATC, a new generic may initially enter the classification at any level (1 to 5), not 
always at the generic level. Reclassification to lower ATC levels may occur later. Therefore, 
the ATC uses a top-down approach. 
When analysing medications across time, a generic medication that is initially classified to a 
higher ATC level will not be identifiable in that data period and may result in 
under-enumeration of that drug during earlier data collection periods. 
• When reporting the 2010–11 annual results for pharmaceutical data, the CAPS database 
is used in tables of the ‘most frequent medications’ (Tables 9.2 to 9.4). 
• When reporting the annual results for pharmaceuticals in terms of the ATC hierarchy 
(Table 9.1), ATC levels 1, 3, and 5 are used. The reader should be aware that the results 
reported at the generic level (Level 5) may differ slightly from those reported in the 
‘most frequent medication’ tables for the reasons described above. 
2.9 Quality assurance 
All morbidity and therapeutic data elements were secondarily coded by staff entering key 
words or word fragments, and selecting the required term or label from a pick list. This was 
then automatically coded and classified by the computer. To ensure reliability of data entry 
we use computer-aided error checks (‘locks’) at the data entry stage, and a physical check of 
samples of data entered versus those on the original recording form. Further logical data 
checks are conducted through SAS regularly. 
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2.10 Validity and reliability 
A discussion of the reliability and validity of the BEACH program has been published 
elsewhere.37 This section touches on some aspects of reliability and validity of active data 
collection from general practice that should be considered by the reader.  
In the development of a database such as BEACH, data gathering moves through specific 
stages: GP sample selection, cluster sampling around each GP, GP data recording, secondary 
coding and data entry. At each stage the data can be invalidated by the application of 
inappropriate methods. The methods adopted to ensure maximum reliability of coding and 
data entry have been described above. The statistical techniques adopted to ensure valid 
analysis and reporting of recorded data are described in Section 2.7. Previous work has 
demonstrated the extent to which a random sample of GPs recording information about a 
cluster of patients represents all GPs and all patients attending GPs.38 Other studies have 
reported the degree to which GP-reported patient RFEs and problems managed accurately 
reflect those recalled by the patient,39 and the reliability of secondary coding of RFEs40 and 
problems managed.33 The validity of ICPC as a tool with which to classify the data has also been 
investigated in earlier work.41 
However, the question of the extent to which the GP-recorded data are a reliable and valid 
reflection of the content of the encounter must also be considered. In many primary care 
consultations, a clear pathophysiological diagnosis is not reached. Bentsen42 and Barsky43 
suggest that a firm and clear diagnosis is not apparent in about half of GPs’ consultations, 
and others suggest the proportion may be even greater.44 Further, studies of general 
ambulatory medical practice have shown that a large number of patients presenting to a 
primary care practitioner are without a serious physical disorder.45,46 As a result, it is often 
necessary for a practitioner to record a problem in terms of symptoms, signs, patient 
concerns, or the service that is requested, such as immunisation. For this reason, this report 
refers to patient ‘problems’ rather than ‘diagnoses’. 
A number of studies have demonstrated wide variance in the way a GP perceives the patient’s 
RFE and the manner in which the GP describes the problem under management. In a direct 
observational study of consultations via a one-way mirror, Bentsen demonstrated differences in 
the way practitioners labelled problems, and suggested that clinical experience may be an 
important influence on the identification of problems within the consultation.42 Two other 
factors that might affect GPs’ descriptions of patient RFEs have been identified: although 
individuals may select the same stimuli, some label each stimulus separately, whereas others 
cluster them under one label; and individuals differ in the number of stimuli they select 
(selective perception).47 
The extent to which therapeutic decisions may influence the diagnostic label selected has also 
been discussed. Howie48 and Anderson45 argue that, while it is assumed that the diagnostic 
process used in general practice is one of symptom  diagnosis  management, the 
therapeutic method may well be selected on the basis of the symptom, and the diagnostic label 
chosen last. They suggest that the selection of the diagnostic label is therefore influenced by the 
management decision already made. 
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Anderson has also pointed out that the therapeutic decision may be influenced by fashion, and, 
in turn, this affects the selection of the problem label. He gives the example of a rise in the 
occurrence of neurotic depression in parallel with a decrease in the use of menopause as a 
diagnosis in the United Kingdom, and suggests this may be the result of a change in the 
preferred treatment from oestrogen therapy to antidepressants.45 This should be remembered 
when considering the changes in general practice described in this report. 
Alderson contends that to many practitioners, ‘diagnostic accuracy is only important to the 
extent that it will assist them in helping the patient’. He further suggests that if major symptoms 
are readily treatable, some practitioners may feel no need to define the problem in diagnostic 
terms.49 Crombie stated that in the second and third national morbidity surveys in the United 
Kingdom there was ‘enormous variability in the rates at which doctors perceive and record 
illnesses’. He concluded that the probable cause arose from the different ways in which GPs 
gave priority in their perceptions and recording of certain morbidities while discounting or 
ignoring others. He was unable to account statistically for this variation by the effect of 
geography, age, sex or class differences in the practice populations.50 Differences in the way 
male and female GPs label problems also appear to be independent of such influences.51 
These problems are inherent in the nature of general practice. Knottnerus argues that the GP 
is confronted with a fundamentally different pattern of problems from the medical specialist, 
the GP often having to draw up general diagnostic hypotheses related to probability, 
severity and consequences.52 Anderson suggests that morbidity statistics from family practice 
should therefore be seen as ‘a reflection of the physician’s diagnostic opinions about the 
problems that patients bring to them rather than an unarguable statement of the problems 
managed’.45 In any case, doctors base their actions on problems as they perceive them. 
While these findings regarding limitations in the reliability and validity of 
practitioner-recorded morbidity should be kept in mind, they apply equally to data drawn 
from medical records, whether paper or electronic, as they do to active data collection 
methods.53,54 There is as yet no more reliable method of gaining detailed data about 
morbidity and its management in general practice. Further, irrespective of the differences 
between individual GPs in their labelling of the problems, morbidity data collected by GPs in 
active data collection methods have been shown to provide a reliable overview of the 
morbidity managed in general practice.55 
2.11 Extrapolated national estimates 
A section at the end of each chapter highlights major changes that have occurred over the 
decade 2001–02 to 2010–11. These sections summarise results published in the companion 
publication, A decade of Australian general practice activity 2001–02 to 2010–11.1 Where the 
results demonstrate a significant change over time, the estimated national change across total 
GP Medicare services from 2001–02 to 2010–11 can be calculated using the method detailed 
below. Note that extrapolations are always based on rate per 100 encounters rather than rate 
per 100 problems because there is no independent measure of the number of problems 
managed in Australian general practice. In contrast, the number of national encounters can 
be drawn from Medicare claims data. 
In this report, we also occasionally extrapolate data for the single year 2010–11 to give the 
reader some feeling of the real size of the issue across Australian general practice. 
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When extrapolating from a single time point we: 
• divide the ‘rate per 100 encounters’ of the selected event by 100, and then multiply by the 
total number of general practitioner service items claimed through Medicare in that year, 
118.1 million in 2010–11 (rounded to the nearest 100,000, see Table 2.1), to give the 
estimated national number of events in 2010–11.  
When extrapolating measured change over the decade to national estimates, we: 
• divide the ‘rate per 100 encounters’ of the selected event for 2001–02 by 100, and then 
multiply by the total number of general practitioner service items claimed through 
Medicare in that year, 99.9 million (rounded to the nearest 100,000, see Table 2.1), to give 
the estimated national number of events in 2001–02.  
• repeat the process using data for 2010–11.  
The difference between the two estimates gives the estimated national change in the 
frequency of that event over the decade. Estimates are rounded to the nearest 100,000 if more 
than a million and to the nearest 10,000 if below a million. 
Change is expressed as the estimated increase or decrease over the study period (from 
2001–02 to 2010–11), in the number of general practice contacts for that event (for example, 
an increase or decrease in the number of GP management contacts with problem X); or an 
increase or decrease in the number of times a particular medication type was prescribed in 
Australia in 2010–11, when compared with 2001–02. 
Table 2.1 provides the total number of general practice professional service items claimed 
from Medicare in each financial year from 2001–02 to 2010–11. Extrapolations are calculated 
using the number of GP Medicare items claimed rounded to the nearest 100,000.  
Table 2.1: Number of general practice professional services claimed from Medicare Australia each 
financial year, 2001–02 to 2010–11 (‘000) 
 2001–02 2002–03 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11(a) 
Number of GP  
MBS items  99,921 96,919 96,330 98,180 101,095 103,433 109,518 113,045 116,646 118,126 
Rounded number of 
GP MBS items 99,900 96,900 96,300 98,200 101,100 103,400 109,500 113,000 116,600 118,100 
(a) Medicare data for the 2010–11 year included data from the April 2010 to March 2011 quarters because the 2010–11 financial year data 
were not available at the time of preparation of this report. 
Source: Medicare statistics4 
Example of extrapolation: Change in the number of problems managed by GPs 
nationally  
There was a significant increase in the number of problems managed at encounter, from 
143.4 per 100 encounters in 2001–02 to 152.5 in 2010–11 (see Table 7.2 in A decade of Australian 
general practice activity 2001–02 to 2010–111). The calculation used to extrapolate the effect of 
this change across Australia is:  
 (143.4/100) x 99.9 million = 143.3 million problems managed nationally in 2001–02, and 
(152.5/100) x 118.1 million = 180.1 million problems managed nationally in 2010–11.  
This suggests there were 36.9 million (180.1 million minus 143.2 million) more problems 
managed at GP–patient encounters in Australia in 2010–11 than in 2001–02.  
This is the result of the compound effect of the increase in the number of problems managed 
by GPs at encounters plus the increased number of visits over the decade across Australia. 
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Considerations and limitations in extrapolations 
The extrapolations to the total events occurring nationally in any one year are only estimates. 
They may provide: 
• an underestimate of the true ‘GP workload’ of a condition/treatment because the 
extrapolations are made to GP Medicare items claimed, not to the total number of GP 
encounters per year – an additional 5% or so of BEACH encounters annually include 
encounters paid by sources other than Medicare, such as DVA, state governments, 
workers compensation insurance, and employers. 
• an underestimate of activities of relatively low frequency with a skewed distribution 
across individual GPs. For example, a study of early uptake of some enhanced primary 
care items by GPs demonstrated that almost half the enhanced primary care items 
claimed through the MBS came from about 6% of active GPs.10 Where activity is so 
skewed across the practising population, a national random sample will provide an 
underestimate of activity because the sample reflects the population rather than the 
minority. 
Further, the base numbers used in the extrapolations are rounded to the nearest 100,000, and 
extrapolation estimates are rounded to the nearest 100,000 if more than a million and to the 
nearest 10,000 if below a million. However, the rounding has been applied to all years, so the 
effect on measures of change will be very small. Therefore, the extrapolation still provides an 
indication of the size of the effect of measured change nationally.  
Extrapolations are based on the unit of the encounter because the number of national 
encounters is quantifiable using Medicare claims data. However, the reader should be aware 
that where an event can occur more than once per encounter, the extrapolation represents 
the number of occasions at which that event occurs in general practice encounters, rather 
than the number of encounters where that event occurs.  
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3 The sample 
This chapter describes the GP sample and sampling methods used in the BEACH program. 
The methods are only summarised in this chapter. A more detailed explanation of the 
BEACH methods are described in Chapter 2. 
A summary of the annual BEACH samples are reported for each year from 2001–02 to  
2010–11 in the companion report A decade of Australian general practice activity 2001–02 to 
2010–11.1 
3.1 Response rate 
A random sample of GPs who claimed at least 375 general practice Medicare items of service 
in the previous 3 months is regularly drawn from Medicare claims data by the Australian 
Government Department of Health and Ageing (DoHA) (see Chapter 2). 
Contact was attempted with 4,493 GPs – 16.3% could not be contacted. More than one-third 
of these had moved, retired or died, and were untraceable (Table 3.1), although more than 
half were those with whom contact could not be established after five calls. Younger GPs 
were harder to contact. Of the GPs approached who were aged less than 35 years, 27.6% 
were no longer at that practice and could not be traced. These would largely be registrars 
moving through practices during training. In contrast, 15.4% of GPs aged 35 years and over 
were not traceable (results not shown). 
The final participating sample consisted of 958 practitioners, representing 25.5% of those 
who were contacted and available, and 21.3% of those with whom contact was attempted 
(Table 3.1). 
Table 3.1: Recruitment and participation rates 
Type of contact Number 
Per cent of  
approached  
(n = 4,493) 
Per cent of contacts 
established  
(n = 3,761) 
Letter sent and phone contact attempted 4,493 100.0 — 
No contact  732 16.3 — 
 No phone number 35 0.8 — 
 Moved/retired/deceased 254 5.7 — 
 Unavailable (overseas, maternity leave, etc) 48 1.0 — 
 No contact after five calls 395 8.8 — 
Telephone contact established 3,761 83.7 100.0 
 Declined to participate 2,512 55.9 66.8 
 Agreed but withdrew 291 6.5 7.7 
 Agreed and completed 958 21.3 25.5 
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3.2 Representativeness of the GP sample 
Whenever possible, the study group of GPs should be compared with the population from 
which the GPs were drawn (the sample frame) to identify and, if necessary, adjust for any 
sample bias that may affect the findings of the study. Comparisons between the final GP 
sample and the sample frame are provided below. Weightings generated as a result of these 
comparisons and applied to the data are described in Section 3.3.  
Statistical comparisons, using the chi-square statistic (χ2) (significant at the 5% level), were 
made between BEACH participants, and all recognised GPs in the sample frame during the 
study period (Table 3.2). The GP characteristics data for BEACH participants were drawn 
from the GP profile questionnaire. DoHA provided the data for all GPs in the sample frame, 
drawn from Medicare claims data. 
Table 3.2 demonstrates that there were no significant differences in GP characteristics 
between the final sample of BEACH participants and all GPs in the sample frame, in terms of 
sex, age, state, place of graduation or practice location as classified by the Australian 
Standard Geographical Classification.  
Occasionally, the random sampling process produces a sample that may be slightly 
disproportionate to the national sample frame, which can then impact on the final 
representativeness of the BEACH participants. In 2010–11 the sample provided by DoHA 
and the final BEACH participant sample were both highly representative of the national 
sample frame (Table 3.3). 
 24 
Table 3.2: Comparison of BEACH participants and all active recognised GPs in Australia 
(the sample frame) 
Variable 
BEACH(a)(b)  Australia(a)(c) 
Number 
Per cent of GPs 
(n = 958)  Number 
Per cent of GPs 
(n = 19,428)  
Sex (χ2 = 0.1, p = 0.8)      
 Males 591 61.7  12,084 62.2 
 Females 367 38.3  7,344 37.8 
Age (χ2 = 6.9, p = 0.08)      
 < 35 years 62 6.5  1,330 6.8 
 35–44 years 159 16.7  3,858 19.9 
 45–54 years 330 34.7  6,219 32.0 
 55+ years 401 42.1  8,021 41.3 
 Missing 6   0  
Place of graduation (χ2 = 1.8 p = 0.2)      
 Australia 661 69.2  13,039 67.1 
 Overseas 294 30.8  6,389 32.9 
 Missing 3     
State (χ2 = 12.5, p = 0.09)      
 New South Wales 339 35.4  6,459 33.2 
 Victoria 234 24.4  4,870 25.1 
 Queensland 164 17.1  3,722 19.2 
 South Australia 76 7.9  1,629 8.4 
 Western Australia 90 9.4  1,797 9.2 
 Tasmania 27 2.8  515 2.7 
 Australian Capital Territory 25 2.6  298 1.5 
 Northern Territory 3 0.3  138 0.7 
ASGC (χ2 = 4.9, p = 0.3)      
 Major Cities of Australia 663 69.2  13,966 71.9 
  Inner Regional Australia 197 20.6  3,599 18.5 
  Outer Regional Australia 84 8.8  1,526 7.9 
  Remote Australia 11 1.2  228 1.2 
 Very Remote Australia 3 0.3  109 0.6 
 Unknown 0   1  
(a) Missing data removed. 
(b) Data drawn from the BEACH GP profile completed by each participating GP. 
(c) All GPs who claimed at least 375 MBS GP consultation services during the most recent 3-month Medicare Australia data period. 
Data provided by the Department of Health and Ageing. 
Note: ASGC – Australian Standard Geographical Classification. 
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Table 3.3: Comparison of all active recognised GPs in Australia (the sample frame), GPs in the 
sample from Medicare claims data (drawn by DoHA), and BEACH participants 2010–11 
 Sample frame  
(all Australia)(a)  
Sample from Medicare 
claims data(b)  BEACH participants  
Variable Number 
Per cent  
of GPs  Number 
Per cent  
of GPs  Number 
Per cent  
of GPs 
Sex (missing) (0)   (1)   (0)  
 Males 12,084 62.2  2,940 65.4  591 61.7 
 Females 7,344 37.8  1,552 34.6  367 38.3 
Age (missing) (0)   (1)   (6)  
 < 35 years 1,330 6.8  341 7.6  62 6.5 
 35–44 years 3,858 19.9  908 20.2  159 16.7 
 45–54 years 6,219 32.0  1,477 32.9  330 34.7 
 55+ years 8,021 41.3  1,766 39.3  401 42.1 
State (missing) (0)   (0)   (0)  
 New South Wales 6,459 33.2  1,490 33.2  339 35.4 
 Victoria 4,870 25.1  1,186 26.4  234 24.4 
 Queensland 3,722 19.2  816 18.2  164 17.1 
 South Australia 1,629 8.4  382 8.5  76 7.9 
 Western Australia 1,797 9.2  422 9.4  90 9.4 
 Tasmania 515 2.7  116 2.6  27 2.8 
 Australian Capital Territory 298 1.5  60 1.3  25 2.6 
 Northern Territory 138 0.7  21 0.5  3 0.3 
Total 19,428 100.0  4,493 100.0  958 100.0 
(a) Sample frame – all recognised (see ‘Glossary’) GPs in Australia who claimed at least 375 general practice service items in the previous 
quarter (from Medicare claims data). 
(b) Random sample of GPs from the sample frame, drawn from Medicare claims data and supplied by DoHA to approach for BEACH 
participation. 
GP activity in the previous quarter 
Data on the number of MBS general practice service items claimed in the previous quarter 
were also provided by DoHA for each GP in the samples drawn, and for all GPs (as a group) 
in the sample frame. These data were used to determine the ‘activity level’ of each GP.  
There were significant differences in the distribution of BEACH participants and non-
participants across activity levels. A greater proportion of participants than non-participants 
were in the 375–750 services and 750–1,500 services groups, and a smaller proportion in the 
high activity group (> 1,500 services) (Table 3.4).  
Participants had a significantly lower mean number of consultation items claimed in the 
previous quarter (1,311.9) compared with GPs who declined to participate (1,384.5) 
(p = 0.008; Table 3.4). Comparisons of the median number of claims for each group showed a 
difference of fewer than eight consultations per week (7.9), and a difference of 5.6 
consultations per week in the mean number.  
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GP activity in the previous year 
When comparing GP activity level in the previous 12 months, there was no significant 
difference between the proportions of participating and non-participating GPs in each of the 
claims categories (p = 0.094; Table 3.5). However, comparison of the median and mean 
number of claims for each group showed a difference in the median of 5.8 consultations per 
week (based on a difference of 306 per year), and a difference in the mean of 5.5 
consultations per week (based on 285 per year). 
Table 3.4: Quarterly activity level of participating and non-participating GPs 
Variable 
Participants(a)  
(n = 958)  
Non-participants(a)  
(n = 2,803) 
Number of GPs Per cent  Number of GPs Per cent 
Activity (χ2 = 8.3, p = 0.015)      
 375–750 services in previous quarter 228 23.8  566 20.2 
 750–1,500 services in previous quarter 417 43.5  1,198 42.7 
 > 1,500 services in previous quarter 313 32.7  1,039 37.1 
 Number of claims   Number of claims  
Mean activity level (t = 2.66, p = 0.008) 1,311.9 —  1,384.5 — 
Median activity level 1,136.0 —  1,239.0 — 
Standard deviation 719.2 —  732.3 — 
(a) Missing data removed. 
Table 3.5: Annual activity level of participating and non-participating GPs 
Variable 
Participants(a)  
(n = 958)  
Non-participants(a)  
(n = 2,803) 
Number of GPs Per cent  Number of GPs Per cent 
Activity (χ2 = 6.4, p = 0.093)      
 1–1,500 services in previous year 39 4.1  91 3.3 
 1,500–3,000 services in previous year 186 19.4  511 18.2 
 3,001–6,000 services in previous year 419 43.7  1,163 41.5 
 > 6,000 services in previous year 314 32.8  1,038 37.0 
 Number of claims   Number of claims  
Mean activity level (t = 2.57, p = 0.0103) 5,222.6 —  5,507.4 — 
Median activity level 4,634.0 —  4,940.0 — 
Standard deviation 2,882.0 —  2,933.0 — 
(a) Missing data removed. 
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3.3 Weighting the data 
Age–sex weights  
As described in Section 3.2, comparisons are made annually to test how representative 
BEACH participants are of the Australian sample frame. Occasionally, where participants in 
a particular age or sex group are over-represented or under-represented, GP age–sex weights 
are applied to the data sets in post-stratification weighting to achieve comparable estimates 
and precision. The BEACH participants were representative in all age and sex categories, but 
because there are always marginal (even if not statistically significant) differences, post-
stratification weighting was applied for consistency over recording years. 
Activity weights  
In BEACH, each GP provides details of 100 consecutive encounters. There is considerable 
variation among GPs in the number of services each provides in a given year. Encounters 
were therefore assigned an additional weight that was directly proportional to the activity 
level of the recording GP. GP activity level was measured as the number of MBS general 
practice service items claimed by the GP in the previous 12 months (data supplied by 
DoHA). 
Total weights  
The final weighted estimates were calculated by multiplying raw rates by the GP age–sex 
weight and the GP sampling fraction of services in the previous 12 months. Table 3.5 shows 
the precision ratio calculated before and after weighting the encounter data. 
3.4 Representativeness of the final encounter 
sample 
BEACH aims to gain a representative sample of GP–patient encounters. To assess the 
representativeness of the final weighted sample of encounters, the age–sex distribution of 
patients at weighted BEACH encounters with GP consultation service items claimed 
(excluding those with Department of Veterans’ Affairs (DVA) patients) was compared with 
that of patients at all encounters claimed as GP consultation service items through Medicare 
in the 2010–11 study period (data provided by DoHA).  
As shown in Table 3.6, there is an excellent fit of the BEACH (weighted) age-sex distribution 
with that of the MBS claims distribution, with precision ratios all within the 0.91–1.06 range. 
Even prior to the application of weightings, the range of raw precision ratios (0.86–1.12) 
indicates that the BEACH sample of encounters is a good representation of Australian  
GP–patient encounters, as no age–sex category varied by more than 20% (maximum variance 
14% in males aged 5–14 years) from the population distribution. 
The age–sex distribution of patients at BEACH encounters and for MBS GP consultation 
service item claims is shown graphically for all patients in Figure 3.1, for males in Figure 3.2, 
and for females in Figure 3.3. 
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Table 3.6: Age–sex distribution of patients at BEACH and MBS GP consultation service items 
Sex/age 
BEACH–raw(a)  BEACH–weighted(b)  Australia(c)  
Precision ratios 
(Australia = 1.00) 
Number 
Per cent  
(n = 79,739)  Number 
Per cent 
(n = 79,853)  
Per cent 
(n = 100,352,765)  Raw(a) Weighted(c) 
Male           
 < 1 year 876  1.1  850 1.1  1.1  1.00 0.96 
 1–4 years 2,033  2.6  2,123 2.7  2.8  0.91 0.95 
 5–14 years 2,255  2.8  2,450  3.1  3.3  0.86 0.93 
 15–24 years 2,419  3.0  2,676  3.4  3.2  0.95 1.05 
 25–44 years 6,229  7.8  6,624  8.3  8.7  0.90 0.95 
 45–64 years 8,822  11.1  9,413  11.8  11.8  0.94 1.00 
 65–74 years 4,784  6.0  4,998  6.3  5.9  1.02 1.06 
 75+ years 4,648  5.8  4,678  5.9  5.9  0.99 0.99 
Female           
 < 1 year 762  1.0  726  0.9  1.0  0.96 0.91 
 1–4 years 1,806  2.3  1,886  2.4  2.5  0.90 0.94 
 5–14 years 2,257 2.8  2,342  2.9  3.1  0.91 0.95 
 15–24 years 4,491 5.6  4,417  5.5  5.5  1.02 1.01 
 25–44 years 11,816 14.8  11,530  14.4  14.3  1.04 1.01 
 45–64 years 13,309 16.7  12,646  15.8  15.6  1.07 1.02 
 65–74 years 6,077 7.6  5,780  7.2  6.8  1.12 1.06 
 75+ years 7,155 9.0  6,713  8.4  8.6  1.04 0.98 
(a) Unweighted GP consultation Medicare service items only, excluding encounters with patients who hold a DVA Repatriation health card. 
(b) Calculated from BEACH weighted data, excluding encounters with patients who hold a DVA Repatriation health card. 
(c) MBS claims data provided by the Primary Care Division of the Department of Health and Ageing. 
Note: GP consultation Medicare services – see ‘Glossary’. Only encounters with a valid age and sex are included in the comparison. 
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 Figure 3.1: Age distribution of all patients at BEACH and MBS GP consultation services 2010–11 
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 Figure 3.2: Age distribution of male patients at BEACH and MBS GP consultation services 
2010–11 
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 Figure 3.3: Age distribution of female patients at BEACH and MBS GP consultation services 
2010–11 
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3.5 The weighted data set 
The final unweighted data set from the 13th year of collection contained encounters, reasons 
for encounters, problems and management/treatments. The apparent number of encounters 
and number of medications increased after weighting, and the number of reasons for 
encounter, problems managed, other treatments, referrals, imaging and pathology all 
decreased after weighting. Raw and weighted totals for each data element are shown in 
Table 3.7. The weighted data set is used for all analyses in the remainder of this report. 
Table 3.7: The BEACH data set, 2010–11 
Variable Raw Weighted 
General practitioners 958 958.0 
Encounters 95,800 95,839.0 
Reasons for encounter 149,503 149,005.1 
Problems managed 150,909 146,141.1 
Medications 100,584 100,816.6 
Other treatments(a) 56,129 54,279.1 
Referrals 51,896 50,235.0 
Pathology 14,494 13,526.1 
Imaging 9,773 9,369.9 
Other investigations 46,827 43,313.0 
(a) Other treatments excludes injections for immunisations/vaccinations (raw n = 4,233, weighted  
n = 4,044) (see Chapter 10). 
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4 The participating GPs 
This chapter reports data collected between April 2010 and March 2011 about the 
participating GPs and their practices from the 13th year of the BEACH program. Data on GP 
and practice characteristics are reported for each year from 2001–02 to 2010–11 in the 10-year 
summary report A decade of Australian general practice activity 2001–02 to 2010–11.1 
4.1 Characteristics of the GP participants 
All participants returned a GP profile questionnaire, although some were incomplete. The 
results are provided in Table 4.1. Of the 958 participants: 
• 62% were male, and 42% were aged 55 years and over 
• Nearly two-thirds had been in general practice for more than 20 years 
• 69% had graduated in Australia 
• 37% spent more than 40 hours each week on direct patient care services (mean hours 
worked was 38.4; median was 39.0 hours)  
• 27% conducted some consultations in a language other than English 
• more than 50% were Fellows of the RACGP, and 9% were Fellows of the Australian 
College of Rural and Remote Medicine (ACRRM) 
• 26% bulk-billed Medicare for all patients and 73% bulk-billed for selected patients; only 
1% did not bulk bill Medicare for any patient consultations 
• 56% had provided care in a residential aged care facility in the previous month 
• 69% practised in Major cities (classified using the Australian Standard Geographical 
Classification) 
• 39% were in practices of fewer than five individual GPs, and 22% were in practices of 10 
or more individual GPs 
• 61% were in practices of fewer than five full-time equivalent GPs 
• 81% of the GPs worked in a practice that employed practice nursing staff – for more than 
half of these, (56.6%) the practice employed less than two full-time equivalents  
(35–45 hours per week)  
• 87% worked in an accredited practice 
• more than half (58.2%) had a co-located pathology laboratory or collection centre  
• 42.6% worked in a practice that provided their own or cooperative after-hours care, and 
52% in a practice that used a deputising service for after-hours patient care (multiple 
responses allowed) 
• 62% worked in a practice teaching undergraduates, junior doctors, registrars, or all three. 
Those interested in the clinical activity of overseas trained doctors will find more 
information in Bayram et al. (2007) Clinical activity of overseas trained doctors practising in 
general practice in Australia.56 Readers interested in the effects of GP age on clinical practice 
will find more information in Charles et al. (2006) The independent effect of age of general 
practitioner on clinical practice.57 For more information about the effect of the sex of the GP on 
clinical practice see Harrison et al. (2011) Sex of the GP.58  
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Table 4.1: Characteristics of participating GPs and their practices 
GP characteristic Number(a) 
Per cent of GPs(a) 
(n = 958) 
Sex (missing = 0)   
 Male 591 61.7 
 Female 367 38.3 
Age (missing = 6)   
 < 35 years 62 6.5 
 35–44 years 159 16.7 
 45–54 years 330 34.7 
 55+ years 401 42.1 
Years in general practice (missing = 8)   
 < 2 years 9 1.0 
 2–5 years 81 8.5 
 6–10 years 94 9.9 
 11–19 years 155 16.3 
 20+ years 611 64.3 
Place of graduation (missing = 3)   
 Australia 661 69.2 
 Overseas 294 30.8 
 Asia 116 12.2 
 United Kingdom 71 7.4 
 Africa 55 5.8 
 Europe 28 2.9 
 New Zealand 13 1.4 
 Other 11 1.2 
Direct patient care hours (worked) per week (missing = 16)   
 ≤ 10 hours 6 0.6 
 11–20 hours 82 8.7 
 21–40 hours 509 54.0 
 41–60 hours 322 34.2 
 61+ hours 23 2.4 
Consult in languages other than English (missing = 5)   
 < 25% of consultations 209 21.9 
 25–50% of consultations 28 2.9 
 > 50% of consultations 18 1.9 
Currently in general practice training program (missing = 8) 30 3.2 
Fellow of RACGP (missing = 4) 497 52.1 
Fellow of ACRRM (missing = 24) 85 9.1 
(continued) 
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Table 4.1 (continued): Characteristics of participating GPs and their practices 
GP characteristic Number(a) 
Per cent of GPs(a) 
 (n = 958) 
Bulk-billing(b) (missing = 4)   
 All patients 249 26.1 
 Some patients 695 72.9 
 No patients 10 1.1 
Patient care provided in previous month(b)    
 In a residential aged care facility (missing = 4) 531 55.7 
 As a salaried/sessional hospital medical officer (missing = 8) 112 11.8 
Practice location by RRMA (missing = 0)   
 Capital 614 64.1 
 Other metropolitan 58 6.1 
 Large rural 59 6.2 
 Small rural 69 7.2 
 Other rural 142 14.8 
 Remote central 8 0.8 
 Other remote, offshore 8 0.8 
Practice location by ASGC remoteness structure (missing = 0)   
 Major cities 663 69.2 
 Inner regional 197 20.6 
 Outer regional 84 8.8 
 Remote 11 1.2 
 Very remote 3 0.3 
Size of practice – number of individual GPs (missing = 12)   
 Solo 102 10.8 
 2–4  269 28.4 
 5–9  365 38.6 
 10–14 140 14.8 
 15+  70 7.4 
Size of practice – full-time equivalent GPs (missing = 28) 
(unspecified = 12) (d)   
 < 1 7 0.8 
 1.0–1.99 151 16.5 
 2.0–2.99 135 14.7 
 3.0–3.99 155 16.9 
 4.0–4.99 110 12.0 
 5.0–9.99 272 29.6 
 10.0–14.99 63 6.9 
 15+ 25 2.7 
(continued) 
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Table 4.1 (continued): Characteristics of participating GPs and their practices 
GP characteristic Number(a) 
Per cent of GPs(a) 
 (n = 958) 
Practice nurse at major practice address (missing = 19) 747 79.6 
Number of individual practice nurses (missing = 25)   
 0 192 20.6 
 1 184 19.7 
 2  191 20.5 
 3 145 15.5 
 4–5  156 16.7 
 6+ 65 7.0 
Number of full-time equivalent practice nurses (missing = 40;  
unspecified = 14)(d)   
 0 192 21.2 
 < 1(d) 90 10.0 
 1.0–1.99  313 34.6 
 2.0–2.99 188 20.8 
 3.0–3.99 68 7.5 
 4.0+ 53 5.9 
Accredited practice (missing = 10) 828 87.3 
Co-located services(c) (missing = 4)   
 Pathology laboratory/collection centre 555 58.2 
 Psychologist 439 46.0 
 Physiotherapist 331 34.7 
 Medical specialist 215 22.5 
 Imaging 168 17.6 
After-hours arrangements(b) (missing = 4)   
 Practice does own and/or cooperative with other practices 406 42.6 
  Practice does its own 284 29.8 
  Cooperative with other practices 136 14.3 
 Deputising service 497 52.1 
 Other arrangement 94 9.9 
Major practice a teaching practice(b) (missing = 2) 594 62.1 
 Not a teaching practice 362 37.9 
 Yes – for undergraduates 507 53.0 
 Yes – for junior doctors 108 11.3 
 Yes – for registrars 335 35.0 
(a) Missing data removed. 
(b) Multiple responses allowed. 
(c) Services located/available on the same premises, in the same building or within 50 metres, available on a daily or regular basis. 
(d) 12 GPs answered ’2’ or more to number of individual GPs but ‘0’ to FTE – these were tabulated as ‘unspecified’ and not included in the 
denominator as numerators could not be determined; 4 GPs answered ‘1’ to individuals but ‘0’ to FTE – these were included in the ‘< 1’ FTE 
group. 14 GPs answered ’2’, or more to individual practice nurse but ‘0’ to FTE - these are tabulated as ‘unspecified’ and not included in the 
denominator; 15 GPs answered ‘1’ to individuals but ‘0’ to FTE – these were included in the ‘< 1’ FTE group. 
Note: RRMA – Rural, Remote and Metropolitan Areas classification; ASGC – Australian Standard Geographical Classification;  
RACGP – Royal Australian College of General Practitioners; ACRRM – Australian College of Rural and Remote Medicine. 
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4.2 Computer use at GP practices 
As computers are increasingly being used by GPs in their clinical activity, the GP profile 
questionnaire was redesigned in 2010–11 so that more comprehensive information could be 
collected about the uses to which computers are put in a general practice clinical 
environment (see Appendix 2). In particular, more specific information was collected about 
pathology and imaging test ordering and receipt of results, and whether the medical records 
used were paper only, a mix of paper and electronic medical records, or whether the practice 
was completely paperless in this regard. 
Table 4.2 shows the proportion of individual participating GPs who used computers for each 
of nine listed activities. 
• Only 4.4% of GPs did not use a computer at all for clinical purposes. 
• Computers were used mainly for prescribing, receiving pathology results electronically 
and for internet use. 
• 93.2% of GPs were producing prescriptions electronically. 
• 91.1% were receiving pathology results online, 81.7% were producing and printing 
pathology orders, and 35.3% were ordering pathology electronically. 
• 79.4% were receiving imaging results online, 74.4% were producing and printing 
imaging orders, and 22.2% were ordering imaging tests electronically. 
• Almost two-thirds (64.7) reported they had electronic medical records exclusively (that 
is, were paperless). 
• Over one-quarter (28.8%) reported maintaining a hybrid record where some patient 
information is kept electronically and some on paper records (for the same patients). 
Table 4.2: Computer applications available/used at major practice address 
Computer use Number 
Per cent of GPs  
(n = 958)(a) 
Not at all 42 4.4 
Internet/email only 5 0.5 
Prescribing 892 93.2 
Internet 811 84.7 
Email 662 65.0 
Pathology ordering (online)(b) 338 35.3 
Produce/print pathology orders(b)  782 81.7 
Pathology results receipt (on line)(b) 872 91.1 
Imaging ordering (online)(b) 212 22.2 
Produce/print imaging orders(b)  712 74.4 
Imaging results receipt (on line)(b) 760 79.4 
Medical records – complete (paperless) 619 64.7 
Partial/hybrid records 276 28.8 
Paper records only 63 6.6 
(a) Missing data removed (n = 1). 
(b) Multiple responses allowed. 
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Further information about reported individual GP use of computers at the practice can be 
found in Henderson et al. (2006) Extent and utilisation of computerisation in Australian general 
practice.59 Those interested in the effect of computerisation on quality of care in general 
practice will find more detailed information in Henderson (2007) The effect of computerisation 
on the quality of care in Australian general practice.60 
4.3 Changes in characteristics of the GPs over the 
decade 2001–02 to 2010–11 
Changes over the decade 2001–02 to 2010–11 are described in detail in the accompanying 
report A decade of Australian general practice activity 2001–02 to 2010–11.1 Briefly, the major 
changes in the characteristics of the participating GP were: 
• the proportion of GP participants who were female increased over time 
• the proportion of GPs who were younger than 44 years decreased, whereas the 
proportion aged 45 years or more increased over the decade 
• reflecting the increase in the age of GP participants, the proportion who had worked in 
general practice for more than 20 years also increased significantly over time 
• the proportion of GPs who graduated from their primary medical degree in Australia 
decreased over the decade 
• the proportion of GPs who provide < 25% of their consultations in a language other than 
English increased 
• the proportion of participants holding the Fellowship of the RACGP increased over the 
decade 
• fewer practices are providing after-hours care on their own, or in cooperation with other 
practices, but more practices are using deputising services for after-hours care 
• computers have become increasingly available at practices, and their use for clinical 
activity also continues to increase.  
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5 The encounters 
This chapter describes the content and type of encounters recorded in the 2010–11 
BEACH year. Data about the encounters are also reported for each year from 2001–02 to 
2010–11 in the 10-year report A decade of Australian general practice activity 2001–02 to  
2010–11.1  
5.1 Content of the encounters 
In 2010–11, details of 95,839 encounters (weighted data) were available for 958 GPs. A 
summary of these encounters is provided as Table 5.1. Reasons for encounter (RFEs) and 
problems managed are expressed as rates per 100 encounters. Each management action is 
presented in terms of both a rate per 100 encounters and a rate per 100 problems managed, 
with 95% confidence limits. 
• On average, patients gave 156 RFEs, and GPs managed about 153 problems per 
100 encounters. 
• Chronic problems accounted for 34.8% of all problems managed, being managed at a 
rate of 53 chronic problems per 100 encounters. 
• New problems accounted for 38% of all problems, being managed at a rate of 57.8 per 
100 encounters. 
• Work-related problems were managed at a rate of 2.5 per 100 encounters. 
• Medications were the most common treatment choice, generated at a rate of 69.0 per 100 
problems managed. Most of these medications were prescribed (55.8 per 100 problems), 
rather than supplied by the GP (6.8 per 100) or advised for over-the-counter purchase 
(6.4 per 100). 
• Clinical treatments (such as advice and counselling) were provided at a rate of 23 per 
100 problems, and procedures undertaken at a rate of 11 per 100 problems. 
• For every 100 problems managed there were 9 referrals for care to other providers, most 
often to medical specialists (6 referrals per 100 problems), and less often to allied health 
services (3 referrals per 100 problems). 
• On average GPs ordered 30 pathology tests/batteries of tests and 6 imaging tests in the 
management of every 100 problems (Table 5.1). 
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Table 5.1: Summary of morbidity and management 
Variable Number 
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems  
(n = 146,141) 
95% 
LCL 
95% 
UCL 
General practitioners 958 — — — — — — 
Encounters 95,839 — — — — — — 
Reasons for encounter 149,005 155.5 153.5 157.5 — — — 
Problems managed 146,141 152.5 150.2 154.7 — — — 
 New problems 55,410 57.8 56.4 59.3 37.9 36.9 38.9 
 Chronic problems 50,911 53.1 51.2 55.0 34.8 33.9 35.8 
 Work-related 2,393 2.5 2.3 2.7 1.6 1.5 1.8 
Medications 100,817 105.2 102.8 107.6 69.0 67.6 70.3 
 Prescribed 81,542 85.1 82.9 87.3 55.8 54.5 57.1 
 GP-supplied 9,903 10.3 9.5 11.2 6.8 6.2 7.3 
 Advised OTC 9,371 9.8 9.0 10.5 6.4 5.9 6.9 
Other treatments 50,235 52.4 49.8 55.1 34.4 32.7 36.0 
 Clinical* 34,019 35.5 33.2 37.8 23.3 21.8 24.8 
 Procedural* 16,216 16.9 16.1 17.8 11.1 10.6 11.6 
Referrals 13,526 14.1 13.5 14.7 9.3 8.9 9.6 
 Medical specialist* 8,248 8.6 8.2 9.0 5.6 5.4 5.9 
 Allied health services* 4,039 4.2 3.9 4.5 2.8 2.6 2.9 
 Hospital* 364 0.4 0.3 0.4 0.2 0.2 0.3 
 Emergency department* 291 0.3 0.3 0.4 0.2 0.2 0.2 
 Other referrals* 584 0.6 0.5 0.7 0.4 0.3 0.5 
Pathology 43,313 45.2 43.4 47.0 29.6 28.6 30.7 
Imaging 9,370 9.8 9.4 10.2 6.4 6.1 6.7 
Other investigations 697 0.7 0.7 0.8 0.5 0.4 0.5 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; OTC – over-the-counter. 
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5.2 Encounter type 
During the first 7 years of the BEACH program, where one (or more) MBS/DVA item 
number was claimable for the encounter, GP participants were instructed to record only one 
item number. Where multiple item numbers (for example, an A1 item such as ‘standard 
surgery consultation’ and a procedural item number) were claimable for an encounter, GPs 
were instructed to record the lower of the item numbers (usually an A1 item number). 
Changes to the BEACH form were made in the 2005–06 BEACH year to capture practice 
nurse activity associated with GP–patient consultations. One of these changes was to allow 
GPs to record up to three Medicare item numbers per encounter. 
For comparability with earlier years, in Tables 5.3, 5.4 and 5.5 only one item number per 
Medicare/DVA-claimable encounter was counted. Selection of one item number was 
undertaken on a priority basis: consultation item numbers override incentive item numbers, 
which override procedural item numbers, which override other Medicare item numbers. 
Table 5.6 provides a breakdown of all item numbers recorded by the GPs. Chapter 13 gives a 
more specific description for each of the practice nurse Medicare item numbers recorded. 
Table 5.2 provides an overview of the MBS/DVA item numbers recorded in BEACH in  
2010–11. At least one MBS/DVA item number was recorded at 83,976 encounters (87.6% of 
all BEACH encounters). A single item number was recorded at three-quarters (76.8%) of 
BEACH encounters said to be claimable from the MBS/DVA. 
Table 5.2: Overview of MBS items recorded 
Variable Number 
Per cent of MBS/DVA 
encounters 
(n = 83,976) 
Encounters at which one MBS item was recorded 64,514 76.8 
Encounters at which two MBS items were recorded 18,210 21.7 
Encounters at which three MBS items were recorded 1,252 1.5 
Total encounters at which at least one item was recorded 83,976 100.0 
Note: MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs. 
In previous years we have reported the breakdown of MBS/DVA services into groups for 
GPs and practice nurses in Table 5.3. The MBS has continued to expand, with some services 
provided by Aboriginal health workers and other allied health services (e.g. physiotherapists 
and speech pathologists) claimable through the MBS. In addition, some items can be claimed 
by combinations of these health professionals, for example practice nurses or Aboriginal 
health workers. To account for these changes, we have modified Table 5.3 to group 
MBS/DVA items according to whether the service was provided by a GP or an ‘other health 
professional’. The group for other health professionals includes practice nurses, Aboriginal 
health workers and allied health services.  
Of the 83,976 MBS/DVA items of service recorded (counting only one item number per 
encounter), 95.4% of encounters related to GP items of service. Items with other health 
professionals not accompanied by a GP item of service were recorded at 0.1% of encounters. 
Direct encounters are defined as those where the patient was physically seen by the GP. At 
indirect encounters, the patient was not physically seen by the GP. 
More detail about item numbers recorded for practice nurse services is given in Chapter 13. 
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Table 5.3: Breakdown of MBS/DVA items of service according to provider (counting one item 
number per encounter) 
Type of encounter Number 
Per cent of 
encounters(a) 
(n = 87,953) 95% LCL 95% UCL 
MBS/DVA GP item of service  83,903 95.4 95.0 95.8 
MBS/DVA item of service with other health professional(b)  
(no related GP item) 73 0.1 0.0 0.1 
Direct encounters  29 0.0 0.0 0.1 
Indirect encounters  37 0.0 0.0 0.1 
Unspecified as direct or indirect 7 0.0 0.0 0.0 
MBS/DVA item of service (all encounters)(b) 83,976 95.5 95.1 95.9 
(a) Missing data removed from analysis (n = 7,886). 
(b) ‘Other health professional’ includes practice nurses, allied health services and Aboriginal health workers. 
(c) Includes direct encounters at which either a GP or a practice nurse item was recorded. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs. 
Table 5.4 reports the breakdown of encounter type by payment source, counting a single 
Medicare item number per encounter (where applicable).  
• Indirect encounters (where the patient was not seen by the GP) accounted for 1.5%, and 
direct encounters for 98.5% of encounters at which a payment source was recorded. 
• The vast majority of all direct encounters (95.4%) were claimable either through 
Medicare or the DVA. 
• Direct encounters where the GP indicated that no charge was made occurred rarely, 
accounting for 0.4% of encounters. 
• Encounters claimable through workers compensation accounted for 1.9% of encounters. 
• Encounters claimable through other sources (e.g. hospital-paid encounters) accounted 
for 0.8% of encounters. 
Table 5.4: Type of encounter at which a source of payment was recorded for the encounter 
(counting one item number per encounter) 
Type of encounter Number 
Per cent of 
encounters(a) 
(n = 87,953) 
95% 
LCL 
95% 
UCL 
Per cent of direct 
encounters 
(n = 86,652) 
Indirect encounters(b) 1,295 1.5 1.2 1.7 — 
Direct encounters 86,652 98.5 98.3 98.8 100.0 
 MBS/DVA items of service (direct encounters only)(c) 83,920 95.4 95.0 95.8 96.8 
 Workers compensation 1,703 1.9 1.8 2.1 2.0 
 Other paid (hospital, state, etc) 659 0.8 0.6 0.9 0.8 
 No charge 370 0.4 0.3 0.5 0.4 
Other health professional only items (unspecified as 
direct or indirect) 7 0.0 0.0 0.0 — 
Total 87,953 100.0 — — — 
(a) Missing data removed from analysis (n = 7,886). 
(b) Twelve encounters involving chronic disease management or case conference items were recorded as indirect encounters. 
(c) Includes direct encounters at which either a GP or an item with an other health professional (or both) was recorded. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs. 
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Table 5.5 provides a summary of the MBS items recorded in BEACH, counting one item 
number per encounter. This provides comparable data about item numbers recorded to those 
reported in previous years.  
• Standard surgery consultations accounted for 83% of MBS/DVA-claimable GP 
consultations, and for 79% of all encounters for which a payment source was recorded.  
• 8% of MBS/DVA claimable encounters were long or prolonged surgery consultations. 
• Home or institution visits, and visits at residential aged care facilities were all relatively 
rare, together accounting for 2.6% of MBS/DVA claimable encounters. 
• About 1% of encounters were claimable as GP mental health care items, with another 1% 
of items claimed as chronic disease management items. Health assessments and case 
conference items were not recorded often.  
Table 5.5: Summary of GP only MBS/DVA items recorded (counting one item number per 
encounter) 
MBS/DVA item Number 
Rate per 100 
encounters(a) 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Per cent of 
Medicare-paid  
GP items  
(n = 83,903) 
Short surgery consultations 1,910 2.2 1.9 2.5 2.3 
Standard surgery consultations 69,299 78.8 77.7 79.8 82.6 
Long surgery consultations 6,545 7.4 6.9 8.0 7.8 
Prolonged surgery consultations 410 0.5 0.4 0.6 0.5 
Home or institution visits (excluding RACF) 990 1.1 0.8 1.5 1.2 
Residential aged care facility (RACF) 1,292 1.5 1.1 1.8 1.5 
Health assessments 309 0.4 0.3 0.4 0.4 
Chronic disease management items 871 1.0 0.9 1.1 1.0 
Case conferences 3 0.0 0.0 0.0 0.0 
GP mental health care 1,022 1.2 1.0 1.3 1.2 
Attendances associated with practice incentive 
payments 
150 0.2 0.1 0.2 0.2 
Other items 1,102 1.3 1.0 1.5 1.3 
Surgical operations 281 0.3 0.2 0.4 0.3 
Therapeutic procedures 447 0.5 0.4 0.6 0.5 
Acupuncture 85 0.1 0.0 0.2 0.1 
Other items 289 0.3 0.2 0.5 0.3 
Total MBS/DVA items of service (GPs only) 83,903 95.4 95.0 95.8 100.0 
(a) Encounters with missing payment source were removed from analysis (n = 7,886). Denominator used for analysis = 95,839. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs;  
GP – general practitioner; RACF – residential aged care facility. 
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Table 5.6 provides the distribution of all Medicare item numbers recorded across Medicare 
item number groups. Overall, there were 104,691 MBS item numbers recorded at 83,976 
Medicare/DVA claimable encounters in 2010–11. This equated to an average of 1.2 items 
recorded at each encounter claimable through Medicare/DVA.  
Surgery consultations (including short, standard, long and prolonged) were the most 
commonly recorded type of item number, at 93% of the encounters where at least one item 
was recorded. They accounted for 75% of all MBS items recorded in BEACH. 
The second most commonly recorded were items for bulk-billed incentive payments, which 
accounted for 14% of all items recorded. Items for hospital, residential aged care and home 
visits together accounted for 2% of all MBS items. Items with practice nurses, Aboriginal 
health workers or allied health services accounted for 3% of all MBS items, and were 
recorded at 3.7% of encounters at which at least one MBS item was recorded. For a more 
detailed breakdown of practice nurse item numbers, and related data on practice nurse 
activity, refer to Chapter 13. 
Table 5.6: Distribution of all Medicare item numbers across item number groups 
Items/encounters 
All MBS items(a) 
(n = 104,691) 
 At least one item recorded(b) 
(n = 83,976)  
Number Per cent  Number Per cent  
95% 
LCL 
95% 
UCL 
Surgery consultations 78,163 74.7  78,163 93.1 92.4 93.8 
Home, institution and residential aged care visits 2,283 2.2  2,283 2.7 2.1 3.3 
Health assessments 379 0.4  378 0.5 0.4 0.5 
Chronic disease management items (including 
case conferences) 1,559 1.5  1,124 1.3 1.2 1.5 
Attendances associated with practice incentive 
payments 179 0.2  179 0.2 0.2 0.3 
Acupuncture 85 0.1  85 0.1 0.0 0.2 
Bulk-billed incentive payment 15,014 14.3  15,014 17.9 15.9 19.8 
Practice nurse/Aboriginal health worker/allied 
health worker services 3,110 3.0  3,068 3.7 3.2 4.1 
Diagnostic procedures and investigations 506 0.5  498 0.6 0.5 0.7 
Therapeutic procedures 594 0.6  582 0.7 0.5 0.9 
Surgical operations 1,043 1.0  1,017 1.2 1.1 1.4 
Diagnostic imaging services 22 0.0  21 0.0 0.0 0.1 
Pathology services 214 0.2  203 0.2 0.2 0.3 
GP mental health care items 1,226 1.2  1,226 1.5 1.3 1.6 
Other items 311 0.3  311 0.4 0.2 0.5 
Total items 104,691 100.0  83,976 — — — 
(a) Up to three MBS items could be recorded at each encounter.  
(b) Identifies encounters where at least one item from a MBS group was recorded. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule. 
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5.3 Consultation length 
In a subsample of 32,257 BEACH encounters containing start and finish times for all 
MBS/DVA-claimable encounters, the mean length of consultation in 2010–11 was 
15.0 minutes (95% CI: 14.8–15.3). The median length was 13.0 minutes (results not tabled). 
For A1 MBS/DVA-claimable encounters, the mean length of consultation in 2010–11 was 
14.7 minutes (95% CI: 14.4–15.0), and the median length was 13.0 minutes (results not 
tabled). Methods describing the substudy from which data on consultation length are 
collected are described in Section 2.6. 
The determinants of consultation length were investigated by Britt et al. (2004) in 
Determinants of GP billing in Australia: content and time61 and Britt et al. (2005) in Determinants 
of consultation length in Australian general practice.62  
5.4 Changes in the encounters over the decade 
2001–02 to 2010–11 
The companion report A decade of Australian general practice activity 2001–02 to 2010–11,1 
provides an overview of changes in general practice encounters over the last decade. The 
major changes between 2001–02 and 2010–11 are summarised below. 
• There was an increase in the average number of problems managed at encounter, from 
144 per 100 encounters in 2001–02 to 153 in 2001–11. This change was reflected in an 
increase in the number of chronic problems managed per 100 encounters. 
• The number of work-related problems managed marginally decreased over the decade 
from 3.0 to 2.5 per 100 encounters.  
Of the encounters claimable from Medicare/DVA: 
• short surgery consultations as a proportion of all Medicare/DVA claimed consultations 
increased over the study period 
• the proportion designated chronic disease management items or health assessments both 
increased significantly. 
The changes in management actions described below are measured in terms of rates per 100 
encounters. As there was a significant increase in the number of problems managed at 
encounters, it may be more informative to consider changes in management actions in terms 
of rates per 100 problems managed as described in Section 8.1. 
• The number of medications supplied direct to the patient by the GP significantly 
increased from 7.6 to 10.3 per 100 encounters, there was no significant change in the 
number prescribed or advised for over-the-counter purchase.  
• The number of procedures undertaken per 100 encounters rose significantly from 13.8 to 
16.9 per 100 encounters.  
• There was an increased rate of referrals, which was reflected in increases in referrals to 
medical specialists, allied health services, emergency departments and ‘other’ referrals.  
• Pathology test/battery order rates increased by nearly 50%. Orders for imaging tests also 
increased.  
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6 The patients 
This chapter reports data collected between April 2010 and March 2011 about the 
characteristics of patients at GP encounters and their reasons for encounter, from the 13th year 
of the BEACH program. Data on patient characteristics and reasons for encounter are 
reported for each year from 2001–02 to 2010–11 in the 10-year summary report A decade of 
Australian general practice activity 2001–02 to 2010–11.1 
6.1 Age–sex distribution of patients at encounter 
The age–sex distribution of patients at the 95,839 encounters is shown in Figure 6.1. Females 
accounted for the greater proportion (57.1%) of encounters (Table 6.1). This was reflected 
across all age groups except for children aged less than 15 years (Figure 6.1). 
Patients aged less than 25 years accounted for 20.6% of encounters; those aged 25–44 years 
for 22.8%; those aged 45–64 years accounted for 27.7% and those aged 65 years and over for 
29.0% of encounters (Table 6.1). 
 
 
0
5
10
15
20
25
30
Female 0.9 2.2 2.7 5.4 14.3 15.5 7.0 9.2
Male 1.0 2.4 2.8 3.2 8.5 12.1 6.3 6.5
< 1 1–4 5–14 15–24 25–44 45–64 65–74 75+
 
 
Note: Missing data removed. The distributions will not agree perfectly with those in Table 6.1 because of missing data in either age or  
sex fields. 
Figure 6.1: Age–sex distribution of patients at encounter 
 
The relationship between patient age, patient general practice attendance rates and the age 
distribution of the Australian population was reported in General practice activity in Australia, 
health priorities and policies 1998 to 2008.63  
Per cent 
Age group (years) 
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6.2 Other patient characteristics 
Table 6.1 summarises other characteristics of the patients at GP encounters. In summary: 
• the patient was new to the practice at 7.3% of encounters 
• nearly half of the encounters were with patients who held a Commonwealth concession 
card (44.9%) and/or a Repatriation health card (2.5%) 
• at 10.7 % of encounters the patient was from a non-English-speaking background 
• at 1.2% of encounters the patient identified themselves as an Aboriginal or Torres Strait 
Islander person. 
Table 6.1: Characteristics of the patients at encounters 
Patient characteristics Number 
Per cent of encounters 
(n = 95,839) 
95% 
LCL 
95%  
UCL 
Sex (missing)(a) (888) — — — 
 Males 40,717 42.9 42.0 43.7 
 Females 54,234 57.1 56.3 58.0 
Age group (missing)(a) (771) — — — 
 < 1 year 1,757 1.8 1.7 2.0 
 1–4 years 4,348 4.6 4.3 4.9 
 5–14 years 5,240 5.5 5.2 5.8 
 15–24 years 8,247 8.7 8.3 9.1 
 25–44 years 21,654 22.8 22.0 23.5 
 45–64 years 26,298 27.7 27.1 28.2 
 65–74 years 12,608 13.3 12.7 13.8 
 75+ years 14,915 15.7 14.8 16.6 
New patient to practice (missing)(a) (1,298) — — — 
 New patient to practice 6,871 7.3 6.6 7.9 
 Patient seen previously 87,670 92.7 92.1 93.4 
Commonwealth concession card status (missing)(a) (7,570) — — — 
 Has a Commonwealth concession card 39,618 44.9 43.3 46.4 
 No Commonwealth concession card 48,650 55.1 53.6 56.7 
Repatriation health card status (missing)(a) (9,187) — — — 
 Has a repatriation health card 2,170 2.5 2.3 2.7 
 No repatriation health card 84,482 97.5 97.3 97.7 
Language status (missing)(a) (9,153) — — — 
 Non-English-speaking background (b) 9,244 10.7 8.9 12.5 
 English-speaking background 77,442 89.3 87.5 91.1 
Indigenous status (missing)(a) (9,218) — — — 
 Aboriginal and/or Torres Strait Islander (C) 1,042 1.2 0.9 1.5 
 Non-Indigenous 85,578 98.8 98.5 99.1 
(a) Missing data removed. 
(b) Speaks a language other than English as their primary language at home 
(c) Self identified  
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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6.3 Patient reasons for encounter 
International interest in reasons for encounter (RFEs) has developed over the past three 
decades. RFEs reflect the patient’s demand for care and can provide an indication of service 
use patterns, which may benefit from intervention on a population level.64  
RFEs are those concerns and expectations that patients bring to the GP. Participating GPs 
were asked to record at least one and up to three patient RFEs in words as close as possible 
to those used by the patient, before the diagnostic or management process had begun. These 
reflect the patient’s view of their reasons for consulting the GP. RFEs can be expressed in 
terms of one or more symptoms (for example, ‘itchy eyes’, ‘chest pain’), in diagnostic terms 
(for example, ‘about my diabetes’, ‘for my hypertension’), a request for a service (‘I need 
more scripts’, ‘I want a referral’), an expressed fear of disease or a need for a check-up. 
Patient RFEs can have a one-to-one, one-to-many, many-to-one or many-to-many 
relationship to problems managed. That is, the patient may describe a single RFE that relates 
to a single problem managed at the encounter, one RFE that relates to multiple problems, 
multiple RFEs that relate to a single problem managed, or multiple RFEs that relate to 
multiple problems managed at the encounter. 
Number of reasons for encounter 
There were 149,005 RFEs recorded at 95,839 encounters in 2010–11. At 57.6% of encounters 
only one RFE was recorded, at 29.4% of encounters two RFEs were recorded and at 13.0% of 
encounters three RFEs were recorded (Table 6.2). Patients presented on average with 155.5 
RFEs per 100 encounters, or about one and a half RFEs per encounter (Table 6.3). 
Table 6.2: Number of patient reasons for encounter 
Number of RFEs at encounter 
Number of encounters 
(n = 95,839) 
Per cent of 
encounters 
95% 
LCL 
95% 
UCL 
One RFE 55,173 57.6 56.3 58.8 
Two RFEs 28,166 29.4 28.7 30.1 
Three RFEs 12,500 13.0 12.3 13.8 
Total 95,839 100.0 — — 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit. 
Reasons for encounter by ICPC-2 component 
The distribution of patient RFEs by ICPC-2 component is presented in Table 6.3, expressed as 
a percentage of all RFEs and as a rate per 100 encounters with 95% confidence limits. In the 
‘diagnosis, disease’ group we provide data about infections, injuries, neoplasms, congenital 
anomalies and ‘other’ diagnoses.  
Over four out of ten (43.0%) patient RFEs were expressed in terms of symptoms or 
complaints (for example, ‘tired’, ‘fever’). RFEs were described in diagnostic terms for 19.9% 
of RFEs (for example, ‘about my diabetes’, ‘for my depression’). The remaining 37.2% of 
RFEs were described in terms of processes of care, such as requests for a health check, to 
renew scripts, to get a referral, to find out test results or to get a medical certificate. 
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Table 6.3: Patient reasons for encounter by ICPC-2 component 
ICPC-2 component Number 
Per cent of  
total RFEs 
(n = 149,005) 
Rate per 100 
encounters 
(n = 95,839) 
95%  
LCL 
95%  
UCL 
Symptoms and complaints 64,036 43.0 66.8 64.7 68.9 
Diagnosis, diseases 29,606 19.9 30.9 29.4 32.4 
 Infections 7,438 5.0 7.8 7.3 8.3 
 Injuries 4,252 2.9 4.4 4.2 4.7 
 Neoplasms 1,059 0.7 1.1 1.0 1.2 
 Congenital anomalies 234 0.2 0.2 0.2 0.3 
 Other diagnoses, diseases 16,622 11.2 17.3 16.3 18.4 
Diagnostic and preventive procedures 24,101 16.2 25.1 24.1 26.2 
Medications, treatments and therapeutics 13,901 9.3 14.5 13.8 15.2 
Results 7,678 5.2 8.0 7.5 8.5 
Referrals and other RFEs 7,198 4.8 7.5 7.1 7.9 
Administrative 2,487 1.7 2.6 2.4 2.8 
Total RFEs 149,005 100.0 155.5 153.5 157.5 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit. 
Reasons for encounter by ICPC-2 chapter 
The distribution of patient RFEs by ICPC-2 chapter and the most common RFEs within each 
chapter are presented in Table 6.4. Each chapter and individual RFE is expressed as a 
percentage of all RFEs and as a rate per 100 encounters with 95% confidence limits.  
RFEs of a general and unspecified nature were presented at a rate of 41.0 per 100 encounters, 
with requests for prescriptions and test results most frequently recorded. RFEs related to the 
respiratory system arose at a rate of 21.7 per 100 encounters, while those related to the 
musculoskeletal system were recorded at a rate of 15.3 per 100 encounters, and those relating 
to skin at a rate of 15.3 per 100 encounters (Table 6.4).  
Most frequent patient reasons for encounter 
The 30 most commonly recorded RFEs (Table 6.5), accounted for more than half of all RFEs. 
In this analysis the specific ICPC-2 chapter to which an across-chapter concept belongs is 
disregarded, so that, for example, ‘check-up – all’ includes all check-ups from all body 
systems, irrespective of whether or not the body system was specified.  
Of the top 30 most common RFEs, the majority were descriptive of symptoms such as cough, 
throat complaint, back complaint and rash. However, four of the top five RFEs reflected 
requests for a process of care (that is, requests for check-up, prescription, test result and 
immunisation), and together accounted for a quarter of all RFEs (24.8%) (Table 6.5). 
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Table 6.4: Patient reasons for encounter by ICPC-2 chapter and most frequent individual reasons 
for encounter within chapter  
Reasons for encounter Number 
Per cent of 
total RFEs(a) 
(n = 149,005) 
Rate per 100 
encounters(b) 
(n = 95,839) 
95%  
LCL 
95%  
UCL 
General and unspecified 39,310 26.4 41.0 39.8 42.3 
 Prescription NOS 8,188 5.5 8.5 8.0 9.1 
 Results tests/procedures NOS 6,441 4.3 6.7 6.3 7.1 
 General check-up* 4,109 2.8 4.3 4.0 4.6 
 Immunisation/vaccination NOS 2,258 1.5 2.4 2.1 2.6 
 Administrative procedure NOS 2,254 1.5 2.4 2.2 2.5 
 Fever 1,956 1.3 2.0 1.8 2.3 
 Weakness/tiredness  1,291 0.9 1.3 1.2 1.5 
 Observation/health education/advice/diet NOS 1,082 0.7 1.1 0.9 1.4 
 Other referrals NEC 1,067 0.7 1.1 1.0 1.2 
 Blood test NOS 1,038 0.7 1.1 0.9 1.2 
 Other reason for encounter NEC 944 0.6 1.0 0.8 1.1 
 Chest pain NOS 891 0.6 0.9 0.9 1.0 
 Trauma/injury NOS 786 0.5 0.8 0.7 0.9 
 Follow-up encounter unspecified  755 0.5 0.8 0.7 0.9 
Respiratory 20,840 14.0 21.7 20.9 22.6 
 Cough 6,445 4.3 6.7 6.3 7.1 
 Throat symptom/complaint 2,960 2.0 3.1 2.8 3.4 
 Immunisation/vaccination – respiratory 2,212 1.5 2.3 2.0 2.7 
 Upper respiratory tract infection 1,963 1.3 2.0 1.8 2.3 
 Sneezing/nasal congestion 1,360 0.9 1.4 1.2 1.7 
 Asthma 765 0.5 0.8 0.7 0.9 
 Shortness of breath/dyspnoea 757 0.5 0.8 0.7 0.9 
Musculoskeletal 14,678 9.9 15.3 14.9 15.8 
 Back complaint* 3,017 2.0 3.1 3.0 3.3 
 Knee symptom/complaint 1,267 0.9 1.3 1.2 1.4 
 Shoulder symptom/complaint 1,104 0.7 1.2 1.1 1.2 
 Foot/toe symptom/complaint 1,011 0.7 1.1 1.0 1.1 
 Leg/thigh symptom/complaint 861 0.6 0.9 0.8 1.0 
 Neck symptom/complaint 808 0.5 0.8 0.8 0.9 
Skin 14,676 9.8 15.3 14.8 15.8 
 Rash* 2,604 1.7 2.7 2.5 2.9 
 Skin symptom/complaint, other 1,463 1.0 1.5 1.4 1.7 
 Swelling (skin)* 1,083 0.7 1.1 1.0 1.2 
 Skin check-up* 1,005 0.7 1.0 0.9 1.2 
 Laceration/cut 734 0.5 0.8 0.7 0.8 
(continued) 
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Table 6.4 (continued): Patient reasons for encounter by ICPC-2 chapter and most frequent 
individual reasons for encounter within chapter  
Reasons for encounter Number 
Per cent of 
total RFEs(a) 
(n = 149,005) 
Rate per 100 
encounters 
(n = 95,839) 
95%  
LCL 
95%  
UCL 
Cardiovascular 10,086 6.8 10.5 10.0 11.1 
 Cardiac check-up* 4,471 3.0 4.7 4.3 5.1 
 Hypertension/high blood pressure* 1,850 1.2 1.9 1.7 2.2 
 Prescription – cardiovascular 756 0.5 0.8 0.6 0.9 
Digestive 9,791 6.6 10.2 9.8 10.6 
 Abdominal pain* 1,742 1.2 1.8 1.7 1.9 
 Diarrhoea 1,135 0.8 1.2 1.1 1.3 
 Vomiting 830 0.6 0.9 0.8 1.0 
Psychological 8,634 5.8 9.0 8.6 9.4 
 Depression* 2,121 1.4 2.2 2.1 2.4 
 Anxiety* 1,160 0.8 1.2 1.1 1.3 
 Sleep disturbance 1,064 0.7 1.1 1.0 1.2 
Endocrine and metabolic 6,273 4.2 6.5 6.2 6.9 
 Diabetes (non-gestational)* 1,359 0.9 1.4 1.3 1.6 
 Prescription – endocrine/metabolic 959 0.6 1.0 0.9 1.1 
Female genital system 4,775 3.2 5.0 4.6 5.3 
 Female genital check-up/Pap smear* 1,679 1.1 1.8 1.6 1.9 
Neurological 4,448 3.0 4.6 4.4 4.9 
 Headache 1,383 0.9 1.4 1.3 1.6 
 Vertigo/dizziness 1,099 0.7 1.1 1.1 1.2 
Ear 3,567 2.4 3.7 3.5 3.9 
 Ear pain 1,391 0.9 1.5 1.3 1.6 
Pregnancy and family planning 3,270 2.2 3.4 3.1 3.7 
 Pre/post natal check-up* 842 0.6 0.9 0.7 1.0 
 Oral contraception* 688 0.5 0.7 0.6 0.8 
Urology 2,616 1.8 2.7 2.6 2.9 
Eye 2,332 1.6 2.4 2.3 2.6 
Blood and blood forming organs 1,541 1.0 1.6 1.4 1.8 
 Blood test – blood and blood forming organs 951 0.6 1.0 0.8 1.1 
Male genital system 1,201 0.8 1.3 1.2 1.3 
Social 968 0.6 1.0 0.9 1.1 
Total RFEs 149,005 100.0 155.5 153.5 157.5 
(a) Only individual RFEs accounting for >= 0.5% of total RFEs are included. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified. 
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Table 6.5: Most frequent patient reasons for encounter 
Patient reason for encounter Number 
Per cent of  
total RFEs 
(n = 149,005) 
Rate per 100 
encounters 
(n = 95,839) 
95%  
LCL 
95%  
UCL 
Check-up – all* 13,090 8.8 13.7 13.0 14.3 
Prescription – all* 11,528 7.7 12.0 11.4 12.7 
Test results* 7,678 5.2 8.0 7.5 8.5 
Cough 6,445 4.3 6.7 6.3 7.1 
Immunisation/vaccination – all* 4,646 3.1 4.8 4.4 5.3 
Back complaint* 3,017 2.0 3.1 3.0 3.3 
Throat symptom/complaint 2,960 2.0 3.1 2.8 3.4 
Rash* 2,604 1.7 2.7 2.5 2.9 
Administrative procedure – all* 2,487 1.7 2.6 2.4 2.8 
Blood test – all* 2,483 1.7 2.6 2.4 2.8 
Depression* 2,121 1.4 2.2 2.1 2.4 
Upper respiratory tract infection 1,963 1.3 2.0 1.8 2.3 
Fever 1,956 1.3 2.0 1.8 2.3 
Hypertension/high blood pressure* 1,850 1.2 1.9 1.7 2.2 
Observation/health education/advice/diet – all* 1,764 1.2 1.8 1.5 2.1 
Abdominal pain* 1,742 1.2 1.8 1.7 1.9 
Skin symptom/complaint, other 1,463 1.0 1.5 1.4 1.7 
Ear pain/earache 1,391 0.9 1.5 1.3 1.6 
Headache 1,383 0.9 1.4 1.3 1.6 
Diabetes – all* 1,371 0.9 1.4 1.3 1.6 
Sneezing/nasal congestion 1,360 0.9 1.4 1.2 1.7 
Weakness/tiredness 1,291 0.9 1.3 1.2 1.5 
Knee symptom/complaint 1,267 0.9 1.3 1.2 1.4 
Anxiety* 1,160 0.8 1.2 1.1 1.3 
Diarrhoea 1,135 0.8 1.2 1.1 1.3 
Shoulder symptom/complaint 1,104 0.7 1.2 1.1 1.2 
Vertigo/dizziness 1,099 0.7 1.1 1.1 1.2 
Swelling (skin)* 1,083 0.7 1.1 1.0 1.2 
Other referrals NEC 1,067 0.7 1.1 1.0 1.2 
Sleep disturbance 1,043 0.7 1.1 1.0 1.2 
Subtotal 85,553 57.4 — — — 
Total RFEs 149,005 100.0 155.5 153.5 157.5 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified;  
NEC – not elsewhere classified. 
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6.4 Changes in patients and reasons for encounter 
over the decade 2001–02 to 2010–11 
An overview of changes in the characteristics of patients at encounters and their reasons for 
encounter over the decade 2001–02 to 2010–11 can be found in Chapter 11 of the companion 
report A decade of Australian general practice activity 2001–02 to 2010–11.1  
Major changes identified between 2001–02 and 2010–11 are summarised below.  
Between 2001–02 and 2010–11, the proportion of encounters with patients aged less than 
45 years decreased from 48.6% to 43.4%, while the proportion with patients aged 45 years 
and over increased from 51.4% to 56.6%. When extrapolated, with the increased number of 
encounters nationally, the number of encounters with younger patients only increased by 
about 2.7 million over the decade, while the number of encounters with older patients 
increased by about 15.5 million nationally. 
Over the decade there was a significant decrease in the proportion of encounters with 
patients who were new to the practice (from 9.2% in 2001–02 to 7.3% in 2010–11). The 
proportion of encounters with patients holding a Commonwealth concession card was 
relatively stable across the decade. Between 2003–04 and 2010–11, the proportion of 
encounters with patients holding a repatriation health card decrease by about a third (from 
3.7% in 2001–02 to 2.5% in 2010–11). 
There was a significant increase in the number of RFEs per 100 encounters across the decade, 
from 149.2 in 2001–02 to 155.5 in 2010–11. Fewer patients were giving single RFEs and more 
were giving two or three RFEs. This increase in RFEs is probably related to the increasing 
proportion of encounters with older people, who are more likely to visit for multiple chronic 
disease management. There was a significant decrease in the rate of RFEs described as 
symptoms and complaints, and increases in rates of patient presentations for medications, 
administrative procedures, tests and test results. The increase in patients’ requests for tests 
and test results ties in with the increased use of pathology testing over the decade (discussed 
in Chapter 12).  
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7 Problems managed 
A ‘problem managed’ is a formal statement of the provider’s understanding of a health 
problem presented by the patient, family or community, and can be described in terms of a 
disease, symptom or complaint, social problem or ill-defined condition managed at the 
encounter. As GPs were instructed to record each problem at the most specific level possible 
from the information available, the problem managed may at times be limited to the level of 
a presenting symptom. 
At each patient encounter, up to four problems could be recorded by the GP. A minimum of 
one problem was compulsory. The status of each problem to the patient – new (first 
presentation to a medical practitioner) or old (follow-up of previous problem) – was also 
indicated. The concept of a principal diagnosis, which is often used in hospital statistics, is 
not adopted in studies of general practice where multiple problem management is the norm 
rather than the exception. Further, the range of problems managed at the encounter often 
crosses multiple body systems and may include undiagnosed symptoms, psychosocial 
problems or chronic disease, which makes the designation of a principal diagnosis difficult. 
Thus, the order in which the problems were recorded by the GP is not significant. All 
problems managed in general practice are included in this section, including those that 
involved management by a practice nurse at the recorded encounter. Problems that included 
management by a practice nurse are reported specifically in Chapter 13. 
There are two ways to describe the relative frequency of problems managed: as a percentage 
of all problems managed in the study, or as a rate at which problems are managed per 
100 encounters. Where groups of problems are reported (for example, cardiovascular 
problems) it must be remembered that more than one of that type of problem (such as 
hypertension and heart failure) may have been managed at a single encounter. In 
considering these results, the reader must be mindful that although a rate per 100 encounters 
for a single ungrouped problem (for example, asthma, 2.2 per 100 encounters) can be 
regarded as equivalent to ‘asthma is managed at 2.2% of encounters’, such a statement 
cannot be made for grouped concepts (ICPC-2 chapters and those marked with asterisks in 
the tables). 
Data on problems managed in Australian general practice from the BEACH study are 
reported for each year from 2001–02 to 2010–11 in the 10-year summary report A decade of 
Australian general practice activity 2001–02 to 2010–11.1  
7.1 Number of problems managed at encounter 
There were 146,141 problems managed, at a rate of 152.5 per 100 encounters in 2010–11 
(Table 5.1). Table 7.1 shows the number of problems managed at each encounter. Only one 
problem was managed at more than 60% of encounters, two problems were managed at 
25% of encounters, and 9% involved the management of three problems. The management of 
four problems at an encounter was less common (3% of encounters). 
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Table 7.1: Number of problems managed at an encounter 
Number of problems managed at encounter Number of encounters Per cent 95% LCL 95% UCL 
One problem 59,948 62.6 61.2 63.9 
Two problems 24,299 25.4 24.6 26.1 
Three problems 8,772 9.2 8.6 9.7 
Four problems 2,820 2.9 2.6 3.3 
Total 95,839 100.0 — — 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
Figure 7.1 shows the age–sex-specific rates of problems managed. The number of problems 
managed at encounter increased steadily with the age of the patient.  
Significantly more problems were managed overall at encounters with female patients 
(155.1 per 100 encounters, 95% CI: 152.7–157.5) than at those with male patients (149.2 per 
100 encounters, 95% CI: 146.8–151.5) (results not tabled). Figure 7.1 demonstrates that this 
difference was particularly evident in the 15–24 year age group. 
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Note: Data with patient age or sex missing were removed  
Figure 7.1: Age–sex-specific rates of problems managed per 100 encounters with 95% CI 
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7.2 Problems managed by ICPC-2 component 
Problems managed in general practice may also be examined using the components of the 
ICPC-2 classification to provide a more thorough understanding of the types of problems 
managed during general practice encounters. Table 7.2 lists the distribution of problems 
managed by ICPC-2 component.  
In the BEACH program, participating GPs are instructed to record the problem being 
managed at the encounter at the highest diagnostic level possible using the currently 
available evidence. As such, two-thirds of problems were expressed as diagnoses or diseases 
(66.3%), with the majority of other problems described as symptoms or complaints (18.5%), 
or as diagnostic or preventive procedures (9.9%) such as check-ups. However, in some 
situations, rather than providing clinical details about the problem under management, a 
‘process’ was recorded: that is, the problem was described in such terms as a ‘prescription’, 
‘test result’, referral, or an administrative procedure (Table 7.2). 
Table 7.2: Problems managed by ICPC-2 component 
ICPC-2 component Number 
Per cent of 
total problems 
(n = 146,141) 
Rate per 100 
encounters 
(n = 95,839) 
95% 
 LCL 
95% 
 UCL 
Diagnosis, diseases 96,864 66.3 101.1 99.2 103.0 
 Infections 23,796 16.3 24.8 24.1 25.6 
 Injuries 6,785 4.6 7.1 6.8 7.3 
 Neoplasms 4,154 2.8 4.3 4.1 4.6 
 Congenital anomalies 625 0.4 0.7 0.6 0.7 
 Other diagnoses 61,505 42.1 64.2 62.2 66.1 
Symptoms and complaints 27,036 18.5 28.2 27.4 29.1 
Diagnostic and preventive procedures 14,501 9.9 15.1 14.3 15.9 
Medications, treatments and therapeutics 3,578 2.5 3.7 3.4 4.1 
Results 1,830 1.3 1.9 1.7 2.1 
Referrals and other RFEs 1,243 0.9 1.3 1.1 1.5 
Administrative 1,089 0.8 1.1 1.0 1.3 
Total problems  146,141 100.0 152.5 150.2 154.7 
Note: LCL – lower confidence limit; UCL – upper confidence limit; RFE – reason for encounter.  
7.3 Problems managed by ICPC-2 chapter 
The frequency and the distribution of problems managed, by ICPC-2 chapter, are presented 
in Table 7.3. Rates per 100 encounters and the proportion of total problems are provided at 
the ICPC-2 chapter level, and for frequent individual problems within each chapter. Only 
those individual problems accounting for at least 0.5% of all problems managed are listed in 
the table, in decreasing order of frequency. 
The most common problems managed were: 
• those classified to the respiratory system (20.4 per 100 encounters) – in particular upper 
respiratory tract infection, respiratory immunisations, acute bronchitis and asthma 
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• problems of a general and unspecified nature (19.2 per 100 encounters) – such as general 
check-ups, and general immunisations and unspecified prescriptions 
• skin problems (16.8 per 100 encounters) – such as contact dermatitis and solar keratosis 
• cardiovascular problems (16.7 per 100 encounters) – such as hypertension and atrial 
fibrillation 
• musculoskeletal problems (16.6 per 100 encounters) – particularly arthritis and back 
complaints (Table 7.3).  
Table 7.3: Problems managed by ICPC-2 chapter and most frequent individual problems within 
chapter  
Problem managed  Number 
Per cent total 
problems  
(n = 146,141) 
Rate per 100 
encounters(a) 
(n = 95,839) 
95%  
LCL 
95%  
UCL 
Respiratory 19,569 13.4 20.4 19.7 21.1 
 Upper respiratory tract infection 5,212 3.6 5.4 5.1 5.8 
 Immunisation/vaccination – respiratory 2,672 1.8 2.8 2.4 3.2 
 Acute bronchitis/bronchiolitis 2,421 1.7 2.5 2.3 2.7 
 Asthma 2,075 1.4 2.2 2.0 2.3 
 Sinusitis  1,273 0.9 1.3 1.2 1.4 
 Tonsillitis* 1,006 0.7 1.0 0.9 1.2 
 Chronic obstructive pulmonary disease 875 0.6 0.9 0.8 1.0 
General and unspecified 18,440 12.6 19.2 18.5 20.0 
 General check-up* 2,572 1.8 2.7 2.5 2.9 
 Immunisation/vaccination NOS 2,350 1.6 2.5 2.2 2.7 
 Prescription NOS 1,741 1.2 1.8 1.6 2.1 
 Results tests/procedures NOS 1,356 0.9 1.4 1.2 1.6 
 Viral disease, other/NOS 1,139 0.8 1.2 1.0 1.4 
 Administrative procedure NOS 996 0.7 1.0 0.9 1.2 
 Abnormal result/investigation NOS 880 0.6 0.9 0.8 1.0 
 Observation/health education/advice/diet NOS 676 0.5 0.7 0.5 0.9 
Skin 16,052 11.0 16.8 16.2 17.2 
 Contact dermatitis 1,632 1.1 1.7 1.6 1.8 
 Solar keratosis/sunburn 1,090 0.7 1.1 1.0 1.3 
 Malignant neoplasm skin 1,060 0.7 1.1 1.0 1.2 
 Laceration/cut 903 0.6 0.9 0.9 1.0 
 Skin disease, other 721 0.5 0.8 0.7 0.8 
Cardiovascular 15,957 10.9 16.7 15.9 17.4 
 Hypertension* 8,314 5.7 8.7 8.2 9.2 
 Atrial fibrillation/flutter 1,250 0.9 1.3 1.2 1.4 
 Ischaemic heart disease* 1,095 0.7 1.1 1.0 1.3 
 Cardiac check-up* 1,075 0.7 1.1 1.0 1.3 
(continued) 
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Table 7.3 (continued): Problems managed by ICPC-2 chapter and most frequent individual 
problems within chapter 
Problem managed  Number 
Per cent total 
problems  
(n = 146,141) 
Rate per 100 
encounters(a) 
(n = 95,839) 
95%  
LCL 
95%  
UCL 
Musculoskeletal 15,926 10.9 16.6 16.1 17.1 
 Arthritis – all* 3,492 2.4 3.6 3.4 3.9 
  Osteoarthritis* 2,590 1.8 2.7 2.5 2.9 
 Back complaint* 2,599 1.8 2.7 2.5 2.9 
 Sprain/strain* 1,335 0.9 1.4 1.3 1.5 
 Bursitis/tendonitis/synovitis NOS 1,019 0.7 1.1 1.0 1.1 
 Fracture* 892 0.6 0.9 0.9 1.0 
 Injury musculoskeletal NOS 721 0.5 0.8 0.7 0.8 
 Osteoporosis 690 0.5 0.7 0.6 0.8 
Endocrine and metabolic 12,243 8.4 12.8 12.2 13.3 
 Diabetes – non-gestational* 3,800 2.6 4.0 3.7 4.2 
 Lipid disorders 2,931 2.0 3.1 2.8 3.3 
 Vitamin/nutritional deficiency 1,216 0.8 1.3 1.1 1.4 
 Obesity (BMI > 30) 761 0.5 0.8 0.6 1.0 
 Hypothyroidism/myxoedema 717 0.5 0.7 0.7 0.8 
Psychological 11,843 8.1 12.4 11.9 12.9 
 Depression* 4,023 2.8 4.2 4.0 4.4 
 Anxiety* 1,849 1.3 1.9 1.8 2.1 
 Sleep disturbance 1,443 1.0 1.5 1.4 1.6 
 Tobacco abuse 889 0.6 0.9 0.8 1.0 
Digestive 10,195 7.0 10.6 10.3 10.9 
 Oesophageal disease 2,205 1.5 2.3 2.1 2.5 
 Gastroenteritis* 1,360 0.9 1.4 1.3 1.5 
Female genital system 5,304 3.6 5.5 5.2 5.9 
 Female genital check-up/Pap smear* 1,645 1.1 1.7 1.5 1.9 
 Menopausal complaint 666 0.5 0.7 0.6 0.8 
Pregnancy and family planning 3,774 2.6 3.9 3.6 4.2 
 Pregnancy* 1,377 0.9 1.4 1.3 1.6 
 Oral contraception* 1,051 0.7 1.1 1.0 1.2 
Ear 3,724 2.6 3.9 3.7 4.1 
 Acute otitis media/myringitis 1,033 0.7 1.1 1.0 1.2 
 Excessive ear wax 762 0.5 0.8 0.7 0.9 
Neurological 3,575 2.5 3.7 3.6 3.9 
Urology 3,103 2.1 3.2 3.1 3.4 
 Urinary tract infection* 1,730 1.2 1.8 1.7 1.9 
 (continued) 
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Table 7.3 (continued): Problems managed by ICPC-2 chapter and most frequent individual 
problems within chapter 
Problem managed  Number 
Per cent total 
problems  
(n = 146,141) 
Rate per 100 
encounters(a) 
(n = 95,839) 
95%  
LCL 
95%  
UCL 
Eye 2,398 1.6 2.5 2.4 2.6 
Male genital system 1,779 1.2 1.9 1.7 2.0 
Blood and blood forming organs 1,510 1.0 1.6 1.5 1.7 
Social 749 0.5 0.8 0.7 0.9 
Total problems 146,141 100.0 152.5 150.2 154.7 
(a) Only those individual problems accounting for ≥  0.5% of total problems are included in the table. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified; BMI – body mass index. 
7.4 Most frequently managed problems 
Table 7.4 shows the most frequently managed individual problems in general practice, in 
decreasing order of frequency. These 30 problems accounted for half of all problems 
managed, and the top 10 problems accounted for 30%. 
In this analysis, the specific chapter to which ‘across chapter concepts’ (for example, 
check-ups, immunisation/vaccination and prescriptions) apply is ignored, and the concept is 
grouped with all similar concepts regardless of body system. For example, immunisation/ 
vaccination includes vaccinations for influenza, childhood diseases, and hepatitis. 
The most common problems managed were hypertension (8.7 per 100 encounters), 
check-ups (6.4 per 100), immunisation/vaccination (5.5 per 100), upper respiratory tract 
infection (URTI) (5.4 per 100), and depression (4.2 per 100) (Table 7.4).  
The far right-hand column in Table 7.4 lists the percentage of each problem that was new to 
the patient. The problem is considered new if it is a new problem or a new episode of a 
recurrent problem, and the patient has not been treated for that problem or episode by any 
medical practitioner before. This can provide a measure of general practice incidence. For 
example, only 5.2% of all contacts with diabetes were new diagnoses. In contrast, more than 
three-quarters of URTI problems were new to the patient, suggesting that the majority of 
people attend the GP for URTI only once per episode.  
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Table 7.4: Most frequently managed problems 
Problem managed Number 
Per cent of 
total problems 
(n = 146,141) 
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Per cent 
of new 
problems(a) 
Hypertension* 8,314 5.7 8.7 8.2 9.2 5.2 
Check-up – all* 6,144 4.2 6.4 6.1 6.8 41.5 
Immunisation/vaccination – all* 5,288 3.6 5.5 5.0 6.0 54.1 
Upper respiratory tract infection 5,212 3.6 5.4 5.1 5.8 76.2 
Depression* 4,023 2.8 4.2 4.0 4.4 15.4 
Diabetes – all* 3,826 2.6 4.0 3.7 4.2 5.2 
Arthritis – all* 3,492 2.4 3.6 3.4 3.9 18.9 
Lipid disorders 2,931 2.0 3.1 2.8 3.3 9.7 
Back complaint* 2,599 1.8 2.7 2.5 2.9 23.5 
Acute bronchitis/bronchiolitis 2,421 1.7 2.5 2.3 2.7 73.1 
Prescription – all* 2,400 1.6 2.5 2.2 2.8 4.9 
Oesophageal disease 2,205 1.5 2.3 2.1 2.5 17.8 
Asthma 2,075 1.4 2.2 2.0 2.3 19.6 
Anxiety* 1,849 1.3 1.9 1.8 2.1 21.1 
Test results* 1,830 1.3 1.9 1.7 2.1 25.6 
Urinary tract infection* 1,730 1.2 1.8 1.7 1.9 61.3 
Contact dermatitis 1,632 1.1 1.7 1.6 1.8 44.1 
Sleep disturbance 1,443 1.0 1.5 1.4 1.6 21.1 
Pregnancy* 1,377 0.9 1.4 1.3 1.6 37.4 
Gastroenteritis* 1,360 0.9 1.4 1.3 1.5 79.3 
Sprain/strain* 1,335 0.9 1.4 1.3 1.5 64.3 
Sinusitis acute/chronic 1,273 0.9 1.3 1.2 1.4 64.9 
Atrial fibrillation/flutter 1,250 0.9 1.3 1.2 1.4 6.0 
Vitamin/nutritional deficiency 1,216 0.8 1.3 1.1 1.4 31.8 
Viral disease, other/NOS 1,139 0.8 1.2 1.0 1.4 75.1 
Ischaemic heart disease* 1,095 0.7 1.1 1.0 1.3 10.7 
Solar keratosis/sunburn 1,090 0.7 1.1 1.0 1.3 47.5 
Administrative procedure – all* 1,089 0.7 1.1 1.0 1.3 43.4 
Abnormal test results* 1,067 0.7 1.1 1.0 1.2 48.2 
Malignant neoplasm skin 1,060 0.7 1.1 1.0 1.2 51.8 
Subtotal  73,765 50.5 — — — — 
Total problems 146,141 100.0 152.5 150.2 154.7 37.9 
(a) The proportion of problems of this type that were new problems (the first presentation of a problem, including the first presentation of a 
recurrence of a previously resolved problem, but excluding the presentation of a problem previously assessed by another provider). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
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7.5 Most common new problems 
For each problem managed, participating GPs are asked to indicate whether the problem 
under management is a new problem for the patient. The problem is considered new if it is a 
new problem or a new episode of a recurrent problem, and the patient has not been treated 
for that problem or episode by any medical practitioner before. Table 7.5 lists the most 
common new problems managed in general practice, in decreasing order of frequency. 
Overall, 55,410 problems (37.9% of all problems) were specified as being new, being 
managed at a rate of 57.8 per 100 encounters. 
The most common new problems managed were largely acute and included upper 
respiratory tract infections (4.1 per 100 encounters), immunisations/vaccinations (3.0),  
check-ups (2.7), acute bronchitis (1.8) and gastroenteritis (1.1) (Table 7.5). 
The far right-hand column of this table shows the new cases of this problem as a proportion 
of total contacts with this problem. This provides an idea of the incidence of each problem. 
For example, the 618 new cases of depression represented only 15% of all GP contacts with 
diagnosed depression, suggesting that by far the majority of contacts for depression were for 
ongoing management. In contrast, four out of five gastroenteritis cases were first 
consultations to a medical practitioner for this episode of gastroenteritis, the balance (21%) 
being follow-up consultations for this episode of this problem. This indicates that most 
patients only require one visit to a GP for the management of an episode of gastroenteritis. 
Table 7.5: Most frequently managed new problems 
New problem managed Number 
Per cent of total 
 new problems 
(n = 55,410) 
Rate per 100 
 encounters 
(n = 95,839) 
95% 
 LCL 
95% 
UCL 
Per cent  
of this 
problem(a) 
Upper respiratory tract infection 3,973 7.2 4.1 3.8 4.5 76.2 
Immunisation/vaccination – all* 2,858 5.2 3.0 2.7 3.3 54.1 
Check-up – all* 2,550 4.6 2.7 2.4 2.9 41.5 
Acute bronchitis/bronchiolitis 1,769 3.2 1.8 1.7 2.0 73.1 
Gastroenteritis* 1,079 1.9 1.1 1.0 1.2 79.3 
Urinary tract infection* 1,061 1.9 1.1 1.0 1.2 61.3 
Sprain/strain* 859 1.5 0.9 0.8 1.0 64.3 
Viral disease, other/NOS 855 1.5 0.9 0.7 1.0 75.1 
Sinusitis acute/chronic  826 1.5 0.9 0.8 1.0 64.9 
Acute otitis media/myringitis 739 1.3 0.8 0.7 0.9 71.5 
Tonsillitis* 721 1.3 0.8 0.7 0.8 71.7 
Contact dermatitis  720 1.3 0.8 0.7 0.8 44.1 
Arthritis – all* 661 1.2 0.7 0.6 0.8 18.9 
Depression* 618 1.1 0.6 0.6 0.7 15.4 
Bursitis/tendonitis/synovitis NOS 617 1.1 0.6 0.6 0.7 60.5 
Back complaint* 610 1.1 0.6 0.6 0.7 23.5 
Malignant neoplasm skin 549 1.0 0.6 0.5 0.6 52.0 
Solar keratosis/sunburn 517 0.9 0.5 0.5 0.6 47.5 
Pregnancy* 515 0.9 0.5 0.5 0.6 37.4 
(continued) 
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Table 7.5 (continued): Most frequently managed new problems 
New problem managed Number 
Per cent of total 
 new problems 
(n = 55,410) 
Rate per 100 
 encounters 
(n = 95,839) 
95% 
 LCL 
95% 
UCL 
Per cent  
of this 
problem(a) 
Abnormal test results* 514 0.9 0.5 0.5 0.6 48.2 
Conjunctivitis, infectious 487 0.9 0.5 0.4 0.6 75.3 
Excessive ear wax 477 0.9 0.5 0.4 0.6 62.5 
Administrative procedure – all* 469 0.8 0.5 0.4 0.6 25.6 
Test results* 442 0.8 0.5 0.4 0.5 68.9 
Observation/health education/ 
advice/diet – all* 
436 0.8 0.5 0.4 0.5 5.2 
Otitis externa 431 0.8 0.4 0.4 0.5 43.3 
Hypertension* 410 0.7 0.4 0.4 0.5 46.0 
Fracture* 408 0.7 0.4 0.4 0.5 19.6 
Asthma 407 0.7 0.4 0.4 0.5 67.5 
Skin infection, post traumatic 405 0.7 0.4 0.4 0.5 44.9 
Subtotal 27,074 48.6 — — — — 
Total new problems 55,410 100.0 57.8 56.4 59.3 — 
(a) The proportion of total contacts with this problem that were accounted for by new problems. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
7.6 Most frequently managed chronic problems 
To identify chronic conditions, a list classified according to ICPC-2, based on work 
undertaken by O’Halloran et al. in 200435 and regularly updated by O’Halloran (see ‘Chronic 
conditions’ grouper G84 <www.fmrc.org.au/icpc2plus/demonstrator.htm>), was applied to 
the BEACH data set. More than one-third (34.8%) of the problems managed in general 
practice were chronic. At least one chronic problem was managed at 40.6% of encounters 
(95% CI: 39.5–41.7), and chronic problems were managed at an average rate of 53.1 per 100 
encounters. 
In other parts of this chapter, both chronic and non-chronic conditions (for example, diabetes 
and gestational diabetes) may have been grouped together when reporting (for example, 
diabetes – all*, Table 7.4). In this section, only problems regarded as chronic have been 
included in the analysis. For this reason, the condition labels and figures in this analysis may 
differ from those in Table 7.4. Where the group used for the chronic analysis differs from that 
used in other analyses in this report, they are marked with a double asterisk. Codes included 
in the chronic group can be found in Appendix 4, Table A4.2. 
Table 7.6 shows the most frequently managed chronic problems in decreasing order of 
frequency. These 30 chronic problems together accounted for 79.5% of all chronic problems 
managed, and for 27.7% of all problems managed. The top six chronic problems made up 
almost half of all chronic problems managed: non-gestational hypertension (16.3% of chronic 
conditions), depressive disorder (7.8%), non-gestational diabetes (7.5%), chronic arthritis 
(7.0%), lipid disorders (5.8%), and oesophageal disease (4.3%) (Table 7.6). 
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Table 7.6: Most frequently managed chronic problems 
Chronic problem managed Number 
Per cent of total 
chronic problems 
(n = 50,911) 
Rate per 100 
 encounters 
(n = 95,839) 
95% 
 LCL 
95% 
UCL 
Hypertension (non-gestational)** 8,294 16.3 8.7 8.2 9.1 
Depressive disorder** 3,985 7.8 4.2 3.9 4.4 
Diabetes (non-gestational)** 3,800 7.5 4.0 3.7 4.2 
Chronic arthritis** 3,540 7.0 3.7 3.5 3.9 
Lipid disorders* 2,931 5.8 3.1 2.8 3.3 
Oesophageal disease 2,205 4.3 2.3 2.1 2.5 
Asthma 2,075 4.1 2.2 2.0 2.3 
Atrial fibrillation/flutter 1,250 2.5 1.3 1.2 1.4 
Ischaemic heart disease** 1,095 2.2 1.1 1.0 1.3 
Malignant neoplasm of skin 1,060 2.1 1.1 1.0 1.2 
Chronic obstructive pulmonary disease 875 1.7 0.9 0.8 1.0 
Back syndrome with radiating pain** 859 1.7 0.9 0.8 1.0 
Obesity (BMI > 30) 761 1.5 0.8 0.6 1.0 
Hypothyroidism/myxoedema 717 1.4 0.7 0.7 0.8 
Osteoporosis 690 1.4 0.7 0.6 0.8 
Migraine 579 1.1 0.6 0.5 0.7 
Heart failure 579 1.1 0.6 0.5 0.7 
Chronic skin ulcer 549 1.1 0.6 0.5 0.6 
Gout 516 1.0 0.5 0.5 0.6 
Shoulder syndrome (excluding arthritis)** 504 1.0 0.5 0.5 0.6 
Dementia (including senile, Alzheimer’s) 443 0.9 0.5 0.4 0.6 
Anxiety disorder** 438 0.9 0.5 0.4 0.5 
Schizophrenia 425 0.8 0.4 0.4 0.5 
Chronic acne** 378 0.7 0.4 0.3 0.4 
Vertiginous syndrome 339 0.7 0.4 0.3 0.4 
Chronic pain NOS 333 0.7 0.3 0.3 0.4 
Chronic kidney disease – all** 322 0.6 0.3 0.3 0.4 
Chronic back pain** 317 0.6 0.3 0.3 0.4 
Back syndrome without radiating pain 
(excluding arthritis, sprains and strains)** 
310 0.6 0.3 0.3 0.4 
Epilepsy 307 0.6 0.3 0.3 0.4 
Subtotal 40,476 79.5 — — — 
Total chronic problems 50,911 100.0 53.1 51.2 55.0 
** Includes multiple ICPC-2 or ICPC-2 PLUS codes and indicates that this group differs from that used for analysis in other sections of this 
chapter, as only chronic conditions have been included in this analysis (see Appendix 4, Table A4.2, 
<purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; BMI – body mass index. 
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7.7 Work-related problems managed 
The work-related status of a problem under management is determined by the GP, and is 
defined as any problem that is likely (in the GP’s view) to have resulted from work-related 
activity or workplace exposure, or a pre-existing condition that had been significantly 
exacerbated by work activity or workplace exposure. Work-related problems accounted for 
1.6% of problems and were managed at a rate of 2.5 per 100 general practice encounters in 
2010–11 (Table 7.7). 
Table 7.7: Work-related problems, by type and most frequently managed individual problems 
Work-related problem managed Number 
Percentage of total 
work-related problems 
(n = 2,393) 
Rate per 100 
 encounters 
(n = 95,839) 
95% 
 LCL 
95% 
UCL 
Percentage 
of this 
problem(a)  
Musculoskeletal problems 1,392 58.2 1.5 1.3 1.6 8.7 
 Back complaint* 349 14.6 0.4 0.3 0.4 13.4 
 Sprain/strain* 253 10.6 0.3 0.2 0.3 19.0 
 Injury musculoskeletal NOS 164 6.9 0.2 0.1 0.2 22.8 
 Fracture* 84 3.5 0.1 0.1 0.1 9.5 
 Shoulder syndrome 67 2.8 0.1 0.0 0.1 13.3 
 Bursitis/tendonitis/synovitis NOS 61 2.5 0.1 0.0 0.1 6.0 
 Arthritis – all* 55 2.3 0.1 0.0 0.1 1.6 
 Acute internal knee damage 53 2.2 0.1 0.0 0.1 19.3 
 Neck syndrome 37 1.5 0.0 0.0 0.1 13.5 
Psychological problems 261 10.9 0.3 0.2 0.3 2.2 
 Depression* 102 4.3 0.1 0.1 0.1 2.5 
 Acute stress reaction 61 2.6 0.1 0.0 0.1 10.7 
 Anxiety 44 1.8 0.0 0.0 0.1 2.4 
 Post traumatic stress disorder 37 1.5 0.0 0.0 0.1 27.6 
Other work-related problems 741 31.0 0.8 0.7 0.9 0.6 
 General check-up* 88 3.7 0.1 0.1 0.1 3.4 
 Injury skin, other 78 3.2 0.1 0.1 0.1 15.4 
 Administrative procedure – all* 52 2.2 0.1 0.0 0.1 4.8 
 Laceration/cut 41 1.7 0.0 0.0 0.1 4.6 
Total work-related problems 2,393 100.0 2.5 2.3 2.7 — 
(a) The proportion of total contacts with this problem that were accounted for by work-related problems. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. Only the most frequent individual work-related 
problems accounting for > 1.5% of total work-related problems are reported. 
 
The most common group of work-related problems were musculoskeletal problems, 
accounting for 58.2% of work-related problems and managed at a rate of 1.5 per 100 general 
practice encounters. Almost 1 in 10 musculoskeletal problems managed in general practice 
were work related. The most common musculoskeletal work-related problems were back 
complaint (14.6% of work-related problems), sprain and strain (10.6%), unspecified 
musculoskeletal injury (6.9%) and fracture (3.5%). 
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Work-related psychological problems accounted for 10.9% of total work-related problems, 
and were managed at a rate of 0.3 per 100 encounters. The most common were depression 
(4.3% of work-related problems), acute stress reaction (2.6%), anxiety (1.8%) and  
post-traumatic stress disorder (1.5%). Psychological work-related problems accounted for 
only 2.2% of total psychological problems managed in general practice.  
7.8 Management of Type 2 diabetes in 2010–11 
This section (Figure 7.2) uses the example of management of Type 2 diabetes to demonstrate 
how BEACH data pertaining to a selected problem can be analysed and viewed. In this 
section Type 2 diabetes is defined as ICPC-2 code T90. 
Type 2 diabetes is commonly managed in general practice, with 3,566 recorded contacts with 
the problem, a management rate of 3.7 per 100 encounters with patients in 2010–11 (Figure 
7.2). This represents about 4.4 million encounters at which a Type 2 diabetes was managed in 
general practice across Australia in that year. 
Patient age and sex 
Male patients were significantly more likely to have Type 2 diabetes managed (4.3 per 100 
male encounters, 95% CI: 4.2–4.5) than females (2.9 per 100 encounters, 95% CI: 2.8–2.9). 
Patients aged 65–74 years were most likely to have Type 2 diabetes managed (7.7 per 
100 encounters with patients in this age group), followed by patients aged 75 years and over 
(5.8) and those aged 45–64 years (4.8). 
Reasons for encounter  
The most common reasons for encounter given by patients were diabetes (32.8 per 100 Type 
2 diabetes encounters), need for a prescription (24.4), test result (13.6) or a check-up classified 
as endocrine/metabolic (9.6).  
Other problems managed 
Hypertension was the comorbidity most often managed with Type 2 diabetes (23.7 per 100 
Type 2 diabetes encounters), followed by lipid disorders (8.1), immunisation/vaccination 
(4.8), ischaemic heart disease (4.1), and osteoarthritis (4.0).  
Medications 
Medications were prescribed/supplied or advised for over-the-counter purchase in the 
management of Type 2 diabetes (77.7 per 100 problems, 95% CI: 72.4–82.7) significantly more 
often than average for all problems (69.0) in the 2010–11 BEACH year (Table 5.1).  
The medications most often prescribed for Type 2 diabetes were metformin (30.3 per 100 
problems), gliclazide (13.9), insulin gargline (3.1), atorvastatin (2.5), and insulin aspart (2.2). 
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Other treatments 
Other treatments were provided at a rate of 36.7 per 100 Type 2 diabetes problems. The vast 
majority (90%) of these treatments were clinical treatments (33.1 per 100 problems), of which 
counselling and advice about nutrition and weight (10.0), counselling about the diabetes 
problem (5.5), and the provision of medical certificates (3.7) were the most common.  
Procedural treatments were provided at a rate of 6.6 per 100 Type 2 diabetes problems.  
Referrals 
Referrals were provided at a rate of 13.9 per 100 Type 2 diabetes problems. Referrals to allied 
health services (8.1 per 100 diabetes problems, 95% CI: 6.6–9.6) were significantly more 
common than referrals to medical specialists (5.1, 95% CI: 4.2–6.0). 
Imaging 
Imaging was rarely ordered in the management of Type 2 diabetes (0.3 per 100 diabetes 
problems). 
Pathology 
Pathology was ordered in the management of Type 2 diabetes (91.6 per 100 problems,  
95% CI: 84.3–98.9) significantly more often than average for all problems (29.6) in the 2010–11 
BEACH year (Table 5.1).  
The most common pathology tests ordered were HbA1c (26.7 per 100 problems), lipids 
(13.2), electrolytes, urea and creatinine (9.1), other chemistry tests (8.7), glucose/glucose 
tolerance (8.2), and full blood count (8.1). 
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Reasons for encounter 
n = 4,888 (165.6 per 100 T2D problems) 
Rate per 100 encounters(c) 
Diabetes – all* 32.8 
Prescription – all* 24.4 
Test results* 13.6 
Endocrine/metabolic check-up* 9.6 
Cardiac check-up* 8.0 
General check-up* 6.1 
Administrative procedure NOS 4.9 
Hypertension/high blood pressure* 4.6 
Immunisation/vaccination – all* 3.7 
Follow-up enc – endocrine/metabolic 3.1 
Medications 
n = 2,772 (77.7 per 100 T2D problems) 
Rate per 100 problems(d) 
Metformin 30.3 
Gliclazide 13.9 
Insulin gargline 3.1 
Atorvastatin 2.5 
Insulin aspart 2.2 
Pioglitazone 2.1 
Glimepiride 2.1 
Sitagliptin 2.0 
Other problems managed 
n = 4,536 (127.3 per 100 T2D problems) 
Rate per 100 encounters(c) 
Hypertension* 23.7 
Lipid disorders 8.1 
Immunisation/vaccination – all* 4.8 
Ischaemic heart disease* 4.1 
Osteoarthritis* 4.0 
Oesophageal disease 3.2 
Depression* 2.9 
Prescription – all* 2.3 
Atrial fibrillation/flutter 2.1 
Vitamin/nutritional deficiency 2.0 
Other treatments 
n = 1,415 (36.7 per 100 T2D problems) 
Rate per 100 problems(d) 
Clinical treatments 33.1 
 Counselling/advice – nutrition/weight*10.0 
 Counselling – problem* 5.5 
 Other administrative/document* 3.7 
 Counselling/advice – exercise* 3.7 
 Advice/education – treatment* 3.3 
 Advice/education – medication* 3.1 
Procedural treatments 6.6 
 Glucose test 3.2 
 Check-up – practice nurse* 1.9 
Pathology 
n = 3,266 (91.6 per 100 T2D problems) 
Rate per 100 problems(d) 
HbA1c* 26.7 
Lipids* 13.2 
Electrolytes, urea and creatinine* 9.1 
Chemistry, other* 8.7 
Glucose/glucose tolerance* 8.2 
Full blood count* 8.1 
Multibiochemical analysis* 5.4 
Liver function* 5.2 
Referrals 
n = 497 (13.9 per 100 T2D problems) 
Rate per 100 problems(d) 
Allied health services* 8.1 
 Podiatrist/chiropodist 2.9 
 Dietitian/nutritionist 1.8 
 Diabetes education 1.7 
Specialists*  5.1 
 Ophthalmologist 2.4 
 Endocrinologist 1.7 
Type 2 diabetes(a) 
n = 3,566 (3.7 per 100 encounters) 
(a) Type 2 diabetes includes the ICPC-2 rubric T90. 
(b) Age and sex-specific rate per 100 encounters in each age/sex group.  
(c) Expressed as a rate per 100 encounters at which Type 2 diabetes problems were managed. 
(d) Expressed as a rate per 100 Type 2 diabetes problems managed  
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: T2D – Type 2 diabetes; enc – encounter; other administrative/document – other administrative procedure/document (excluding sickness 
certificate) 
Figure 7.2: Management of Type 2 diabetes in general practice, 2010–11 
 
 
 
Imaging 
n = 10 (0.3 per 100 T2D problems) 
Rate per 100 problems(d) 
Test; Doppler 0.1 
The patients  
Sex  Per cent Rate(b) 
Males    54.9 4.3 
Females   45.1 2.9 
 
Age group Per cent Rate(b) 
5–14 years  0.1 0.1 
15–24 years 0.5 0.1 
25–44 years 5.5 0.9 
45–64 years 38.8 4.8 
65–74 years 28.8 7.7 
75+ years  26.3 5.8 
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7.9 Changes in problems managed over the decade 
2001–02 to 2010–11 
Data about the problems managed in general practice from each of the past 10 years of the 
BEACH study, 2001–02 to 2010–11 are reported in the companion report A decade of 
Australian general practice activity 2001–02 to 2010–11.1 Major changes that have occurred over 
the decade are summarised below. 
There was a significant increase in the average number of problems managed at encounter, 
from 143.4 per 100 encounters in 2001–02 to 152.5 in 2010–11. This suggests there were an 
additional 36.8 million problems managed at GP encounters in Australia in 2010–11 than in 
2001–02. This was reflected in a significant increase in the management rate of chronic 
conditions (49.3 rising to 53.1 per 100 encounters) over the decade. 
Changes in the most common individual problems managed in general practice are 
summarised below. 
• The management rate of depression increased from 3.4 per 100 encounters in 2001–02  
to 4.2 in 2010–11, an estimated national increase of 1.7 million occasions of depression 
management in 2010–11 since 2001–02.  
• The management rate of diabetes increased significantly from 3.1 per 100 encounters in 
2001–02 to 4.0 in 2010–11, suggesting about 1.6 million more occasions of diabetes 
management in 2010–11 than in 2001–02. 
• The management rate of general check-up increased from 1.8 per 100 encounters in  
2001–02 to 2.7 in 2010–11. This represents an estimated national increase of 1.4 million 
occasions where a general check-up was managed in 2010–11 since 2001–02. This 
increase possibly reflects the many MBS items for health assessments including the 
annual assessment of patients aged 75 years and over, the health assessment for 45–49 
year olds at risk of developing chronic disease and the assessment of 40–49 year olds at 
risk of Type 2 diabetes.65 
• The management rate of immunisation/vaccinations did not change between 2001–02 
(4.7 per 100 encounters) and 2010–11 (5.5). However there was a significant spike in the 
management rate in 2009–10 (7.3 per 100) that coincided with the concern about H1N1 
influenza. 
• The management rate of URTI decreased marginally from 6.2 per 100 encounters in 
2001–02 to 5.4 in 2010–11. However, the large increase in the number of GP encounters 
provided in Australia (99.9 million in 2001–02 and 118.1 million in 2010–11) outweighed 
this decrease, resulting in 180,000 more occasions where URTI was managed nationally 
in 2010–11 than in 2001–02.  
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8 Overview of management 
The BEACH survey form allows GPs to record several aspects of patient management for 
each problem managed at each encounter. Pharmaceutical management is recorded in detail. 
Other modes of treatment, including clinical treatments (for example, counselling) and 
procedures, recorded briefly in the GP’s own words, are also related to a single problem. The 
form allows for referrals, hospital admissions, pathology and imaging test orders to be 
related to a single problem or to multiple problems (see Appendix 1). 
A summary of management at general practice encounters from 2001–02 to 2010–11 is 
reported for each year in the 10-year report A decade of Australian general practice activity  
2001–02 to 2010–11.1  
At the 95,839 encounters, GPs undertook 217,958 management activities in total. The most 
common management form was medication, either prescribed, GP-supplied, or advised for 
over-the-counter purchase. ‘Other treatments’ were the second most common management 
activity, with clinical treatments more frequent than procedural treatments (Table 8.1). 
For an ‘average’ 100 GP–patient encounters, GPs provided 85 prescriptions, and 36 clinical 
treatments, undertook 17 procedures, made 9 referrals to medical specialists and 4 to allied 
health services, and placed 45 pathology test orders and 10 imaging test orders. 
Table 8.1: Summary of management 
Management type Number 
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems  
(n = 146,141) 
95% 
LCL 
95% 
UCL 
Medications 100,817 105.2 102.8 107.6 69.0 67.6 70.3 
 Prescribed 81,542 85.1 82.9 87.3 55.8 54.5 57.1 
 GP-supplied 9,903 10.3 9.5 11.2 6.8 6.2 7.3 
 Advised OTC 9,371 9.8 9.0 10.5 6.4 5.9 6.9 
Other treatments 50,235 52.4 49.8 55.1 34.4 32.7 36.0 
 Clinical* 34,019 35.5 33.2 37.8 23.3 21.8 24.8 
 Procedural* 16,216 16.9 16.1 17.8 11.1 10.6 11.6 
Referrals 13,526 14.1 13.5 14.7 9.3 8.9 9.6 
 Medical specialist* 8,248 8.6 8.2 9.0 5.6 5.4 5.9 
 Allied health services* 4,039 4.2 3.9 4.5 2.8 2.6 2.9 
 Hospital* 364 0.4 0.3 0.4 0.3 0.2 0.3 
 Emergency department* 291 0.3 0.3 0.4 0.2 0.2 0.2 
 Other referrals* 584 0.6 0.5 0.7 0.4 0.3 0.5 
Pathology 43,313 45.2 43.4 47.0 29.6 28.6 30.7 
Imaging 9,370 9.8 9.4 10.2 6.4 6.1 6.7 
Other investigations(a) 697 0.7 0.7 0.8 0.5 0.4 0.5 
Total management activities 217,958 227.4 — — 149.2 — — 
(a) Other investigations reported here include only those ordered by the GP. Other investigations in Chapter 12 include those ordered by the GP 
and those done by the GP or practice staff. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; OTC – over-the-counter. 
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Analysing the number of encounters or problems for which at least one form of management 
was recorded by the GPs gives us another perspective (Table 8.2). At least one management 
action was recorded at 91.5% of encounters, for 85.9% of problems managed. 
• At least one medication or other treatment was given for nearly three-quarters (72.4%) of 
the problems managed. 
• At least one medication (most commonly prescribed) was prescribed, supplied or 
advised for more than half (54.0%) of the problems managed. 
• At least one other treatment (most commonly clinical) was provided for nearly one-third 
(30.4%) of problems managed. 
• At least one referral (most commonly to a medical specialist) was made for 9.2% of 
problems managed. 
• At least one investigation (most commonly pathology) was requested for 18.2% of 
problems managed (Table 8.2). 
Table 8.2: Encounters and problems for which management was recorded 
Management type 
Number of 
encounters 
Per cent of all 
encounters 
(n = 95,839) 
Number of 
problems 
Per cent of all 
problems 
(n = 146,141) 
At least one management type 87,656 91.5 125,541 85.9 
 At least one medication or other treatment 78,005 81.4 105,830 72.4 
  At least one medication  62,019 64.7 78,987 54.0 
  At least one prescription 52,016 54.3 65,262 44.7 
  At least one GP-supplied 7,684 8.0 7,897 5.4 
  At least one OTC advised 8,257 8.6 8,499 5.8 
  At least one other treatment 38,411 40.1 44,447 30.4 
  At least one clinical treatment 26,772 27.9 30,507 20.9 
  At least one procedural treatment 14,499 15.1 15,194 10.4 
 At least one referral 12,486 13.0 13,461 9.2 
  At least one referral to a medical specialist 7,874 8.2 8,353 5.7 
  At least one referral to allied health services 3,780 3.9 3,995 2.7 
  At least one referral to hospital 364 0.4 386 0.3 
  At least one referral to emergency department 291 0.3 315 0.2 
  At least one other referral 584 0.6 609 0.4 
 At least one investigation 23,121 24.1 26,579 18.2 
  At least one pathology order 17,072 17.8 19,493 13.3 
  At least one imaging order 8,009 8.4 8,315 5.7 
  At least one other investigation(a) 675 0.7 680 0.5 
(a) Other investigations reported here only include those ordered by the GP. Other investigations in Chapter 12 include those ordered by the 
GP and those done by the GP or practice staff. 
Note: OTC – over-the-counter; NOS – not otherwise specified. 
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The combinations of management types related to each problem were investigated. The 
majority of treatments occurred either as a single component or in combination with one 
other component. Management was provided: 
• as a single component for almost two-thirds (63.0%) of the problems managed 
• as a double component for 19.0% of problems managed 
• rarely with more than two components (results not tabled). 
Table 8.3 lists the most common management combinations. Medication alone was the most 
common management, followed by a clinical treatment alone, and the combination of a 
medication and a clinical treatment. When a problem was referred to another health 
professional it was most likely that no other treatments were given for the problem at the 
encounter.  
Table 8.3: Most common management combinations 
1+ 
medication 
1+ clinical 
treatment 
1+ procedural  
treatment 1+ referral 
1+ imaging 
order 
1+ pathology 
order 
Per cent of 
total problems  
(n = 146,141) 
Per cent  
of total 
encounters 
 (n = 95,839) 
No recorded management 14.1 8.5 
1+ management recorded 85.9 91.5 
      37.4 31.4 
      9.4 6.9 
      6.1 10.2 
      5.0 2.9 
      4.6 3.4 
      4.3 3.7 
      3.2 4.7 
      2.6 4.3 
      2.3 1.7 
      1.3 1.3 
      1.3 3.0 
      1.2 1.3 
      1.0 1.9 
      0.9 1.2 
      0.5 1.7 
      0.5 0.6 
      0.4 1.1 
      0.3 1.1 
      0.3 0.6 
      0.3 0.5 
      0.3 0.4 
Note: 1+ – at least one specified management type. 
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8.1 Changes in management over the decade 
2001–02 to 2010–11 
Changes over the decade 2001–02 to 2010–11 are described in detail in the accompanying 
report A decade of Australian general practice activity 2001–02 to 2010–11.1 In that publication, 
changes over time are largely reported in terms of change in management actions as a rate 
per 100 problems. This reflects change in how GPs are managing problems after accounting 
for the significant increase in the number of problems managed per encounter over the 
decade (see Section 7.9). 
The major changes over the 10 years to 2010–11 are summarised below. 
• There was a significant decrease in the proportion of problems managed for which one 
or more medications were prescribed (from 49.8% to 44.7%), and in the total number of 
medications prescribed (from 61.3 per 100 problems managed to 55.8).  
• There was a significant increase in the proportion of problems for which the GP supplied 
medication direct to the patients (from 4.3% to 5.4% of problems managed), and an 
increase in the total number of medications supplied in this manner (5.3 medications to 
6.8 per 100 problems managed). 
• One or more procedures were undertaken for a significantly greater proportion of the 
problems managed in 2010–11 (10.4%) than in 2001–02 (9.1%). The rate at which 
procedures were undertaken by GPs increased from 9.6 to 11.1 procedures per 100 
problems managed over the decade.  
• The likelihood of patients being referred for the problem being managed increased 
significantly (from 7.3% of problems managed in 2001–02 to 9.2% in 2010–11 being 
referred), particularly to medical specialists (from 5.1% in 2001–02 to 5.7% in 2010–11), 
allied health services (1.6% to 2.7%), and emergency departments (from 0.1% to 0.2%).  
• There was an increase in the likelihood of the GP ordering at least one investigation for 
the problem under management, 15.3% of problems being sent for investigation in 2001–
02 and 18.2% in 2010–11. In 2001–02, at least one pathology test was ordered for 10.8% of 
problems managed, and at least one imaging test was ordered for 5.0%. By 2010–11 these 
proportions had significantly increased to 13.3% and 5.7% of problems, respectively.  
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9 Medications 
GPs could record up to four medications for each of four problems – a maximum of 
16 medications per encounter. Each medication could be recorded as prescribed (the default), 
supplied by the GP, or recommended for over-the-counter (OTC) purchase. 
• GPs were asked to: 
– record the generic or brand name, the strength, regimen and number of repeats 
ordered for each medication 
– designate this as a new or continued medication for this patient for this problem. 
• Generic or brand names were entered into the database in the form recorded by the GP. 
• Medications were coded using the Coding Atlas of Pharmaceutical Substances (CAPS) 
system (developed by the FMRC) which is able to capture details of products at the 
brand and generic level. Every medication in the CAPS coding system is mapped to the 
international Anatomical Therapeutic Chemical (ATC) classification.66 
• The reporting of results at drug group, subgroup and generic level uses 
ATC levels 1, 3 and 5. The most frequently prescribed, supplied or advised individual 
medications are reported at the CAPS generic level (the equivalent of ATC Level 5) 
because ATC does not include many over-the-counter medications that arise in BEACH. 
Further, some ATC level 5 labels are not specific enough for clarity. 
Data on medications are reported for each year from 2001–02 to 2010–11 in the 10-year 
summary report, A decade of Australian general practice activity 2001–02 to 2010–11.1 
Readers interested in adverse drug events will find more detailed information from the 
BEACH program in Miller et al. (2006) Adverse drug events in general practice patients in 
Australia.67 
9.1 Source of medications 
As reported in Chapter 8, a total of 100,817 medications were recorded, at rates of 105 per 
100 encounters and 69 per 100 problems managed. 
• Four out of five medications (80.9%) were prescribed. 
• One in ten (9.8%) medications was supplied to the patient by the GP. 
• There were 9.3% of medications recommended by the GP for OTC purchase. 
When rate per 100 encounter results are extrapolated to the 118.1 million general practice 
Medicare-claimed encounters in Australia April 2010 – March 2011, GPs in Australia: 
• prescribed medications more than 100.5 million times 
• supplied 12.2 million medications directly to the patient 
• recommended medications for OTC purchase 11.6 million times. 
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9.2 Prescribed medications 
There were 81,542 prescriptions recorded, at rates of 85 per 100 encounters and 
56 per 100 problems managed (Table 8.1). GPs recorded 84.2% of prescribed medications by 
brand (proprietary) name and 15.8% by their generic (non-proprietary) name (results not 
tabled). 
On a per problem basis: 
• no prescription was given for 55.3% of all problems managed 
• one prescription was given for 36.3% of problems managed 
• two prescriptions were given for 6.2% of problems managed 
• three or four prescriptions were given for 2.1% of problems managed (Figure 9.1). 
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Figure 9.1: Number of medications prescribed per problem 
Number of repeats 
For 62,602 prescriptions (76.8% of all prescriptions) the GPs recorded ‘number of repeats’. 
The distribution of the specified number of repeats (from nil to more than five) is provided in 
Figure 9.2. For 34.7% of these prescriptions, the GP specified that no repeats had been 
prescribed, and for 35.4% five repeats were ordered. The latter proportion reflects the PBS 
provision of 1 month’s supply and five repeats for many medications used for chronic 
conditions such as hypertension. The ordering of one repeat was also quite common (15.9%). 
 
Per cent of problems 
Number of medications prescribed 
 73 
 
0
5
10
15
20
25
30
35
40
34.7 15.9 9.8 3.3 0.8 35.4 0.2
Nil One Two Three Four Five > Five
 
 
Figure 9.2: Number of repeats ordered per prescription 
Age–sex-specific rates of prescribed medications 
Age–sex-specific analysis found similar prescription rates per 100 encounters (where age and 
sex was known) for males and females (87 and 84 respectively). It also showed the well-
described tendency for the number of prescriptions written at each encounter to rise with the 
advancing age of the patient, with the rate of 58 per 100 encounters with patients aged less 
than 25 years almost doubling to 109 per 100 encounters for patients aged 65 years and over 
(results not tabled). 
Figure 9.3, however, demonstrates that this age-based increase lessens if the prescription rate 
is considered in terms of the number of problems being managed in each age group. This 
suggests that a substantial part of the increase in prescription rate for older patients is due to 
the increased number of health problems they have managed at an encounter. The remaining 
increase in prescription rate associated with patient age is probably a reflection of the 
problems under management, which are more likely to be chronic at encounters with older 
patients.  
Per cent of prescriptions 
Number of repeats ordered 
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Figure 9.3: Age–sex-specific prescription rates per 100 problems managed 
Types of medications prescribed 
Table 9.1 shows the distribution of prescribed medications using the WHO ATC 
classification.66 This allows comparison with other data sources such as those produced by 
Medicare Australia for PBS data. The table lists medications in frequency order within ATC 
levels 1, 3 and 5. Prescriptions are presented as a percentage of total prescriptions, as a rate 
per 100 encounters, and as a rate per 100 problems managed, with 95% confidence intervals.  
The high number of opioids shown in this table (compared with BEACH data published 
before 2010) is due to our re-classification of some medications in 2010. We decided to recode 
codeine combinations which contained 30 mg of codeine as opioids in the ATC Index, 
whereas in the past they were coded as ‘other analgesics and antipyretics’. In the ATC 
classification, either grouping is correct. We took the decision to place high-dose codeine 
products in the opioid group in accordance with MIMS grouping68 and following the Poisons 
Regulations of the Therapeutic Goods Administration,69 which stipulates that high-dose 
codeine combinations are Schedule 4 (prescription only) medications. However, a few 
combination analgesics containing less than 30 mg of codeine but classified as Schedule 4 
may be missed because there are other criteria which form part of the scheduling of 
prescription-only codeine. One of these is pack-size, which is not recorded in BEACH. 
Similarly, before 2010 all aspirin (acetylsalicylic acid) was classified in the analgesic group of 
neurological medications. In 2010 we split aspirin into two different codes depending on 
dosage. We reclassified low-dose (100 mg) plain aspirin as an anti-thrombotic medication in 
the blood medications group, while higher doses and combinations with other 
analgesic/antipyretics remain in the neurological group. 
If readers are making comparisons with previous BEACH publications, they should note that 
this change has caused the opioid and anti-thrombotic groups to increase, and ‘other 
analgesics and antipyretics’ to decrease. In the companion report to this current publication, 
A decade of Australian general practice activity 2001–02 to 2010–11,1 medications have been re-
analysed across all 10 years to incorporate the adjustment.  
Rate per 100 problems 
Age group (years) 
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Table 9.1: Prescribed medications by ATC levels 1, 3 and 5  
ATC  
Level 1 ATC Level 3 ATC Level 5 Number 
Per cent of 
prescribed 
medications 
(n = 81,542) 
Rate per 100 
encounters 
(95% CI) 
(n = 95,839) 
Rate per 100 
problems 
(95% CI) 
(n = 146,141) 
Nervous system    18,124 22.2 18.9 
(18.1–19.7) 
12.4 
(11.9–12.9) 
  Opioids  5,235 6.4 5.5 
5.1–5.8 
3.6 
(3.4–3.8) 
   Codeine, combinations excl. 
psycholeptics 
1,714 2.1 1.8 
(1.7–1.9) 
1.2 
(1.1–1.3) 
   Oxycodone 1,401 1.7 1.5 
(1.3–1.6) 
1.0 
(0.9–1.0) 
   Tramadol 830 1.0 0.9 
(0.8–1.0) 
0.6 
(0.5–0.6) 
  Antidepressants  3,757 4.6 3.9 
(3.7–4.1) 
2.6 
(2.4–2.7) 
   Sertraline 553 0.7 0.6 
(0.5–0.6) 
0.4 
(0.3–0.4) 
   Venlafaxine 496 0.6 0.5 
(0.5–0.6) 
0.3 
(0.3–0.4) 
  Other analgesics and antipyretics 2,734 3.4 2.9 
(2.6–3.1) 
1.9 
(1.7–2.0) 
   Paracetamol [plain] 2,427 3.0 2.5 
(2.3–2.8) 
1.7 
(1.5–1.8) 
  Anxiolytics  1,742 2.1 1.8 
(1.6–2.0) 
1.2 
(1.1–1.3) 
   Diazepam 996 1.2 1.0 
(0.9–1.2) 
0.7 
(0.6–0.8) 
  Hypnotics and sedatives 1,438 1.8 1.5 
(1.4–1.6) 
1.0 
(0.9–1.1) 
   Temazepam 955 1.2 1.0 
(0.9–1.1) 
0.7 
(0.6–0.7) 
  Antipsychotics  1,146 1.4 1.2 
(1.1–1.3) 
0.8 
(0.7–0.9) 
   Prochlorperazine 505 0.6 0.5 
(0.5–0.6) 
0.3 
(0.3–0.4) 
  Drugs used in addictive disorders 770 0.9 0.8 
(0.7–0.9) 
0.5 
(0.5–0.6) 
   Varenicline 513 0.6 0.5 
(0.5–0.6) 
0.4 
(0.3–0.4) 
  Antiepileptics  737 0.9 0.8 
(0.7–0.9) 
0.5 
(0.4–0.6) 
Anti-infective for systemic use 15,787 19.4 16.5 
(15.9–17.0) 
10.8 
(10.4–11.2) 
  Beta-lactam antibacterials, penicillins 6,089 7.5 6.4 
(6.0–6.7) 
4.2 
(3.9–4.4) 
 
 Amoxycillin 3,117 3.8 3.3 
(3.0–3.5) 
2.1 
(2.0–2.3) 
 
 Amoxycillin and enzyme 
inhibitor 
1,905 2.3 2.0 
(1.8–2.2) 
1.3 
(1.2–1.4) 
 (continued) 
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5 
ATC  
Level 1 ATC Level 3 ATC Level 5 Number 
Per cent of 
prescribed 
medications 
(n = 81,542) 
Rate per 100 
encounters 
(95% CI) 
(n = 95,839) 
Rate per 100 
problems 
(95% CI) 
(n = 146,141) 
 Other beta-lactam antibacterials 3,155 3.9 3.3 
(3.1–3.5) 
2.2 
(2.0–2.3) 
  Cefalexin 2,616 3.2 2.7 
(2.5–2.9) 
1.8 
(1.7–1.9) 
 Macrolides, lincosamides and streptogramins 2,434 3.0 2.5 
(2.4–2.7) 
1.7 
(1.5–1.8) 
  Roxithromycin 1,060 1.3 1.1 
(1.0–1.2) 
0.7 
(0.7–0.8) 
  Erythromycin 663 0.8 0.7 
(0.6–0.8) 
0.5 
(0.4–0.5) 
  Clarithromycin 488 0.6 0.5 
(0.4–0.6) 
0.3 
(0.3–0.4) 
 Viral vaccines 822 1.0 0.9 
(0.7–1.0) 
0.6 
(0.5–0.7) 
 Tetracyclines 756 0.9 0.8 
(0.7–0.9) 
0.5 
(0.5–0.6) 
  Doxycycline 673 0.8 0.7 
(0.6–0.8) 
0.5 
(0.4–0.5) 
 Sulfonamides and trimethoprim 707 0.9 0.7 
(0.7–0.8) 
0.5 
(0.4–0.5) 
  Trimethoprim 481 0.6 0.5 
(0.4–0.6) 
0.3 
(0.3–0.4) 
Cardiovascular system  15,664 19.2 16.3 
(15.5–17.2) 
10.7 
(10.2–11.2) 
 Lipid modifying agents, plain 3,436 4.2 3.6 
(3.4–3.8) 
2.4 
(2.2–2.5) 
  Atorvastatin 1,516 1.9 1.6 
(1.5–1.7) 
1.0 
(1.0–1.1) 
  Rosuvastatin 909 1.1 0.9 
(0.9–1.0) 
0.6 
(0.6–0.7) 
  Simvastatin 593 0.7 0.6 
(0.6–0.7) 
0.4 
(0.4–0.4) 
 Angiotensin II antagonists, plain 2,192 2.7 2.3 
(2.1–2.5) 
1.5 
(1.4–1.6) 
  Irbesartan 806 1.0 0.8 
(0.7–0.9) 
0.6 
(0.5–0.6) 
  Candesartan 616 0.8 0.6 
(0.6–0.7) 
0.4 
(0.4–0.5) 
  Telmisartan 602 0.7 0.6 
(0.5–0.7) 
0.4 
(0.4–0.5) 
 ACE inhibitors, plain 2,121 2.6 2.2 
(2.1–2.4) 
1.5 
(1.4–1.6) 
  Perindopril 1,116 1.4 1.2 
(1.1–1.3) 
0.8 
(0.7–0.8) 
  Ramipril 625 0.8 0.7 
(0.6–0.7) 
0.4 
(0.4–0.5) 
(continued) 
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5 
ATC  
Level 1 ATC Level 3 ATC Level 5 Number 
Per cent of 
prescribed 
medications 
(n = 81,542) 
Rate per 100 
encounters 
(95% CI) 
(n = 95,839) 
Rate per 100 
problems 
(95% CI) 
(n = 146,141) 
 Beta blocking agents 1,629 2.0 1.7 
(1.6–1.8) 
1.1 
(1.0–1.2) 
  Atenolol 716 0.9 0.7 
(0.7–0.8) 
0.5 
(0.4–0.5) 
  Metoprolol 498 0.6 0.5 
(0.5–0.6) 
0.3 
(0.3–0.4) 
 Angiotensin II antagonists, combinations 1,405 1.7 1.5 
(1.3–1.6) 
1.0 
(0.9–1.0) 
  Irbesartan and diuretics 685 0.8 0.7 
(0.6–0.8) 
0.5 
(0.4–0.5) 
 Selective calcium channel blockers with mainly 
vascular effects 
1,367 1.7 1.4 
(1.3–1.5) 
0.9 
(0.9–1.0) 
  Amlodipine 579 0.7 0.6 
(0.5–0.7) 
0.4 
(0.4–0.4) 
 ACE inhibitors, combinations 579 0.7 0.6 
(0.5–0.7) 
0.4 
(0.4–0.4) 
 High-ceiling diuretics 576 0.7 0.6 
(0.5–0.7) 
0.4 
(0.4–0.4) 
  Furosemide 568 0.7 0.6 
(0.5–0.7) 
0.4 
(0.3–0.4) 
Alimentary tract and metabolism 7,971 9.8 8.3 
(7.9–8.7) 
5.5 
(5.2–5.7) 
 Drugs for peptic ulcer and gastro-oesophageal 
reflux 
2,939 3.6 3.1 
(2.9–3.2) 
2.0 
(1.9–2.1) 
  Esomeprazole 1,184 1.5 1.2 
(1.1–1.3) 
0.8 
(0.7–0.9) 
  Pantoprazole 628 0.8 0.7 
(0.6–0.7) 
0.4 
(0.4–0.5) 
 Blood glucose lowering drugs, excluding insulins 2,200 2.7 2.3 
(2.1–2.5) 
1.5 
(1.4–1.6) 
  Metformin 1,254 1.5 1.3 
(1.2–1.4) 
0.9 
(0.8–0.9) 
  Gliclazide 554 0.7 0.6 
(0.5–0.6) 
0.4 
(0.3–0.4) 
 Propulsives 636 0.8 0.7 
(0.6–0.7) 
0.4 
(0.4–0.5) 
  Metoclopramide 525 0.6 0.5 
(0.5–0.6) 
0.4 
(0.3–0.4) 
(continued) 
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5  
ATC  
Level 1 ATC Level 3 ATC Level 5 Number 
Per cent of 
prescribed 
medications 
(n = 81,542) 
Rate per 100 
encounters 
(95% CI) 
(n = 95,839) 
Rate per 100 
problems 
(95% CI) 
(n = 146,141) 
Respiratory system 5,297 6.5 5.5 
(5.1–5.9) 
3.6 
(3.4–3.9) 
 Adrenergics, inhalants 2,746 3.4 2.9 
(2.7–3.1) 
1.9 
(1.7–2.0) 
  Salbutamol 1,284 1.6 1.3 
(1.2–1.5) 
0.9 
(0.8–1.0) 
  Salmeterol and other drugs for 
obstructive airways disease 
812 1.0 0.8 
(0.8–0.9) 
0.6 
(0.5–0.6) 
  Formoterol and other drugs for 
obstructive airways disease 
519 0.6 0.5 
(0.5–0.6) 
0.4 
(0.3–0.4) 
 Decongestants and other nasal preparations for 
topical use 
890 1.1 0.9 
(0.8–1.0) 
0.6 
(0.5–0.7) 
 Other drugs for obstructive airway diseases, 
inhalants 
841 1.0 0.9 
(0.8–1.0) 
0.6 
(0.5–0.6) 
Musculoskeletal system 4,141 5.1 4.3 
(4.1–4.6) 
2.8 
(2.7–3.0) 
 Anti-inflammatory and antirheumatic products, 
non-steroid 
3,040 3.7 3.2 
(3.0–3.4) 
2.1 
(1.9–2.2) 
  Meloxicam 922 1.1 1.0 
(0.9–1.1) 
0.6 
(0.6–0.7) 
  Diclofenac 597 0.7 0.6 
(0.5–0.7) 
0.4 
(0.4–0.5) 
  Celecoxib 498 0.6 0.5 
(0.5–0.6) 
0.3 
(0.3–0.4) 
Dermatologicals 3,683 4.5 3.8 
(3.6–4.1) 
2.5 
(2.4–2.7) 
 Corticosteroids, plain 2,218 2.7 2.3 
(2.2–2.5) 
1.5 
(1.4–1.6) 
  Betamethasone 757 0.9 0.8 
(0.7–0.9) 
0.5 
(0.5–0.6) 
  Mometasone 627 0.8 0.7 
(0.6–0.7) 
0.4 
(0.4–0.5) 
Genitourinary system and sex hormones 3,014 3.7 3.1 
(3.0–3.3) 
2.1 
(1.9–2.2) 
 Hormonal contraceptives for systemic use 1,343 1.6 1.4 
(1.3–1.5) 
0.9 
(0.8–1.0) 
  Levonorgestrel and oestrogen 742 0.9 0.8 
(0.7–0.9) 
0.5 
(0.5–0.6) 
Blood and blood forming organs 2,647 3.2 2.8 
(2.5–3.0) 
1.8 
(1.7–1.9) 
 Antithrombotic agents 2,046 2.5 2.1 
(2.0–2.3) 
1.4 
(1.3–1.5) 
  Warfarin 1,129 1.4 1.2 
(1.0–1.3) 
0.8 
(0.7–0.9) 
(continued) 
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5  
ATC  
Level 1 ATC Level 3 ATC Level 5 Number 
Per cent of 
prescribed 
medications 
(n = 81,542) 
Rate per 100 
encounters 
(95% CI) 
(n = 95,839) 
Rate per 100 
problems 
(95% CI) 
(n = 146,141) 
Sensory organs  2,351 2.9 2.5 
(2.3–2.6) 
1.6 
(1.5–1.7) 
  Anti-infective ophthalmological  923 1.1 1.0 
(0.9–1.0) 
0.6 
(0.6–0.7) 
    Chloramphenicol 
ophthalmological 
850 1.0 0.9 
(0.8–1.0) 
0.6 
(0.5–0.6) 
  Corticosteroids and anti-infective in combination 
otological  
660 0.8 0.7 
(0.6–0.8) 
0.5 
(0.4–0.5) 
Systemic hormonal preparations, excl. sex hormones  2,078 2.5 2.2 
(2.0–2.3) 
1.4 
(1.3–1.5) 
  Corticosteroids for systemic use, plain  1,199 1.5 1.3 
(1.1–1.4) 
0.8 
(0.7–0.9) 
    Prednisolone 780 1.0 0.8 
(0.7–0.9) 
0.5 
(0.5–0.6) 
  Thyroid preparations  673 0.8 0.7 
(0.6–0.8) 
0.5 
(0.4–0.5) 
    Levothyroxine sodium 672 0.8 0.7 
(0.6–0.8) 
0.5 
(0.4–0.5) 
Antineoplastic and immunomodulating agents  377 0.5 0.4 
(0.3–0.4) 
0.3 
(0.2–0.3) 
Various  254 0.3 0.3 
(0.2–0.3) 
0.2 
(0.1–0.2) 
Antiparasitic products, insecticides and repellent 156 0.2 0.2 
(0.1–0.2) 
0.1 
(0.1–0.1) 
Total prescribed medications 81,542 100.0 85.1 
(82.9–87.3) 
55.8 
(54.5–57.1) 
Note: ATC – Anatomical Therapeutic Chemical classification; CI – confidence interval; ACE – angiotensin-converting enzyme. 
Most frequently prescribed medications 
The most frequently prescribed individual medications are reported at the CAPS generic 
level (ATC Level 5 equivalent) in Table 9.2. Together these 30 medications made up 43.0% of 
all prescribed medications.  
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Table 9.2: Most frequently prescribed medications  
Generic medication Number 
Per cent of 
prescribed 
medications 
(n = 81,542) 
Rate per 100 
encounters  
(95% CI) 
(n = 95,839) 
Rate per 100 
problems 
(95% CI) 
(n = 146,141) 
Amoxycillin 3,117 3.8 3.3 (3.0–3.5) 2.1 (2.0–2.3) 
Cephalexin 2,616 3.2 2.7 (2.5–2.9) 1.8 (1.7–1.9) 
Paracetamol [plain] 2,427 3.0 2.5 (2.3–2.8) 1.7 (1.5–1.8) 
Amoxycillin/potassium clavulanate 1,905 2.3 2.0 (1.8–2.2) 1.3 (1.2–1.4) 
Paracetamol/codeine [all] 1,793 2.2 1.9 (1.7–2.0) 1.2 (1.1–1.3) 
Atorvastatin 1,516 1.9 1.6 (1.5–1.7) 1.0 (1.0–1.1) 
Oxycodone 1,401 1.7 1.5 (1.3–1.6) 1.0 (0.9–1.0) 
Salbutamol 1,327 1.6 1.4 (1.2–1.5) 0.9 (0.8–1.0) 
Metformin 1,254 1.5 1.3 (1.2–1.4) 0.9 (0.8–0.9) 
Esomeprazole 1,184 1.5 1.2 (1.1–1.3) 0.8 (0.7–0.9) 
Warfarin sodium 1,129 1.4 1.2 (1.0–1.3) 0.8 (0.7–0.9) 
Perindopril 1,116 1.4 1.2 (1.1–1.3) 0.8 (0.7–0.8) 
Roxithromycin 1,060 1.3 1.1 (1.0–1.2) 0.7 (0.7–0.8) 
Diazepam 996 1.2 1.0 (0.9–1.2) 0.7 (0.6–0.8) 
Temazepam 955 1.2 1.0 (0.9–1.1) 0.7 (0.6–0.7) 
Meloxicam 922 1.1 1.0 (0.9–1.1) 0.6 (0.6–0.7) 
Rosuvastatin 909 1.1 0.9 (0.9–1.0) 0.6 (0.6–0.7) 
Chloramphenicol eye 850 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
Tramadol 830 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
Fluticasone/salmeterol 812 1.0 0.8 (0.8–0.9) 0.6 (0.5–0.6) 
Irbesartan 806 1.0 0.8 (0.7–0.9) 0.6 (0.5–0.6) 
Betamethasone topical 757 0.9 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Levonorgestrel/ethinyloestradiol 740 0.9 0.8 (0.7–0.8) 0.5 (0.5–0.6) 
Atenolol 716 0.9 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
Irbesartan/hydrochlorothiazide 685 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
Doxycycline 673 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
Thyroxine 672 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
Erythromycin 663 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
Pantoprazole 628 0.8 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
Mometasone 627 0.8 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
Subtotal 35,084 43.0 — — 
Total prescribed medications 81,542 100.0 85.1 (82.9–87.3) 55.8 (54.5–57.1) 
Note: CI – confidence interval. 
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9.3 Medications supplied by GPs 
GPs supplied patients with 9,903 medications in 2010–11, at a rate of 10.3 medications per 
100 encounters. At least one medication was supplied at 8.0% of encounters for 5.4% of 
problems. Table 9.3 shows the medications supplied most often at the CAPS generic level 
(ATC Level 5 equivalent), with vaccines accounting for six out of ten supplied medications.  
Table 9.3: Medications most frequently supplied by GPs  
Generic medication Number 
Per cent of GP 
supplied 
medications 
(n = 9,903) 
Rate per 100 
encounters 
(95% CI) 
(n = 95,839) 
Rate per 100 
problems 
(95% CI) 
(n = 146,141) 
Influenza virus vaccine 2,550 25.7 2.7 (2.2–3.1) 1.7 (1.5–2.0) 
Pneumococcal vaccine 574 5.8 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
Vitamin B12 (Cobalamin) 366 3.7 0.4 (0.3–0.4) 0.3 (0.2–0.3) 
Diphtheria/pertussis/tetanus/hepatitis B/polio/Hib vaccine 357 3.6 0.4 (0.3–0.4) 0.2 (0.2–0.3) 
Mumps/measles/rubella vaccine 352 3.6 0.4 (0.3–0.4) 0.2 (0.2–0.3) 
Triple antigen (diphtheria/pertussis/tetanus)  321 3.2 0.3 (0.3–0.4) 0.2 (0.2–0.3) 
Rotavirus vaccine 240 2.4 0.3 (0.2–0.3) 0.2 (0.1–0.2) 
Diphtheria/pertussis/tetanus/polio vaccine 209 2.1 0.2 (0.2–0.3) 0.1 (0.1–0.2) 
ADT/CDT (diphtheria/tetanus) vaccine 192 1.9 0.2 (0.2–0.2) 0.1 (0.1–0.2) 
Meningitis vaccine 172 1.7 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Haemophilus B vaccine 167 1.7 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Chickenpox (Varicella zoster) vaccine 166 1.7 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Hepatitis B vaccine 142 1.4 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Hepatitis A/Typhoid vaccine (Salmonella typhi) 134 1.3 0.1 (0.1–0.2) 0.1 (0.0–0.1) 
Hepatitis A vaccine 132 1.3 0.1 (0.1–0.2) 0.1 (0.0–0.1) 
Immunization 129 1.3 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Typhoid vaccine (Salmonella typhi) 127 1.3 0.1 (0.1–0.2) 0.1 (0.0–0.1) 
Allergen treatment 115 1.2 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Metoclopramide 84 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Esomeprazole 82 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Betamethasone systemic 81 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Methylprednisolone 71 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Hepatitis A and B vaccine 66 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Medroxyprogesterone 64 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Budesonide/eformoterol 64 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Steroid injection NEC 62 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Meloxicam 59 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Paracetamol 56 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Celecoxib 56 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Testosterone 55 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Subtotal 7,243 73.1 — — 
Total supplied medications 9,903 100.0 10.3 (9.5–11.2) 6.8 (6.2–7.3) 
Note: CI – confidence interval; NEC – not elsewhere classified. 
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9.4 Medications advised for over-the-counter 
purchase 
The GPs recorded 9,371 medications as recommended for OTC purchase, at rates of 9.8 per 
100 encounters and 6.4 per 100 problems managed. At least one OTC medication was 
recorded as advised at 8.6% of encounters and for 5.8% of problems. Table 9.4 shows the top 
30 advised medications at the CAPS generic level (ATC Level 5 equivalent). A wide range of 
medications was recorded in this group, the most common being paracetamol, which 
accounted for 26.9% of these medications. 
The re-classification of aspirin described in section 9.2 also has an impact on the rate of OTC-
advised aspirin, which is lower than that published before 2010. Only the higher-dose 
analgesic aspirin appears in this table because the frequency of OTC-advised low-dose 
aspirin for anti-thrombotic purposes was too low for inclusion. 
Table 9.4: Most frequently advised over-the-counter medications  
Generic medication Number 
Per cent of OTC 
medications 
(n = 9,371) 
Rate per 100 
encounters  
(95% CI) 
(n = 95,839) 
Rate per 100 
problems 
(95% CI) 
(n = 146,141) 
Paracetamol [plain] 2,519 26.9 2.6 (2.3–2.9) 1.7 (1.5–1.9) 
Ibuprofen 549 5.9 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
Saline bath/solution/gargle 226 2.4 0.2 (0.2–0.3) 0.2 (0.1–0.2) 
Sodium chloride topical nasal 218 2.3 0.2 (0.2–0.3) 0.1 (0.1–0.2) 
Loratadine 190 2.0 0.2 (0.2–0.2) 0.1 (0.1–0.2) 
Cetirizine 184 2.0 0.2 (0.1–0.2) 0.1 (0.1–0.2) 
Ergocalciferol (Vitamin D analogue) 174 1.9 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Diclofenac topical 162 1.7 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Sodium/potassium/citric/glucose 155 1.7 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Clotrimazole topical 131 1.4 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Hydrocortisone/clotrimazole 117 1.2 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Fexofenadine 101 1.1 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Aspirin [analgesic] 89 1.0 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Cold and Flu medication NEC 87 0.9 0.1 (0.0–0.1) 0.1 (0.0–0.1) 
Hyoscine butylbromide 85 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Docusate otic 79 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Codeine/paracetamol/pseudoephedrine 78 0.8 0.1 (0.0–0.1) 0.1 (0.0–0.1) 
Paracetamol/codeine [all] 75 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Clotrimazole vaginal 74 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Cream/ointment/lotion NEC 69 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Multivitamins with minerals 66 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Cholecalciferol 65 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Sodium bicarbonate/citrate/tartaric acid 65 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
(continued) 
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Table 9.4 (continued): Most frequently advised over-the-counter medications  
Generic medication Number 
Per cent of OTC 
medications 
(n = 9,371) 
Rate per 100 
encounters(a)  
(95% CI) 
(n = 95,839) 
Rate per 100 
problems(a) 
(95% CI) 
(n = 146,141) 
Folic acid 64 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Simple analgesics 64 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Hydrocortisone topical 61 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Loperamide 60 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Vitamin D 60 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Sorbolene/glycerol/cetomacrogol 60 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Codeine phosphate/ibuprofen 57 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Subtotal 5,985 63.9 — — 
Total advised medications 9,371 100.0 9.8 (9.0–10.5) 6.4 (5.9–6.9) 
Note: OTC – over-the-counter medication; CI – confidence interval; NEC – not elsewhere classified. 
9.5 Statins prescribed or supplied in 2010–11  
Included in this analysis were all HMG CoA reductase inhibitors (ATC code C10AA), 
commonly called statins, and combination products of statins with other medications (ATC 
code C10B). The relationships between patients, their reasons for encounter and the 
problems managed with statins are presented in Figure 9.4. Statins were prescribed or 
supplied by GPs at a rate of 3.7 per 100 total encounters, and 2.4 per 100 problems managed, 
and they accounted for 3.5% of all medications recorded. For every 100 problems managed 
with a statin, 99 statins were prescribed and one was supplied by the GP. 
Patient age and sex 
While 45–64 year old patients accounted for the largest proportion (42.1%) of patients 
prescribed/supplied a statin, those aged 65–74 years were the most likely to be prescribed or 
supplied a statin at encounter (8.3%). At encounters with patients aged 45–64 years, 5.6% 
included prescription/supply of a statin. No statins were recorded for patients aged less 
than 24 years. A statin was prescribed at 4.4% of encounters with males, significantly more 
often than at female encounters (3.1%). 
Reasons for encounter  
The reason for encounter most often given by patients at encounters where a statin was 
prescribed or supplied was a prescription request (56.4 per 100 statin encounters). Other 
common reasons were for test results (15.0 per 100) and for a cardiac check-up (14.9 per 100 
statin encounters). 
Problems managed with a statin 
Lipid disorders accounted for more than half (54.0%) of problems managed with a statin, 
while the GP labelled the problem under management as prescription request for 13.4%. 
Hypertension accounted for 10.1% of problems managed with a statin, ischaemic heart 
disease 7.9%, and diabetes 6.0%. 
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Individual statins prescribed or supplied 
The most frequently prescribed/supplied statin was atorvastatin, which accounted for 
43.4% of all statins recorded. The second most common was rosuvastatin, accounting for 
26.3%. Simvastatin was also frequently prescribed/supplied, accounting for 17.1% of statins, 
while the combination product atorvastatin/amlodipine made up 5.4% of statins. 
 
 
 
The patients  
Sex  Per cent Rate(d) 
Males  52.1 4.4 
Females 47.9 3.1 
 
Age group  Per cent Rate(d) 
15–24 years 0.1 0.0 
25–44 years 4.5 0.7 
45–64 years 42.1 5.6 
65–74 years 29.8 8.3 
75+ years 23.4 5.5 
Reasons for encounter 
n = 6,779 (193 per 100 statin encounters) 
Rate per 100 encounters(c) 
Prescription – all* 56.4 
Test results* 15.0 
Cardiac check-up* 14.9 
Lipid disorders 7.2 
General check-up 6.7 
Hypertension/high blood pressure* 5.5 
Diabetes – all* 4.9 
Immunisation – all* 4.8 
Blood test NOS 3.3 
Administrative procedure NOS 2.6 
Statins—prescribed or supplied 
n = 3,528 (100 per 100 statin problems) 
Per cent of statins 
Atorvastatin 43.4 
Rosuvastatin 26.3 
Simvastatin 17.1 
Atorvastatin/amlodipine 5.4 
Pravastatin 4.5 
Simvastatin/ezetimibe 2.9 
Fluvastatin 0.4 
Problems managed with a statin 
(n = 3,525)  
Per cent of problems(b) 
Lipid disorders 54.0 
Prescription – all* 13.4 
Hypertension* 10.1 
Ischaemic heart disease 7.9 
Diabetes – all* 6.0 
Cardiac check-up* 0.8 
Test results* 0.7 
Blood test – endocrine/metabolic 0.6 
Acute myocardial infarction 0.5 
Transient cerebral ischaemia 0.4 
(a) Includes plain statins – ATC group C10AA, and statins in combination with other medications – ATC group C10B. 
(b) Expressed as a per cent of problems managed with a statin. 
(c) Expressed as a rate per 100 encounters at which a statin was prescribed or supplied. 
(d) Age and sex-specific rate per 100 encounters in each age and sex group. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1    
 <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: NOS – not otherwise specified. 
Figure 9.4: Statins prescribed or supplied in general practice, 2010–11 
Statins(a) prescribed or supplied 
n = 3,528 (3.7 per 100 total encounters) 
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9.6 Changes in medications over the decade 
2001–02 to 2010–11  
Data on medications are reported for each year from 2001–02 to 2010–11 in Chapter 9 of the 
companion report entitled A decade of Australian general practice activity 2001–02 to 2010–11.1 
In that report, changes over time are measured as change in the management of problems 
(that is, as a rate per 100 problems). This reflects change in how GPs are managing problems, 
and takes into account the significant increase in the number of problems managed per 
encounter over the decade to 2010–11 (see Section 7.9). 
The rate at which medications were prescribed fell from 61.3 per 100 problems managed in 
2001–02 to 55.8 per 100 in 2010–11. This significant decrease means that in 2010–11 an 
average 5.5 fewer prescriptions were being written for every 100 problems managed than  
10 years earlier. However, in 2010–11 there were 18.2 million (18%) more encounters claimed 
through Medicare than there were in 2001–02. As a result, the extrapolated national effect of 
this change is 12.6 million more prescriptions given by GPs in 2010–11 than in 2001–02. If the 
estimated 26% increase over the 10 years in number of problems managed nationally is 
considered, the increase in number of prescriptions recorded would have been 21.9 million if 
not for the decrease in GP prescribing rates. 
Among the prescribed drug groups that increased significantly were agents acting on the 
renin-angiotensin system, serum lipid-reducing agents, psychoanaleptics, anti-thrombotic 
agents and thyroid medications. At the same time, prescribing rates of several drug groups 
decreased, including psycholeptics, drugs for obstructive airways disease, systemic anti-
inflammatory medications and sex hormones. 
At the individual generic level, significant increases were found in the prescribing rates of a 
number of medications. Among them were oxycodone, esomeprazole, meloxicam and 
rosuvastatin. On the other hand, roxithromycin, simvastatin, celecoxib and cefaclor were 
among the medications for which significant decreases in prescribing rates occurred over 
time.  
Other changes that occurred over the 10-year period were a steady rise in the proportion of 
prescriptions for which five repeats were recorded, and an increase in the rate of medications 
supplied by GPs (mainly vaccines). Rates of medications recommended by GPs for 
over-the-counter purchases showed no significant change either in total rates or in the 
individual medications advised.  
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10 Other treatments 
The BEACH survey form allows GPs to record up to two other (non-pharmacological) 
treatments for each problem managed at the encounter. Other treatments include all clinical 
and procedural treatments provided. These groups are defined in Appendix 4, Tables A4.4 
and A4.5. Routine clinical measurements or observations, such as measurements of blood 
pressure and physical examinations, were not included if they were undertaken by the GP. 
However GPs were instructed to record and indicate clinical measurements or observations 
if these were undertaken by the practice nurse in conjunction with the GP at the encounter. 
In this chapter ‘other treatments’ are reported, irrespective of whether they were done by the 
GP or by the practice nurse. That is, the non-pharmacological management provided in 
general practice patient encounters is described, rather than management provided 
specifically by the GP. However in the analysis of procedural treatments, injections given in 
provision of vaccines were removed, as this action has already been counted and reported in 
medications. Treatments provided by the practice nurse (including the injections given for 
vaccination) are reported separately in Chapter 13. 
Data on other treatments are reported for each year from 2001–02 to 2010–11 in the 10-year 
summary report A decade of Australian general practice activity 2001–02 to 2010–11.1 
10.1 Number of other treatments 
At least one other treatment was provided at 40.1% of all encounters. In 2010–11, a total of 
50,235 other treatments were recorded, at a rate of 52.4 per 100 encounters. More than two-
thirds (67.7%) of these were clinical treatments. For every 100 problems managed, GPs 
provided 23.3 clinical treatments and 11.1 procedures (Table 10.1).  
Table 10.1: Summary of other treatments 
Variable Number 
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 146,141) 
95% 
LCL 
95% 
UCL 
At least one other treatment 38,411 40.1 38.4 41.7 — — — 
Other treatments 50,235 52.4 49.8 55.1 34.4 32.7 36.0 
 Clinical treatments 34,019 35.5 33.2 37.8 23.3 21.8 24.8 
 Procedural treatments 16,216 16.9 16.1 17.8 11.1 10.6 11.6 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
Table 10.2 shows the relationship between other treatments and pharmacological treatments 
given for problems managed.  
• In 60.4% of the problems that were managed with an ‘other treatment’, no concurrent 
pharmacological treatment was provided. 
• At least one clinical treatment was provided in the management of 20.9% of problems. 
For 59.1% of these problems, no medication was provided.  
• At least one procedural treatment was undertaken in the management of 10.4% of 
problems, with no pharmacological management given for 62.4% of these problems. 
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Table 10.2: Relationship between other treatments and pharmacological treatments 
Co-management of problems with other treatments 
Number of 
problems  
Per cent  
within class 
Per cent of  
problems 
(n = 146,141) 95% LCL 95% UCL 
At least one other treatment  44,447 100.0 30.4 29.1 31.7 
 Without pharmacological treatment 26,843 60.4 18.4 17.6 19.1 
At least one clinical treatment  30,507 100.0 20.9 19.6 22.1 
 Without pharmacological treatment 18,035 59.1 12.3 11.7 13.0 
At least one procedural treatment 15,194 100.0 10.4 9.9 10.9 
 Without pharmacological treatment  9,484 62.4 6.5 6.2 6.8 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
10.2 Clinical treatments 
Clinical treatments include general and specific advice, counselling or education, and 
administrative processes. During 2010–11, there were 34,019 clinical treatments recorded, at a 
rate of 35.5 per 100 encounters, or 23.3 per 100 problems managed (Table 10.1). 
Most frequent clinical treatments 
Table 10.3 lists the most common clinical treatments provided. Each treatment is expressed 
as a percentage of all other treatments, as a rate per 100 encounters with 95% confidence 
limits and as a rate per 100 problems with 95% confidence limits. 
General advice and education was the most frequently recorded clinical treatment in 2010–11 
(6.0 per 100 encounters), accounting for 16.8% of all clinical treatments. This was followed by 
counselling about the problem under management (5.3 per 100 encounters), counselling and 
advice about nutrition and weight (4.0 per 100 encounters), and advice and education about 
treatment (3.4 per 100 encounters). Psychological counselling was provided at a rate of 3.2 
per 100 encounters, and advice and education about medication at 2.7 per 100 encounters 
(Table 10.3). 
Several recorded clinical treatments related to preventive activities. The most common was 
counselling and advice about nutrition and weight, followed by counselling/advice for 
exercise, smoking, lifestyle, prevention, and alcohol. Together, these preventive treatments 
accounted for 21.1% of clinical treatments, provided at a rate of 7.5 per 100 encounters (Table 
10.3). 
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Table 10.3: Most frequent clinical treatments 
Clinical treatment Number 
Per cent of 
clinical 
treatments 
(n = 34,019) 
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 146,141) 
95% 
LCL 
95% 
UCL 
Advice/education NEC* 5,705 16.8 6.0 5.1 6.8 3.9 3.4 4.4 
Counselling – problem* 5,088 15.0 5.3 4.4 6.2 3.5 2.9 4.0 
Counselling/advice – nutrition/weight* 3,821 11.2 4.0 3.5 4.4 2.6 2.3 2.9 
Advice/education – treatment* 3,233 9.5 3.4 2.9 3.8 2.2 1.9 2.5 
Counselling – psychological* 3,085 9.1 3.2 3.0 3.5 2.1 1.9 2.3 
Advice/education – medication* 2,628 7.7 2.7 2.5 3.0 1.8 1.6 2.0 
Other administrative 
procedure/document (excluding 
sickness certificate)* 
1,822 5.4 1.9 1.7 2.1 1.2 1.1 1.4 
Sickness certificate* 1,539 4.5 1.6 1.4 1.8 1.1 0.9 1.2 
Counselling/advice – exercise*  1,302 3.8 1.4 1.1 1.6 0.9 0.7 1.0 
Reassurance, support 1,280 3.8 1.3 1.1 1.5 0.9 0.7 1.0 
Counselling/advice – smoking* 833 2.4 0.9 0.8 1.0 0.6 0.5 0.6 
Counselling/advice – life style* 453 1.3 0.5 0.4 0.6 0.3 0.2 0.4 
Counselling/advice – prevention* 414 1.2 0.4 0.3 0.5 0.3 0.2 0.4 
Counselling/advice – health/body* 388 1.1 0.4 0.3 0.5 0.3 0.2 0.3 
Counselling/advice – alcohol* 368 1.1 0.4 0.3 0.4 0.3 0.2 0.3 
Family planning* 285 0.8 0.3 0.2 0.3 0.2 0.2 0.2 
Observe/wait* 256 0.8 0.3 0.2 0.3 0.2 0.1 0.2 
Subtotal  32,500 95.5 — — — — — — 
Total clinical treatments 34,019 100.0 35.5 33.2 37.8 23.3 21.8 24.8 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.4 <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified. 
Problems managed with clinical treatments 
Table 10.4 lists the top 10 problems managed with a clinical treatment. It also shows the 
extent to which clinical treatments were used for each problem, and the relationship between 
the use of a clinical treatment and the provision of medication for individual problems at 
that encounter.  
• A total of 30,507 problems (20.9% of all problems) involved one or more clinical 
treatments in their management. 
• The top 10 problems accounted for 30.1% of all problems for which clinical treatments 
were provided. 
• Depression accounted for the most clinical treatments provided for 5.6% of problems 
managed with clinical treatments, followed by upper respiratory tract infection (5.2%), 
hypertension (3.4%) and diabetes (3.4%).  
• A clinical treatment was provided at 42.4% of depression contacts. Almost half (47%) of 
these contacts did not involve medication for that problem at that encounter. 
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• Tobacco abuse was the problem most likely to be managed with clinical treatments 
(61.3% of contacts). Almost half (45.6%) of tobacco abuse contacts where a clinical 
treatment was provided did not result in concurrent medication being 
prescribed/supplied or advised for that problem at that encounter. 
• Almost two-thirds (64.1%) of anxiety contacts managed with a clinical treatment had no 
concurrent pharmacological treatment provided at that encounter for that problem.  
Table 10.4: The 10 most common problems managed with a clinical treatment 
Problem managed Number 
Per cent of 
problems 
with clinical 
 treatment  
Rate per 100 
encounters(a) 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Per cent 
 of this 
problem(b) 
Per cent of 
treated 
 problems no 
medications(c) 
Depression* 1,706 5.6 1.8 1.6 1.9 42.4 47.0 
Upper respiratory tract infection 1,584 5.2 1.7 1.4 1.9 30.4 51.7 
Hypertension* 1,039 3.4 1.1 0.9 1.3 12.5 40.3 
Diabetes – all* 1,035 3.4 1.1 1.0 1.2 27.0 59.3 
Anxiety* 826 2.7 0.9 0.8 1.0 44.7 64.1 
Lipid disorders 735 2.4 0.8 0.7 0.9 25.1 63.0 
Gastroenteritis* 655 2.2 0.7 0.6 0.8 48.2 56.7 
Back complaint* 564 1.9 0.6 0.5 0.7 21.7 51.5 
Tobacco abuse  545 1.8 0.6 0.5 0.6 61.3 45.6 
Test results* 484 1.6 0.5 0.4 0.6 26.5 92.0 
Subtotal  9,173 30.1 — — — — — 
Total problems with clinical 
treatments 30,507 100.0 31.8 29.8 33.8 — — 
(a) Rate of provision of clinical treatment for selected problem per 100 total encounters. 
(b) Percentage of contacts with this problem that generated at least one clinical treatment. 
(c) The numerator is the number of cases of this problem that generated at least one clinical treatment but generated no medications.  
The denominator is the total number of contacts for this problem that generated at least one clinical treatment (with or without medications). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
10.3 Procedural treatments 
Procedural treatments included therapeutic actions and diagnostic procedures undertaken at 
the encounter. Injections for immunisations/vaccinations (n = 4,044) are not counted here as 
procedures, as these have already been reported as medications (see Chapter 9). There were 
16,216 procedural treatments provided in these general practice encounters during 2010–11, 
at a rate of 16.9 per 100 encounters, or 11.1 per 100 problems (Table 10.1). 
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Most frequent procedures 
Table 10.5 lists the most common procedural treatments provided. Each treatment is 
expressed as a percentage of all procedural treatments, as a rate per 100 encounters with 
95% confidence limits and as a rate per 100 problems with 95% confidence limits.  
Some of the procedures (for example INR test, electrical tracings, physical function test) are 
investigations undertaken at the encounter. These results do not include investigations that 
were ordered by the GP to be performed by an external provider. A summary of all 
investigations (both undertaken and ordered) is provided in Table 12.6. 
The most frequently recorded group of procedures in 2010–11 were excisions (2.9 per 
100 encounters), accounting for 17.0% of all procedural treatments. Other procedural 
treatments frequently recorded included dressings (2.6 per 100 encounters), local injections 
(excluding all local injection/infiltrations performed for immunisations) (2.4 per 100 
encounters) and rehabilitation (1.2 per 100 encounters) (Table 10.5). 
Table 10.5: Most frequent procedural treatments 
Procedural treatment Number 
Per cent  
of 
procedural 
treatments 
(n = 16,216) 
Rate per 100 
encounters 
(n = 95,839) 
95% 
 LCL 
95% 
 UCL 
Rate per 100 
problems 
(n = 146,141) 
95% 
 LCL 
95% 
 UCL 
Excision/removal tissue/biopsy/ 
destruction/debridement/cauterisation* 
2,755 17.0 2.9 2.6 3.1 1.9 1.7 2.0 
Dressing/pressure/compression/ 
tamponade* 
2,441 15.1 2.6 2.4 2.7 1.7 1.5 1.8 
Local injection/infiltration*(a) 2,324 14.3 2.4 2.2 2.7 1.6 1.4 1.8 
Physical medicine/rehabilitation – all* 1,155 7.1 1.2 1.1 1.4 0.8 0.7 0.9 
Incision/drainage/flushing/aspiration/ 
removal body fluid* 
1,154 7.1 1.2 1.1 1.3 0.9 0.7 0.9 
Pap smear* 912 5.6 1.0 0.8 1.1 0.6 0.5 0.7 
Repair/fixation – suture/cast/prosthetic 
device (apply/remove)* 815 5.0 0.9 0.8 0.9 0.6 0.5 0.6 
Other therapeutic procedures/ minor 
surgery*  
680 4.2 0.7 0.5 0.9 0.5 0.3 0.6 
INR test  648 4.0 0.7 0.6 0.8 0.4 0.4 0.5 
Other preventive procedures/high-risk 
medication* 568 3.5 0.6 0.5 0.7 0.4 0.3 0.4 
Check-up – practice nurse* 545 3.4 0.6 0.4 0.8 0.4 0.3 0.5 
Electrical tracings* 532 3.3 0.6 0.5 0.6 0.4 0.3 0.4 
Physical function test* 463 2.9 0.5 0.4 0.6 0.3 0.2 0.4 
Subtotal  14,992 92.5 — — — — — — 
Total procedural treatments  16,216 100.0 16.9 16.1 17.8 11.1 10.6 11.6 
(a) Excludes all local injection/infiltrations performed for immunisations/vaccinations. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Tables A4.5 and A4.6, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified; INR – international normalised ratio. 
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Problems managed with a procedural treatment 
Table 10.6 lists the top 10 problems managed with a procedural treatment. It also shows the 
proportion of contacts with each problem that was managed with a procedure, and the 
proportion of problems managed with a procedure without medication given concurrently. 
• One or more procedural treatments were provided in the management of 15,194 
problems (10.4% of all problems). 
• The top 10 problems accounted for more than a third (34.4%) of all problems for which a 
procedure was used. 
• Female genital check-up/pap smear accounted for the most procedures (5.5% of 
problems managed with procedures), followed by solar keratosis/sunburn (4.9%), 
laceration/cut (4.7%) and excessive ear wax (3.6). 
• Laceration/cut was the problem most likely to be managed with a procedural treatment 
with a procedure being undertaken at nearly four-fifths (79.3%) of contacts. Of these 
contacts where a procedural treatment was provided, 77.7% were not 
prescribed/supplied or advised a medication for that problem at that encounter. 
Table 10.6: The 10 most common problems managed with a procedural treatment 
Problem managed Number 
Per cent of 
problems with 
procedure  
Rate per 100 
encounters(a) 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Per cent of 
this 
problem(b) 
Per cent of 
treated problems 
no medications(c) 
Female genital check-up/ 
Pap smear* 835 5.5 0.9 0.8 1.0 50.8 97.3 
Solar keratosis/sunburn 744 4.9 0.8 0.7 0.9 68.3 97.1 
Laceration/cut 716 4.7 0.8 0.7 0.8 79.3 77.7 
Excessive ear wax 539 3.6 0.6 0.5 0.6 70.8 91.1 
Malignant neoplasm of skin 485 3.2 0.5 0.4 0.6 45.7 92.6 
Warts  449 3.0 0.5 0.4 0.5 75.0 94.7 
Chronic ulcer skin 
(including varicose ulcer) 423 2.8 0.4 0.4 0.5 77.1 80.3 
General check-up* 383 2.5 0.4 0.3 0.5 14.9 83.5 
Atrial fibrillation/flutter 353 2.3 0.4 0.3 0.4 28.2 72.4 
Sprain/strain* 300 2.0 0.3 0.3 0.4 22.5 44.9 
Subtotal  5,228  34.4 — — — — — 
Total problems with 
procedural treatments 15,194 100.0 15.9 15.1 16.6 — — 
(a) Rate of provision of procedural treatment for selected problem per 100 total encounters. 
(b) Percentage of contacts with this problem that generated at least one procedural treatment. 
(c) The numerator is the number of cases of this problem that generated at least one procedural treatment but generated no medications. The 
denominator is the total number of contacts (for this problem) that generated at least one procedural treatment (with or without medications). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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10.4 Changes in other treatments over the decade 
2001–02 to 2010–11 
An overview of changes in other treatments provided in general practice over the decade can 
be found in Chapter 10 of the companion report A decade of Australian general practice activity 
2001–02 to 2010–11.1 In that report, changes over time are measured as change in the 
management of problems (that is, as a rate per 100 problems). This reflects change in how 
GPs are managing problems and accounts for the significant increase in the number of 
problems managed per encounter over the decade (see Section 7.9). 
Clinical treatments 
In summary, there was a significant decrease in the rate of clinical treatments provided for 
every 100 problems managed between 2001–02 and 2010–11. In particular, rates of 
counselling and advice about nutrition and weight, advice and education about treatment, 
and counselling and advice about exercise all decreased over the past ten years.  
While there was a significant decline in the number of clinical treatments given per 100 
problems managed over the decade, as more problems were managed per 100 encounters in 
2010–11 than in 2001–02 there was no significant change in the total number of clinical 
treatments provided per 100 encounters.  
Overall, there was little change in the total number of problems managed with clinical 
treatments from 2001–02 to 2010–11. However, there were some significant changes during 
this time. The rate at which clinical treatments were given in the management of tobacco 
abuse doubled from 0.3 per 100 encounters in 2001–02 to 0.6 per 100 in 2010–11. We estimate 
this increase equates to 410,000 more occasions where clinical treatments were provided for 
tobacco abuse nationally in 2010–11 than a decade earlier. However, this increase in the rate 
of clinical treatments being given in the management of tobacco abuse was not accompanied 
by an increase in the overall rate of counselling and advice about smoking.  
The increase may also be associated with an increase in the number of tobacco abuse 
problems being managed by GPs with a clinical procedure whereas in the past, counselling 
and advice about smoking may have been provided at the same rate but was provided 
opportunistically in the management of other problems.  
Procedural treatments 
There was a significant increase in the number of procedures performed between 2001–02 
(9.6 per 100 problems) and 2010–11 (11.1 per 100 problems). This increase was reflected in the 
rates of procedures from the group dressing/pressure/compression/tamponade which rose 
from 1.3 per 100 problems managed in 2001–02 to 1.7 per 100 problems managed in 2010–11, 
and in the rate of local injections which doubled from 0.8 per 100 problems in 2001–02 to 1.6 
per 100 in 2010–11.  
There was also an overall increase in the number of problems managed with procedural 
treatment from 2001–02 to 2010–11. Female genital check up/pap smear continued to be the 
most common problem to be managed with a procedure, increasing from 0.6 per 100 total 
problems managed in 2001–02 to 0.9 per 100 in 2010–11.  
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11 Referrals and admissions 
A referral is defined as the process by which the responsibility for part or all of the care of a 
patient is temporarily transferred to another health care provider. Only new referrals arising 
at the encounter were included (that is, continuations were not recorded). For each 
encounter, GPs could record up to two referrals. These included referrals to medical 
specialists, allied health services, hospitals for admission or emergency departments.  
Data on referrals and admissions are reported for each of the most recent BEACH years from 
2001–02 to 2010–11 in the 10-year summary report A decade of Australian general practice 
activity 2001–02 to 2010–11.1 
11.1 Number of referrals and admissions 
Table 11.1 provides a summary of referrals and admissions, and the rates per 100 encounters 
and per 100 problems managed. The patient was given at least one referral at 13.0% of all 
encounters, and for 9.2% of all problems managed. There were a total of 13,526 referrals 
made at a rate of 14.1 per 100 encounters. The most frequent referrals were to medical 
specialists (8.6 per 100 encounters, 5.6 per 100 problems managed), followed by referrals to 
allied health services (4.2 per 100 encounters, 2.8 per 100 problems). Very few patients were 
referred to hospitals, or to the hospital emergency department. 
Table 11.1: Summary of referrals and admissions 
Variable Number 
Rate per 100 
encounters 
(n = 95,839) 
95% 
 LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 146,141) 
95% 
LCL 
95% 
UCL 
At least one referral(a) 12,486 13.0 12.5 13.5 9.2 8.9 9.5 
Referrals  13,526 14.1 13.5 14.7 9.3 8.9 9.6 
 Medical specialist* 8,248 8.6 8.2 9.0 5.6 5.4 5.9 
 Allied health services* 4,039 4.2 3.9 4.5 2.8 2.6 2.9 
 Hospital* 364 0.4 0.3 0.4 0.2 0.2 0.3 
 Emergency department* 291 0.3 0.3 0.4 0.2 0.2 0.2 
 Other referrals* 584 0.6 0.5 0.7 0.4 0.3 0.5 
Total referrals 13,526 14.1 13.5 14.7 9.3 8.9 9.6 
(a) Rate per 100 problems for at least one referral is calculated using a numerator of number of individual problems with at least one 
 referral (n = 13,461). 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.7, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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11.2 Most frequent referrals 
Table 11.2 shows the medical specialists and allied health service groups to whom GPs most 
often referred patients. The most common referrals to medical specialist were to surgeons 
(9.8% of specialist referrals), orthopaedic surgeons (8.3%), dermatologists (8.0%) and 
ophthalmologists (7.5%).  
A little over one-quarter (26.7%) of referrals to allied health services were to 
physiotherapists, one-fifth (20.7%) were to psychologists, one-tenth (10.4%) to podiatrists or 
chiropodists, and 8.7% to dentists. 
Table 11.2: Most frequent referrals, by type 
Professional/organisation Number Per cents 
Per cent of 
referral group 
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 146,141) 
95% 
LCL 
95% 
UCL 
Medical specialist* 8,248 67.1 100.0 8.6 8.2 9.0 5.6 5.4 5.9 
 Surgeon  809 6.6 9.8 0.8 0.8 0.9 0.6 0.5 0.6 
 Orthopaedic surgeon  682 5.5 8.3 0.7 0.6 0.8 0.5 0.4 0.5 
 Dermatologist  663 5.4 8.0 0.7 0.6 0.8 0.5 0.4 0.5 
 Ophthalmologist 617 5.0 7.5 0.6 0.6 0.7 0.4 0.4 0.5 
 Cardiologist 594 4.8 7.2 0.6 0.6 0.7 0.4 0.4 0.4 
 Gastroenterologist 497 4.0 6.0 0.5 0.5 0.6 0.3 0.3 0.4 
 Ear, nose and throat  481 3.9 5.8 0.5 0.4 0.6 0.3 0.3 0.4 
 Gynaecologist 478 3.9 5.8 0.5 0.4 0.6 0.3 0.3 0.4 
 Urologist  321 2.6 3.9 0.3 0.3 0.4 0.2 0.2 0.3 
 Neurologist 253 2.1 3.1 0.3 0.2 0.3 0.2 0.1 0.2 
 Subtotal: top 10 medical  
 specialist referrals  5,395 43.8 65.4 — — — — — — 
Allied health services* 4,039 32.9 100.0 4.2 3.9 4.5 2.8 2.6 2.9 
 Physiotherapy  1,079 8.8 26.7 1.1 1.0 1.2 0.7 0.7 0.8 
 Psychologist  835 6.8 20.7 0.9 0.8 1.0 0.6 0.5 0.6 
 Podiatrist/chiropodist 422 3.4 10.4 0.4 0.4 0.5 0.3 0.2 0.3 
 Dentist  350 2.9 8.7 0.4 0.3 0.4 0.2 0.2 0.3 
 Dietitian/nutritionist 241 2.0 6.0 0.3 0.2 0.3 0.2 0.1 0.2 
 Audiologist/acoustic testing 104 0.8 2.6 0.1 0.1 0.1 0.1 0.1 0.1 
 Diabetes education  85 0.7 2.1 0.1 0.1 0.1 0.1 0.0 0.1 
 Optometrist  82 0.7 2.0 0.1 0.1 0.1 0.1 0.0 0.1 
 Patient support group 69 0.6 1.7 0.1 0.1 0.1 0.0 0.0 0.1 
 Counsellor  59 0.5 1.5 0.1 0.0 0.1 0.0 0.0 0.1 
 Subtotal: top 10 allied  
 health referrals 3,326 27.2 82.4 — — — — — — 
Subtotal: all referrals listed 8,721 71.0 — — — — — — — 
Total allied health and 
medical specialist referrals 12,287 100.0 — 12.8 12.3 13.4 8.4 8.1 8.7 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.7, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: AHS – allied health services; LCL – lower confidence limit; UCL – upper confidence limit. 
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11.3 Problems most often referred 
Each referral may have been provided for management of multiple problems, and multiple 
referrals may have been made in management of a single problem. Therefore, there are more 
problem–referral links than referrals. Table 11.3 shows the most common problems referred 
to medical specialists, in decreasing frequency order of problem–referral combinations. 
The 8,248 referrals to medical specialists were provided in management of 8,477 problems. 
The 10 problems most often referred to a specialist accounted for 19.2% of all problem–
referral links. Those most often referred were malignant skin neoplasm (2.7% of problem–
referral links), pregnancy (2.6%), diabetes (2.5%) and osteoarthritis (2.0%) (Table 11.3). The 
far right hand column of Table 11.3 shows the likelihood of referral when each problem is 
managed. The problems (listed above) that were most often referred were also those most 
likely to be referred. 
Table 11.3: The 10 problems most frequently referred to a medical specialist 
Problem managed Number 
Per cent of 
problem–
referral links  
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
contacts of 
this problem(a) 
Malignant skin neoplasm 229 2.7 0.2 0.2 0.3 21.7 
Pregnancy* 224 2.6 0.2 0.2 0.3 16.3 
Diabetes – all* 211 2.5 0.2 0.2 0.3 5.5 
Osteoarthritis* 170 2.0 0.2 0.1 0.2 6.6 
Ischaemic heart disease* 154 1.8 0.2 0.1 0.2 14.1 
Sleep disturbance 139 1.6 0.1 0.1 0.2 9.6 
Abnormal test results* 136 1.6 0.1 0.1 0.2 13.1 
Oesophageal disease 135 1.6 0.1 0.1 0.2 6.1 
Other referrals NOS 118 1.4 0.1 0.1 0.2 62.7 
Back complaint* 117 1.4 0.1 0.1 0.1 4.5 
Subtotal: top 10 problems referred 
to a medical specialist 1,633 19.3 — — — — 
Total problems referred to 
medical specialist  8,477 100.0 8.8 8.5 9.2 — 
(a) The rate of referrals to medical specialists per 100 contacts with the problem. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
The 4,039 referrals to an allied health service were provided in the management of 4,188 
problems. The 10 most common of these accounted for 46.4% of all problem–referral links. 
Depression was the problem most frequently referred to an allied health service (11.4% of 
problem–referral links). However, the problem most likely to result in a referral to an allied 
health service was teeth/gum disease, with almost one-third (30.7%) of all contacts resulting 
in a referral (Table 11.4). 
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Table 11.4: The 10 problems most frequently referred to allied health services 
Problem managed Number 
Per cent of 
problem–
referral links  
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
contacts of 
this problem(a) 
Depression* 478 11.4 0.5 0.4 0.6 11.9 
Diabetes – all*  311 7.4 0.3 0.3 0.4 8.1 
Back complaint* 237 5.7 0.2 0.2 0.3 9.1 
Anxiety*  176 4.2 0.2 0.2 0.2 9.5 
Sprain/strain* 167 4.0 0.2 0.1 0.2 12.5 
Osteoarthritis* 167 4.0 0.2 0.1 0.2 6.4 
Teeth/gum disease 142 3.4 0.1 0.1 0.2 30.7 
Administrative procedure NOS 116 2.8 0.1 0.1 0.2 11.6 
Bursitis/tendonitis/synovitis NOS  80 1.9 0.1 0.1 0.1 7.9 
Acute stress reaction 71 1.7 0.1 0.1 0.1 12.3 
Subtotal: top 10 problems referred to AHS 1,944 46.4 — — — — 
Total problems referred to AHS  4,188 100.0 4.4 4.1 4.7 — 
(a) The rate of referrals to allied health services per 100 contacts with the problem. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified; AHS – allied health service. 
The 364 referrals to a hospital were provided in the management of 386 problems. The 
10 problems most frequently referred to hospital are shown in Table 11.5. Pregnancy was the 
most common. However, appendicitis was the problem most likely to be referred. 
Table 11.5: The 10 problems most frequently referred to hospital 
Problem managed Number 
Per cent of 
problem–
referral links  
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
contacts of 
this problem(a) 
Pregnancy*  25 6.5 0.03 0.01 0.04 1.8 
Digestive system disease, other 14 3.7 0.02 0.01 0.02 5.2 
Ischaemic heart disease* 11 2.7 0.01 0.00 0.02 1.0 
Appendicitis 10 2.5 0.01 0.00 0.02 22.0 
Fracture* 9 2.4 0.01 0.00 0.02 1.1 
Pneumonia 9 2.3 0.01 0.00 0.02 2.7 
Chest pain, NOS 9 2.3 0.01 0.00 0.02 3.1 
Acute bronchitis/bronchiolitis 8 2.1 0.01 0.00 0.02 0.3 
Boil/carbuncle 8 2.0 0.01 0.00 0.02 1.3 
Diabetes–all* 8 2.0 0.01 0.00 0.02 0.2 
Subtotal: top 10 problems referred for 
admission 111 28.6 — — — — 
Total problems referred to hospital 386 100.0 0.40 0.33 0.47 — 
(a) The rate of referrals to hospital per 100 contacts with the problem. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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The 291 referrals to an emergency department were provided in the management of 
315 problems. The 10 problems most frequently referred to an emergency department are 
shown in Table 11.6. Fracture was the most common. However, appendicitis was the 
problem most likely to be referred. 
Table 11.6: The 10 problems most frequently referred to an emergency department 
Problem managed Number 
Per cent of 
problem–
referral links  
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
contacts of 
this problem(a) 
Fracture* 15 4.8 0.02 0.01 0.03 1.7 
Appendicitis 13 4.1 0.01 0.01 0.02 29.3 
Abdominal pain* 12 3.8 0.01 0.01 0.02 1.8 
Ischaemic heart disease* 9 2.8 0.01 0.00 0.02 0.8 
Skin infection, other 9 2.8 0.01 0.00 0.02 2.6 
Pneumonia 8 2.7 0.01 0.00 0.02 2.4 
Gastroenteritis* 8 2.6 0.01 0.00 0.02 0.6 
Boil/carbuncle 7 2.4 0.01 0.00 0.01 1.3 
Chest pain NOS 7 2.3 0.01 0.00 0.01 2.5 
Urinary tract infection* 7 2.2 0.01 0.00 0.01 0.4 
Subtotal: top 10 problems referred to 
emergency department 96 30.4 — — — — 
Total problems referred to emergency 
department 315 100.0 0.33 0.27 0.38 — 
(a) The rate of referrals to an emergency department per 100 contacts with the problem. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
11.4 Changes in referrals over the decade 2001–02 
to 2010–11 
An overview of changes in referrals over the decade can be found in Chapter 11 of the 
companion report A decade of Australian general practice activity 2001–02 to 2010–11.1 In that 
report, changes over time are measured as change in the management of problems (that is, as 
a rate per 100 problems). This reflects change in how GPs are managing problems, and 
accounts for the significant increase in the number of problems managed per encounter over 
the decade (see Section 7.9).  
In summary, over the 10 years there was a significant increase in the proportion of problems 
that were referred to other health providers: in 2001–02 at least one referral was made in the 
management of 7.3% of problems and this increased to 9.2% of problems managed in  
2010–11. Referrals to medical specialists significantly rose from 5.1 to 5.6 per 100 problems 
managed, reflected in marginal increases in referrals to cardiologists, gastroenterologists and 
urologists. However, referrals to allied health services rose far more, from 1.6 to 2.8 per 100 
problems managed (a 75% increase). This was reflected in significant increases in referral 
rates to psychologists, podiatrist or chiropodists, dentists, and marginal increases in the rate 
of referral to dietitians or nutritionists, and physiotherapists per 100 problems. 
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12 Investigations 
The GPs participating in the study were asked to record (in free text) any pathology, imaging 
or other tests ordered or undertaken at the encounter, and to nominate the patient 
problem(s) associated with each test order placed. This allows the linkage of test orders to a 
single problem or multiple problems. Up to five orders for pathology, and two for imaging 
and other tests could be recorded at each encounter. A single test may have been ordered for 
the management of multiple problems, and multiple tests may have been used in the 
management of a single problem. 
A pathology test order may be for a single test (for example, Pap smear, HbA1c) or for a 
battery of tests (for example, lipids, full blood count). Where a battery of tests was ordered, 
the battery name was recorded rather than each individual test. GPs also recorded the body 
site for any imaging ordered (for example, x-ray chest, CT head). 
Data on investigations are reported for each year from 2001–02 to 2010–11 in the 10-year 
summary report A decade of Australian general practice activity 2001–02 to 2010–11.1  
12.1 Number of investigations 
Table 12.1 shows the number of encounters and problems at which a pathology or imaging 
test was ordered. There were no tests recorded at a large majority (76.2%) of encounters. 
At least one pathology test order was recorded at 17.8% of encounters (for 13.3% of problems 
managed), and at least one imaging test was ordered at 8.4% of encounters (for 5.7% of 
problems managed). 
Table 12.1: Number of encounters and problems for which pathology or imaging was ordered 
Pathology/imaging test 
ordered 
Number of 
encounters  
Per cent of 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Number of 
problems 
Per cent of 
problems 
(n = 146,141) 
95% 
LCL 
95% 
UCL 
Pathology and imaging ordered 2,309 2.4 2.2 2.6 1,658 1.1 1.0 1.2 
Pathology only ordered 14,763 15.4 14.9 15.9 17,835 12.2 11.8 12.6 
Imaging only ordered 5,700 5.9 5.7 6.2 6,657 4.6 4.4 4.7 
No pathology or imaging tests 
ordered 
73,067 76.2 75.5 76.9 119,991 82.1 81.6 82.6 
At least one pathology ordered 17,072 17.8 17.2 18.4 19,493 13.3 12.9 13.7 
At least one imaging ordered 8,009 8.4 8.0 8.7 8,315 5.7 5.5 5.9 
At least one other investigation 
ordered 
675 0.7 0.6 0.8 680 0.5 0.4 0.5 
At least one other investigation 
performed in the practice 
1,173 1.2 1.1 1.4 1,184 0.8 0.7 0.9 
At least one other investigation 
ordered or performed 
1,811 1.9 1.7 2.1 1,830 1.3 1.1 1.4 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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12.2 Pathology ordering 
A report on changes in pathology ordering by GPs from 1998 to 2001 was produced in 2003.15 
A review of GP pathology orders in the National Health Priority Areas and other selected 
problems between 2000 and 2008 is reported in General practice in Australia, health priorities 
and policies 1998 to 2008.12 A report Evidence-practice gap in pathology test ordering: a comparison 
of BEACH pathology data and recommended testing was produced by the FMRC for the 
Australian Government Quality Use of Pathology Program in June 2009.14 Readers may wish 
to consider those reports in conjunction with the information presented below.  
Nature of pathology orders at encounter 
The GPs recorded 43,313 orders for pathology tests/batteries of tests, at a rate of 45.2 per 
100 encounters or 29.6 per 100 problems managed. The pathology tests recorded were 
grouped according to the categories set out in Appendix 4, Table A4.8. The main pathology 
groups reflect those used by Medicare Australia.70  
The distribution of pathology tests by MBS group, and the most common tests within each 
group are presented in Table 12.2. Each group and individual test is expressed as a 
percentage of all pathology tests, as a percentage of the group, as a rate per 100 encounters 
and as a rate per 100 problems with 95% confidence limits. 
Test orders classed as chemistry accounted for more than half of all pathology test orders, 
the most common being: lipid tests, for which there were 4.0 orders per 100 encounters and 
2.6 per 100 problems; electrolytes, urea and creatinine (3.3; 2.2); liver function (2.9; 1.9); and 
thyroid function tests (2.6 per 100 encounters; 1.7 per 100 problems). Haematology tests 
accounted for 17.8% of all pathology including the most frequently ordered individual 
pathology test, full blood count, at 14.7% of all pathology and 6.2 orders per 100 encounters 
and 4.1 per 100 problems managed. Microbiology accounted for 14.4% of pathology orders, 
with urine microscopy, culture and sensitivity were the most frequent test in the group at 1.9 
tests per 100 patient encounters and 1.2 per 100 problems managed. 
Table 12.2: Pathology orders by MBS pathology groups and most frequent individual test orders 
within group 
Pathology test ordered Number 
Per cent  
of all 
pathology  
Per cent  
of group 
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 146,141) 
95% 
LCL 
95% 
UCL 
Chemistry*  25,094 57.9 100.0 26.2 25.0 27.4 17.2 16.5 17.9 
 Lipids* 3,802 8.8 15.2 4.0 3.7 4.2 2.6 2.5 2.8 
 Electrolytes, urea and creatinine* 3,194 7.4 12.7 3.3 3.1 3.6 2.2 2.0 2.4 
 Liver function* 2,818 6.5 11.2 2.9 2.7 3.2 1.9 1.8 2.1 
 Thyroid function* 2,470 5.7 9.8 2.6 2.4 2.8 1.7 1.6 1.8 
 Multibiochemical analysis* 2,252 5.2 9.0 2.3 2.1 2.6 1.5 1.4 1.7 
 Glucose/glucose tolerance* 2,180 5.0 8.7 2.3 2.1 2.5 1.5 1.4 1.6 
 Chemistry; other* 1,372 3.2 5.5 1.4 1.3 1.6 0.9 0.8 1.0 
 Ferritin* 1,294 3.0 5.2 1.3 1.2 1.5 0.9 0.8 1.0 
 HbA1c* 1,205 2.8 4.8 1.3 1.1 1.4 0.8 0.7 0.9 
 Prostate specific antigen* 939 2.2 3.7 1.0 0.9 1.1 0.6 0.6 0.7 
(continued) 
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Table 12.2 (continued): Pathology orders by MBS pathology groups and most frequent individual 
test orders within group 
Pathology test ordered Number 
Per cent  
of all 
pathology  
Per cent  
of group 
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 146,141) 
95% 
LCL 
95% 
UCL 
 C reactive protein  850 2.0 3.4 0.9 0.8 1.0 0.6 0.5 0.7 
 Calcium/phosphate/magnesium* 779 1.8 3.1 0.8 0.7 0.9 0.5 0.5 0.6 
Haematology*  7,719 17.8 100.0 8.1 7.6 8.5 5.3 5.0 5.5 
 Full blood count*  5,947 13.7 77.0 6.2 5.9 6.5 4.1 3.9 4.3 
 Erythrocyte sedimentation rate  812 1.9 10.5 0.8 0.7 1.0 0.6 0.5 0.6 
 Coagulation*  726 1.7 9.4 0.8 0.7 0.9 0.5 0.4 0.6 
Microbiology*  6,219 14.4 100.0 6.5 6.0 7.0 4.3 3.9 4.6 
 Urine M,C&S* 1,800 4.2 28.9 1.9 1.7 2.0 1.2 1.1 1.3 
 Microbiology; other* 871 2.0 14.0 0.9 0.8 1.0 0.6 0.5 0.7 
 Hepatitis serology* 530 1.2 8.5 0.6 0.5 0.7 0.4 0.3 0.4 
 Faeces M,C&S* 431 1.0 6.9 0.4 0.4 0.5 0.3 0.3 0.3 
 Chlamydia* 345 0.8 5.5 0.4 0.3 0.4 0.2 0.2 0.3 
 Venereal disease* 339 0.8 5.5 0.4 0.3 0.4 0.2 0.2 0.3 
 Vaginal swab M,C&S* 320 0.7 5.1 0.3 0.3 0.4 0.2 0.2 0.3 
 HIV* 264 0.6 4.2 0.3 0.2 0.4 0.2 0.1 0.2 
Cytopathology*  1,601 3.7 100.0 1.7 1.5 1.8 1.1 1.0 1.2 
 Pap smear*  1,567 3.6 97.9 1.6 1.5 1.8 1.1 1.0 1.2 
Other NEC*  833 1.9 100.0 0.9 0.7 1.0 0.6 0.5 0.7 
 Blood test  401 0.9 48.1 0.4 0.3 0.5 0.3 0.2 0.3 
 Other test 268 0.6 32.2 0.3 0.2 0.3 0.2 0.1 0.2 
Tissue pathology*  591 1.4 100.0 0.6 0.5 0.7 0.4 0.3 0.5 
 Histology; skin 523 1.2 88.5 0.5 0.5 0.6 0.4 0.3 0.4 
Immunology*  788 1.8 100.0 0.8 0.7 0.9 0.5 0.5 0.6 
 Immunology, other* 423 1.0 53.7 0.4 0.4 0.5 0.3 0.3 0.3 
 Anti-nuclear antibodies 146 0.3 18.5 0.2 0.1 0.2 0.1 0.1 0.1 
 Rheumatoid factor 123 0.3 15.6 0.1 0.1 0.2 0.1 0.1 0.1 
Simple tests*  216 0.5 100.0 0.2 0.2 0.3 0.1 0.1 0.2 
Infertility/pregnancy* 253 0.6 100.0 0.3 0.2 0.3 0.2 0.1 0.2 
Total pathology tests  43,313 100.0 — 45.2 43.4 47.0 29.6 28.6 30.7 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.8, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; M,C&S – microscopy, culture and sensitivity; HIV – human immunodeficiency 
virus; NEC – not elsewhere classified. 
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Problems for which pathology tests were ordered 
Table 12.3 describes the most common problems for which pathology was ordered, in 
decreasing frequency order of problem–pathology combinations. Diabetes, accounting for 
7.6%of all problem–pathology combinations, followed by hypertension, general check-ups 
and lipid disorders were the most common problems for which pathology tests were 
ordered. The two right-hand columns show the proportion of each problem that resulted in a 
pathology order, and the rate of pathology tests/batteries of tests per 100 specified problems 
when at least one test is ordered. For example, 30.9% of contacts with diabetes resulted in 
pathology orders, and when pathology was ordered for diabetes, 290 tests/batteries of tests 
were ordered per 100 diabetes contacts that resulted in a pathology test order. In contrast, 
only 11.2% of contacts with hypertension problems resulted in a pathology test, but the 
resulting test orders accounted for almost as many tests (5.9%) as did diabetes. 
Table 12.3: The 10 problems for which pathology was most frequently ordered 
Problem managed 
Number of 
problems 
Number of 
problem–
pathology 
combinations(a) 
Per cent of 
problem–
pathology 
combinations(a) 
Per cent of 
problems with 
test(b) 
Rate of pathology 
orders per 100 
problems with 
pathology(c) 
Diabetes – all* 3,826 3,426 7.6 30.9 289.5 
Hypertension* 8,314 2,656 5.9 11.2 284.2 
General check-up* 2,572 2,391 5.3 27.4 338.7 
Lipid disorders 2,931 1,774 3.9 27.4 221.1 
Weakness/tiredness  635 1,623 3.6 66.0 387.6 
Female genital check-up/Pap 
smear* 
1,645 1,517 3.4 75.7 121.8 
Blood test NOS 383 1,131 2.5 85.7 344.8 
Urinary tract infection* 1,730 1,130 2.5 55.4 118.0 
Pregnancy* 1,377 994 2.2 33.2 217.4 
Abnormal test results* 1,067 864 1.9 48.6 166.7 
Subtotal 24,445 17,500 38.8 — — 
Total problems 146,141 45,185 100.0 13.3 231.8 
(a) A test was counted more than once if it was ordered for the management of more than one problem at an encounter. There were 43,313 
pathology test orders and 45,185 problem–pathology combinations. 
(b) The percentage of total contacts with the problem that generated at least one order for pathology. 
(c) The rate of pathology orders placed per 100 tested problem contacts with at least one order for pathology. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: NOS – not otherwise specified. 
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12.3 Imaging ordering 
Readers wanting a more detailed study of imaging orders should consult the comprehensive 
report on imaging orders by GPs in Australia in 1999–00, written by the FMRC using 
BEACH data, and published by the AIHW and the University of Sydney in 2001.71 
Nature of imaging orders at encounter 
There were 9,370 imaging test orders recorded, at a rate of 9.8 per 100 encounters and 6.4 per 
100 problems managed.  
The distribution of imaging tests by MBS group, and the most common tests within each 
group are presented in Table 12.4. Each group and individual test is expressed as a 
percentage of all imaging tests, as a percentage of the group, as a rate per 100 encounters, 
and as a rate per 100 problems with 95% confidence limits. Diagnostic radiology accounted 
for almost half (47.2%) of all imaging test orders, and ultrasound accounted for 39.2%. 
Table 12.4: Imaging orders by MBS imaging groups and the most frequent imaging tests ordered 
within group 
Imaging test ordered Number 
Per cent of all 
imaging  
 Per cent of 
group 
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 146,141) 
95% 
LCL 
95% 
UCL 
Diagnostic radiology* 4,426 47.2 100.0 4.6 4.4 4.9 3.0 2.9 3.2 
 X-ray; chest 978 10.4 22.1 1.0 0.9 1.1 0.7 0.6 0.7 
 X-ray; knee 475 5.1 10.7 0.5 0.4 0.6 0.3 0.3 0.4 
 Mammography; female 336 3.6 7.6 0.4 0.3 0.4 0.2 0.2 0.3 
 X-ray; foot/feet  259 2.8 5.9 0.3 0.2 0.3 0.2 0.2 0.2 
 X-ray; shoulder 249 2.7 5.6 0.3 0.2 0.3 0.2 0.1 0.2 
 X-ray; hip  236 2.5 5.3 0.2 0.2 0.3 0.2 0.1 0.2 
 Test; densitometry 226 2.4 5.1 0.2 0.2 0.3 0.2 0.1 0.2 
 X-ray; ankle 185 2.0 4.2 0.2 0.2 0.2 0.1 0.1 0.2 
 X-ray; wrist  169 1.8 3.8 0.2 0.1 0.2 0.1 0.1 0.1 
  X-ray; hand 140 1.5 3.2 0.1 0.1 0.2 0.1 0.1 0.1 
 X-ray; spine; lumbosacral 103 1.1 2.3 0.1 0.1 0.1 0.1 0.1 0.1 
 X-ray; spine; lumbar  92 1.0 2.1 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; spine; cervical  92 1.0 2.1 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; abdomen 91 1.0 2.1 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; finger(s)/thumb 83 0.9 1.9 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; spine; thoracic 68 0.7 1.5 0.1 0.1 0.1 0.0 0.0 0.1 
Ultrasound* 3,671 39.2 100.0 3.8 3.6 4.0 2.5 2.4 2.6 
 Ultrasound; pelvis 575 6.1 15.7 0.6 0.5 0.7 0.4 0.3 0.4 
 Ultrasound; abdomen  407 4.3 11.1 0.4 0.4 0.5 0.3 0.2 0.3 
 Ultrasound; shoulder 390 4.2 10.6 0.4 0.4 0.5 0.3 0.2 0.3 
 Ultrasound; breast; female 315 3.4 8.6 0.3 0.3 0.4 0.2 0.2 0.2 
 Ultrasound; obstetric 257 2.7 7.0 0.3 0.2 0.3 0.2 0.1 0.2 
(continued) 
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Table 12.4 (continued): Imaging orders by MBS imaging groups and the most frequent imaging 
tests ordered within group  
Imaging test ordered Number 
Per cent of 
all imaging  
 Per cent of 
group 
Rate per 100 
encounters 
(n = 95,839) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 146,141) 
95% 
LCL 
95% 
UCL 
 Echocardiography 134 1.4 3.7 0.1 0.1 0.2 0.1 0.1 0.1 
 Test; Doppler  126 1.3 3.4 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; kidney 123 1.3 3.4 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; leg 97 1.0 2.6 0.1 0.1 0.1 0.1 0.1 0.1 
 Ultrasound; thyroid  86 0.9 2.3 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; knee 85 0.9 2.3 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; scrotum 80 0.9 2.2 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; foot/toe(s) 77 0.8 2.1 0.1 0.1 0.1 0.1 0.0 0.1 
 Test; Doppler carotid  75 0.8 2.0 0.1 0.1 0.1 0.1 0.0 0.1 
Computerised tomography* 1,058 11.3 100.0 1.1 1.0 1.2 0.7 0.7 0.8 
 CT scan; brain 153 1.6 14.5 0.2 0.1 0.2 0.1 0.1 0.1 
 CT scan; abdomen  132 1.4 12.5 0.1 0.1 0.2 0.1 0.1 0.1 
 CT scan; spine; lumbar 121 1.3 11.4 0.1 0.1 0.2 0.1 0.1 0.1 
 CT scan; head  103 1.1 9.7 0.1 0.1 0.1 0.1 0.1 0.1 
 CT scan; chest  95 1.0 9.0 0.1 0.1 0.1 0.1 0.0 0.1 
 CT scan; sinus 73 0.8 6.9 0.1 0.1 0.1 0.0 0.0 0.1 
 CT scan; spine; lumbosacral 60 0.6 5.7 0.1 0.0 0.1 0.0 0.0 0.1 
Magnetic resonance imaging 127 1.4 100.0 0.1 0.1 0.2 0.1 0.1 0.1 
Nuclear medicine* 88 0.9 100.0 0.1 0.1 0.1 0.1 0.0 0.1 
Total imaging tests 9,370 100.0 — 9.8 9.4 10.2 6.4 6.1 6.7 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.9 <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; CT – computerised tomography. 
Problems for which imaging tests were ordered 
Table 12.5 lists the most common problems for which imaging was ordered, in decreasing 
frequency order of problem–imaging combinations. The most common was osteoarthritis, 
accounting for 5.2% of orders, followed by back complaint (4.6%), and sprain/strain (3.8%). 
The two right-hand columns show the proportion of each problem that resulted in an 
imaging test, and the rate of imaging tests per 100 specified problems when at least one test 
was ordered. For example, 33.8% of contacts with fractures resulted in an imaging test, and 
109.7 tests were ordered per 100 fracture contacts when at least one test was ordered. 
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Table 12.5: The 10 problems for which an imaging test was most frequently ordered 
Problem managed 
Number of 
problems 
Number of  
problem–imaging 
 combinations(a) 
Per cent of 
problem–imaging 
combinations 
Per cent  
of problems 
with test(b) 
Rate of imaging 
orders per 100 
problems with 
imaging(c) 
Osteoarthritis* 2,590 491 5.2 16.9 112.2 
Back complaint* 2,599 434 4.6 14.8 112.9 
Sprain/strain* 1,335 364 3.8 22.5 121.4 
Pregnancy* 1,377 363 3.8 25.8 102.2 
Fracture* 892 330 3.5 33.8 109.7 
Abdominal pain* 656 277 2.9 37.0 114.3 
Bursitis/tendonitis/synovitis NOS 1,019 276 2.9 22.8 118.8 
Injury musculoskeletal NOS 721 257 2.7 30.9 115.3 
Shoulder syndrome 504 217 2.3 32.2 133.4 
Breast lump/mass (female) 179 191 2.0 72.3 147.4 
Subtotal 11,872 3200 33.7 — — 
Total problems 146,141 9,472 100.0 5.7 113.9 
(a) A test was counted more than once if it was ordered for the management of more than one problem at an encounter. There were 9,370 
imaging test orders and 9,472 problem–imaging combinations. 
(b) The percentage of total contacts with the problem that generated at least one order for imaging. 
(c) The rate of imaging orders placed per 100 tested problem contacts with at least one order for imaging. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: NOS – not otherwise specified. 
12.4 Other investigations 
Other investigations include diagnostic procedures ordered by the GP at the encounter or 
undertaken by the GP or practice staff. GPs ordered 697 other investigations during the 
study year, and GPs or practice staff undertook 1,247 other investigations. There were, in 
total, 1,944 other investigations either ordered or undertaken in the practice (Table 12.6). 
The first part of Table 12.6 lists the other investigations ordered by GPs. The second part lists 
the other investigations undertaken in the practice by GPs or practice staff. The third part 
lists total other investigations either ordered or undertaken in the practice. Each 
investigation is expressed as a percentage of total other investigations ordered or 
undertaken, as a rate per 100 encounters, and as a rate per 100 problems, each with 
95% confidence limits. Electrical tracings were the most common group of other 
investigations ordered or undertaken making up 44.5% of other investigations followed by 
physical function test (32.5%).  
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Table 12.6: Other investigations ordered by GPs or performed in the practice 
 Investigations ordered by the GP  Investigations undertaken in the practice  All investigation (ordered or undertaken) 
Investigation ordered Number Per cent 
Rate per 100 
encounters 
(95% CI) 
(n = 95,839) 
Rate per 100 
problems 
(95% CI) 
(n = 146,141)  Number Per cent 
Rate per 100 
encounters 
(95% CI) 
(n = 95,839) 
Rate per 100 
problems 
(95% CI) 
(n = 146,141) 
 
Number Per cent 
Rate per 100 
encounters 
(95% CI) 
(n = 95,839) 
Rate per 100 
problems 
(95% CI) 
(n = 146,141) 
Electrical tracings* 
333 47.8 0.35  
(0.30–0.40) 
0.23  
(0.20–0.26) 
 532 42.7 0.56  
(0.48–0.63) 
0.36  
(0.31–0.42) 
 866 44.5 0.90  (0.81–1.00) 
0.59  
(0.53–0.65) 
Diagnostic endoscopy* 
176 25.3 0.18  
(0.15–0.22) 
0.12  
(0.10–0.15) 
 463 37.1 0.48  
(0.36–0.61) 
0.32  
(0.24–0.40) 
 632 32.5 0.66  (0.53–0.79) 
0.43  
(0.35–0.52) 
Physical function test*  
169 24.2 0.18  
(0.14–0.21) 
0.12  
(0.09–0.14) 
 236 18.9 0.25  
(0.15–0.34) 
0.16  
(0.10–0.22) 
 255 13.1 0.27  (0.17–0.36) 
0.17  
(0.11–0.24) 
Other diagnostic procedures* 
18 2.6 0.02  
(0.01–0.03) 
0.01  
(0.01–0.02) 
 16 1.3 0.02  
(0.01–0.03) 
0.01  
(0.00–0.02) 
 192 9.9 0.20  (0.16–0.24) 
0.13  
(0.11–0.16) 
Total other investigations 
ordered 
697 100.0 0.73  
(0.65–0.80) 
0.48  
(0.43–0.52) 
 1,247 100.0 1.30  
(1.11–1.49) 
0.85  
(0.73–0.98) 
 1,944 100.0 2.03  (1.82–2.23) 
1.33  
(1.20–1.46) 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.6 <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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12.5 Lipid tests 
Lipid tests have become the chemistry test most frequently ordered by Australian GPs and 
the second most frequently ordered test overall after full blood counts. Lipid tests accounted 
for 8.8% of all pathology and 15.2% of all chemistry. Lipid tests were ordered at 3,639 
encounters for the management of 3,848 problems representing about 4.5 million GP–patient 
encounters at which a lipid test was ordered in general practice across Australia in 2010–11. 
Figure 12.1 shows the patients and problems for which a lipid test was ordered and describes 
other management for the same problems.  
Patient age and sex  
The sex distribution of patients receiving lipid tests (52.3% male) differed from the sex 
distribution of the BEACH sample (42.9% male; Table 6.1). Lipid tests were ordered at 4.6% 
of encounters with male patients and at 3.2% of encounters with female patients.  
The age distribution also differed from that of the BEACH sample, with more patients at 
lipid test encounters aged 45–64 years (48.8%) and very few aged less than 25 years (1.7%) 
than in the total BEACH sample (20.6% aged < 25 years; Table 6.1). Patients aged 45–64 years 
were those most likely to have a lipid test ordered (6.7% of encounters with this age group 
involved lipid tests), followed by patients aged 65–74 years (5.9%).  
Reasons for encounter  
The spectrum of reasons for encounter given by patients at encounters where lipid tests were 
ordered reflects the mainly preventive and monitoring use of lipid tests by GPs. The most 
frequent RFEs were check-ups of various kinds and problems such as diabetes and 
hypertension where lipid level monitoring may be appropriate. 
Problems for which lipid tests were ordered 
Three quarters of the problems for which lipid tests were ordered were established patient 
diagnoses, reflecting the preventive and monitoring nature of most lipid tests.  
Although lipid disorders were the most common problem for which lipid tests were ordered, 
they accounted for less than 20% of lipid test problems. Hypertension and diabetes 
constituted the next most common problems for which lipid tests were ordered. These are 
common and carry known risk associated with lipid levels. Down in the list were ischaemic 
heart disease and obesity which are also associated with lipid management or increased risk 
associated with lipid levels. The remaining problems were mainly associated with the 
ordering of lipid tests for prevention, screening or ongoing monitoring. The exception was 
‘weakness/tiredness general’ where lipid testing may be used in a diagnostic mode.  
Other management actions at encounters where a lipid test was ordered 
At least one medication was prescribed, supplied or advised for over-the-counter purchase 
for nearly 40% of problems for which a lipid test was ordered. GPs also commonly provided 
other treatments (including clinical and procedural treatments) (for 24.5% of lipid test 
problems), and less commonly ordered referrals (6.1%) and imaging (3.6%). 
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Lipid tests* 
n = 3,802 (8.8% of all Pathology) 
(15.2% of all Chemistry) 
4.0 per 100 encounters 
n = 4,020 Lipid test–problem linkages 
 
Reasons for encounter 
n = 6,892 (189.4 per 100 lipid test  
 encounters) 
Rate per 100 lipid test encounters(b) 
Prescription – all* 12.0 
General check-up* 8.2 
Blood test NOS 6.3 
Cardiac check-up* 6.2 
Test results*  4.3 
Diabetes – all* 2.9 
Blood test – endocrine/metabolic 2.6 
Hypertension/high blood pressure* 2.3 
Female genital check-up/Pap smear* 2.0 
Other management actions 
(at least one) 
Per cent of lipid test problems(a) 
Medications (n = 1,492) 38.8 
Other treatments (n = 942) 24.5 
Referrals (n = 233) 6.1 
Imaging (n = 140) 3.6 
The patients  
Sex  Per cent Rate(c) 
 Males 52.3 4.6 
 Females 47.7 3.2 
 
Age group Per cent Rate(c) 
 < 25 years 1.7 0.8 
 25–44 years 17.1 2.9 
 45–64 years 48.8 6.7 
 65–74 years 20.4 5.9 
 75+ years 12.1 2.9 
Problems managed with an lipid test 
n = 3,848 
Per cent of lipid test problems(a) 
New problems 25.2 
Old problems 74.8 
Per cent of lipid test problems(a) 
Lipid disorders 18.8 
Hypertension* 13.5 
Diabetes – all* 12.6 
General check-up 10.6 
Blood test NOS 4.6 
Ischaemic heart disease* 2.6 
Blood test – endocrine/metabolic 2.2 
Weakness/tiredness 2.0 
Cardiac check-up* 1.5 
Prescription – all* 1.4 
Obesity (BMI > 30) 1.4 
 
(a) Expressed as a per cent of problems for which lipid tests were ordered.  
(b) Expressed as a rate per 100 encounters at which lipid tests were ordered.  
(c) Age and sex-specific rates, per cent of encounters involving lipid tests in each age or sex group. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: NOS – not otherwise specified; BMI – body mass index; NEC – not elsewhere classified. 
Figure 12.1: Lipid tests ordered in general practice, 2010–11 
 
Discussion 
The rate of lipid testing increased from 3.1 per 100 encounters in 2001–02 to 4.0 per 100 
encounters in 2010–11 representing an additional 1.6 million encounters in 2010–11 at which 
lipid tests were ordered. This rise appears to have been driven by the increasing awareness 
of the role of lipids in cardiovascular disease, particularly in association with other 
conditions such as diabetes and hypertension, and the development of effective drug 
management. This is reflected in guidelines for management of lipid levels which GPs 
appear to be following. 
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12.6 Changes in investigations over the decade 
2001–02 to 2010–11 
Data on investigations are reported for each year from 2001–02 to 2010–11 in Chapter 12 of 
the companion report A decade of Australian general practice activity 2001–02 to 2010–11.1 In that 
report, changes over time are measured as change in the management of problems (that is, as 
a rate per 100 problems). This reflects change in how GPs are managing problems, and 
accounts for the significant increase in the number of problems managed per encounter over 
the decade (see Section 7.9). The major changes are highlighted below. 
• At least one pathology test was ordered for 10.8% of problems managed in 2001–02 
rising to 13.3% of problems in 2010–11. The largest increase was in orders for chemical 
pathology, which increased from 11.5 per 100 problems in 2001–02 to 17.2 per 
100 problems in 2010–11. Haematology increased at a slower rate, from 4.3 per 
100 problems in 2001–02 to 5.3 in 2010–11. Microbiology test orders increased from 
3.4 per 100 problems in 2001–02 to 4.3 in 2010–11.  
• Between 2001–02 and 2010–11 the number of problems managed per 100 encounters rose 
from 143.4 to 152.5 (Table 5.1). Both the rise in the number of tested problems and the 
rise in the number of problems managed at encounter contributed to an overall increase 
in the proportion of encounters involving a pathology test. These rose from 14.0% of 
encounters in 2001–02 to 17.8% in 2010–11, which is over 7 million more encounters at 
which pathology was ordered in 2010–11 than in 2001–02. 
• The number of pathology tests ordered increased from 21.6 tests (or battery of tests) per 
100 problems managed in 2001–02 to 29.6 per 100 problems in 2010–11. The rate of 
pathology orders per 100 encounters increased from 31.0 per 100 encounters in 2001–02 
to 45.2 in 2010–11, which extrapolates to approximately 22.4 million more tests (or 
battery of tests) ordered in 2010–11.  
• At least one imaging test was ordered for 5.0% of all problems managed in 2001–02, 
rising to 5.7% of all problems in 2010–11. The proportion of encounters generating 
imaging orders increased from 6.9% in 2001–02 to 8.4% in 2010–11, resulting in an 
estimated 3 million more encounters nationally at which imaging was ordered in  
2010–11. 
• The number of imaging tests ordered increased from 5.5 tests (or battery of tests) per 
100 problems managed in 2001–02 to 6.4 per 100 problems in 2010–11. Total imaging 
orders per 100 encounters also increased significantly from 7.9 per 100 encounters in 
2001–02 to 9.8 in 2010–11, suggesting there were almost 3.7 million more imaging orders 
in 2010–11 than in 2001–02. 
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13 Practice nurse activity 
This section describes the activities of practice nurses recorded in association with the  
GP–patient encounters by the GPs in BEACH. 
In February 2004, two Medicare item numbers were introduced into the MBS that allowed 
GPs to claim for specified tasks undertaken by a practice nurse under the direction of the GP. 
The BEACH recording form (see Appendix 1) was amended to allow the capture of this 
information from April 2005 onwards. 
• GPs were allowed to record multiple (up to three) Medicare item numbers where 
appropriate, rather than be limited to one item number. 
• In the ‘other treatments’ section, for each problem managed GPs were asked to tick the 
‘practice nurse’ box if the treatment recorded was provided by the practice nurse rather 
than by the GP. If the box was not ticked it was assumed that the GP provided the ‘other 
treatment’. 
The survey form allows GPs to record up to two other treatments for each problem managed 
at the encounter (i.e. up to eight per encounter). Other treatments include all clinical and 
procedural treatments provided at the encounters. These groups are defined in Appendix 4, 
Tables A4.4 and A4.5. 
Since February 2004 additional practice nurse items have been added. The nine practice 
nurse Medicare items recorded by GPs during the 2010–11 BEACH data period are listed 
with a short description in Table 13.2.  
This section investigates: the proportion of encounters involving the practice nurse; the 
proportion of these that were recorded as claimable under a practice nurse Medicare item 
number; the distribution of the practice nurse items recorded; treatments provided by 
practice nurses in association with the GP-recorded encounters; and the problems for which 
practice nurses provided treatments (in direct association with the GP-recorded encounters). 
In Chapter 10, all clinical and procedural treatments recorded by the GPs were reported, 
irrespective of whether they were provided by the GP or by a practice nurse. As in previous 
years, injections recorded in the provision of immunisations and vaccinations were not 
included, as these were already counted as pharmacological management (in Chapter 9). In 
contrast, this section, being a description of practice nurse activity, reports only the activities 
indicated as being conducted by a practice nurse and includes the injections for 
immunisation/vaccination (when given by a practice nurse). GPs are also instructed not to 
record their taking of routine clinical measurements, such as blood pressure. However, where 
practice nurses undertook these activities at the consultation, and it was recorded as a practice 
nurse activity, they have been included in the analysis in this chapter. 
When viewing these results, it must be remembered that these practice nurse data will not 
include activities undertaken by practice nurses during the GP’s BEACH recording period 
that were outside (not associated with) the recorded encounter. Such activities could include 
Medicare-claimable activities (for example, immunisations/vaccinations) provided under 
instruction from the GP but not provided at the time of the encounter recorded in BEACH, or 
provision of other services not currently claimable from Medicare (for example, dietary 
advice on a one-to-one basis, or in a group situation). 
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13.1 Practice nurse Medicare claims 
There were 7,625 (8.0%) GP–patient encounters for which at least one practice nurse item 
and/or nurse activity was recorded. However, for 195 of these their activity was not 
described. At the remaining 7,432 encounters a practice nurse was involved in the 
management of 7,826 problems (5.4% of all problems managed at all encounters). Simple 
extrapolation of these results suggests that during 2010–11 practice nurses were involved in 
almost 9.4 million GP–patient consultations across Australia.  
As shown in Table 5.6, at only 3,068 encounters (3.7% of all encounters with at least one MBS 
item number recorded and 40.2% of the 7,625 encounters involving practice nurses) was a 
practice nurse Medicare item recorded (Table 13.1), and 3,109 practice nurse items recorded 
(Table 13.2). Practice nurse items accounted for 3.0% of all Medicare items recorded in 
BEACH 2010–11 (Table 5.6). 
Table 13.1: Summary of practice nurse involvement at encounter 
Variable Number 
Total encounters  95,839 
Encounters involving practice nurse  7,625 
 Encounters at which practice nurse activity described 7,432 
 Encounters with MBS practice nurse item number(s) recorded but activity not described  195 
Encounters at which one or more MBS practice nurse item numbers were recorded as 
claimable 
3,068 
Total problems managed 146,141 
 Problems managed with practice nurse involvement 7,826 
 Per cent (95% CI) 
Encounters involving practice nurses as a proportion of total encounters  8.0 (7.3–8.7) 
Problems involving practice nurses as a proportion of total problems 5.4 (4.9–5.8) 
Practice nurse claimable encounters as a proportion of total encounters with at least one 
MBS item recorded 
3.7 (3.2–4.1) 
Proportion of encounters involving practice nurses for which one or more MBS practice nurse 
item numbers were recorded as claimable 
40.2 (36.9–43.6) 
Note: MBS – Medicare Benefits Schedule; CI – confidence interval. 
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Distribution of practice nurse item numbers claimed at encounters 
A total of 3,108 practice nurse item numbers were recorded at 3,068 encounters. Two-thirds 
(67.0%) of the practice nurse item numbers recorded were for immunisations and a further 
28.1% were for wound treatments. Items recorded for practice nurse services to a person 
with chronic disease accounted for 3.6%, and those claimed for practice nurse conduct of 
cervical smears (with or without preventive checks) for 1.1% of total practice nurse item 
numbers recorded. Recorded claims for health checks by nurses were few.  
Comparison of the distribution of BEACH practice nurse item numbers recorded and the 
distribution of the 6.1 million claims made for such items from Medicare in the same data 
period demonstrated a relatively good fit, with a marked under-representation of claims for 
chronic disease services (items 10997) and cervical smears (items 10994–10999 inclusive) and 
an over-representation of claims for immunisations by a practice nurse (item 10993) (Table 
13.2). These results suggest that practice nurse conduct of cervical smears and chronic 
disease services are more likely to occur separately from the GP encounter, while practice 
nurse immunisations are more likely to be done in association with a GP-patient encounter. 
Table 13.2: Distribution of practice nurse item numbers recorded at encounter 
Medicare item 
number Short descriptor Number 
Per cent 
 of total 
Per cent of Medicare 
practice nurse 
claims(a) 
(n = 6.1 million) 
00711/10986(b) Health assessment of four year old who has had /is 
having 4 year old immunisation, by practice nurse or 
registered Aboriginal health worker 
6 0.2 
(0.0–0.4) 
0.4 
10993 Immunisation by practice nurse 2,082 67.0 
(63.1–70.9) 
60.4 
10996 Wound treatment (other than normal aftercare) by 
practice nurse 
875 28.1 
(24.6–31.7) 
30.7 
10997 Service provided to a person with a chronic disease by a 
practice nurse or registered Aboriginal Health Worker  
111 3.6 
(2.5–4.6) 
6.2 
10994 Cervical smear and preventive checks by practice nurse 20 0.6 
(0.0–0.1) 
2.0 
(all cervical  
smears) 
10995 Cervical smear and preventive checks – women aged 
20–69 years, no smear in previous 4 years 
1 0.0Ŧ 
(0.0–0.0) 
10998 Cervical smear by practice nurse 12 0.4 
(0.0–0.8) 
10999 Cervical smear – women 20–69 years, no smear in past 
4 years 
1 0.0Ŧ  
(0.0–0.0) 
Total(c) All Medicare practice nurse item numbers 3,108 100.0 100.0 
(a) Total Medicare practice nurse claims July 2010–June 2011 – Medicare health statistics. <www.medicareaustralia.gov.au> 
(b) Item 00711 – Health check by a practice nurse or registered Aboriginal health worker – was introduced in 2008 and replaced with  
item 10986 in May 2010 
(c) Two of the 3,110 practice nurse/Aboriginal health worker item numbers (Table 5.6) were excluded due to incomplete data. 
Ŧ Rates are reported to one decimal place. This indicates that the rate is less than 0.05 per 100 encounters. 
Note: there were no recordings of items: 10987 – Follow-up by practice nurse or registered Aboriginal health worker for Indigenous person who 
has received a health assessment; 10988 – Immunisation provided by a registered Aboriginal health worker; 10989 – Wound treatment provided 
by a registered Aboriginal health worker; 16400 – Antenatal services provided by midwives, practice nurses and Aboriginal health workers in rural 
and remote areas. 
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Treatments provided by practice nurses 
As shown in Chapter 10, GPs reported 50,235 other treatments at encounters. A further 2,266 
local injections in administration of immunisations were given by a practice nurse and 1,778 
by the recording GP (these were not reported in Chapter 10). So, in total 54,279 other 
treatments were recorded. Practice nurses provided 8,384 other treatments (representing 
15.4% of all other treatments recorded at BEACH encounters) at a rate of 8.7 per 100 recorded 
encounters. The majority (91.7%) of the practice nurse activity was procedural, and these 
procedures represented 38.0% of all procedures recorded. In contrast, clinical treatments 
accounted for 8.3% of practice nurse activity, but practice nurses provided only 2.0% of all 
recorded clinical treatments. Practice nurses did the majority of the immunisation injections 
(56.0%) at GPs encounters (Table 13.3). 
Table 13.3: Summary of treatments given by practice nurse 
Treatment 
Performed/assisted by 
practice nurse 
 
Performed by the GP 
Total number 
recorded(a) Number 
Row per cent  
of total  Number 
Row per cent  
of total 
Procedures(a) 7,689 38.0  12,571 62.0 20,260 
 (Immunisation injections) (2,266) (56.0)  (1,778) (44.0) (4,044) 
Clinical treatments 695  2.0  33,324 98.0 34,019  
All other treatments 8,384 15.4  45,895 84.6 54,279 
(a) Procedural treatments here include all injections given by a practice nurse for immunisations/vaccinations (n = 4,044). These are not 
included in the summary of the content of encounter in Table 5.1, summary of management in Table 8.1 or in the analyses of other 
treatments in Chapter 10, because the immunisation/vaccination is already counted as a prescription or GP-supplied medication. 
Of the 7,689 procedures performed by practice nurses, 39.7% were injections (74.2% of which 
were for immunisations), and a further 18.9% were dressing/pressure/compression/ 
tamponade. Together these accounted for 58.6% of all procedures undertaken by practice 
nurses in association with the recorded GP encounters. Check-ups made up 7.1% of 
procedures undertaken by the nurse, followed by INR tests (6.5%), incision/drainage/ 
aspirations (5.5%). Practice nurses also undertook a wide range of other procedural activities 
in association with the GP encounters. The most common are listed in Table 13.4. 
Other administrative procedure (which includes administrative/documentation work but 
excludes provision of sickness certificates) was the most frequently recorded clinical activity, 
accounting for 23.6% of the 695 clinical treatments provided by nurses, followed by 
counselling the patient about their health problem (13.1%), general advice/education 
(10.3%), consultation with a primary care provider (7.5%), counselling about nutrition or 
weight (6.6%) and advice/education about medication (5.8%) or treatment (5.4%)  
(Table 13.4).  
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Table 13.4: Most frequent activities done by a practice nurse 
Activity Number 
Per cent of 
group(a) 
Rate per 100 
encounters involving 
practice nurse(a) 
 (n = 7,625) 
95% 
LCL 
95% 
UCL 
Procedural treatments 7,689 100.0 103.5 101.6 105.4 
 Local injection/infiltration* 3,054 39.7 41.1 37.7 44.5 
 Dressing/pressure/compression/tamponade* 1,451 18.9 19.5 17.8 21.2 
 Check-up – practice nurse* 545 7.1 7.3 5.2 9.5 
 INR test 503 6.5 6.8 5.5 8.1 
 Incision/drainage/flushing/aspiration/removal 
 body fluid* 
426 5.5 5.7 4.7 6.7 
 Repair/fixation-suture/cast/prosthetic device  
 (apply/remove)* 
324 4.2 4.4 3.6 5.1 
 Electrical tracings* 322 4.2 4.3 3.7 5.0 
 Excision/removal tissue/biopsy/destruction/ 
 debridement/cauterisation* 
235 3.1 3.2 2.5 3.9 
 Physical function test* 194 2.5 2.6 2.0 3.3 
 Urine test*  172 2.2 2.3 1.6 3.0 
 Glucose test 109 1.4 1.5 0.7 2.3 
 Other diagnostic procedures* 96 1.2 1.3 0.2 2.3 
 Pap smear* 70 0.9 0.9 0.5 1.3 
 Physical medicine/rehabilitation – all* 64 0.8 0.9 0.5 1.2 
Clinical treatments 695 100.0 9.1 7.6 11.1 
 Other administrative procedure (excluding 
 sickness certificate)* 
164 23.6 2.2 1.6 2.8 
 Counselling – problem* 91 13.1 1.2 0.6 1.8 
 Advice/education NEC* 71 10.3 1.0 0.5 1.4 
 Consultation with primary care provider* 52 7.5 0.7 0.4 1.0 
 Counselling/advice – nutrition/weight* 46 6.6 0.6 0.4 0.8 
 Advice/education – medication* 40 5.8 0.5 0.3 0.8 
 Advice/education – treatment* 37 5.4 0.5 0.3 0.7 
(a) Only those individual treatments accounting for ≥ 0.5% of total treatments by practice nurse are included. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Tables A4.4–A4.6 <purl.library.usyd.edu.au/sup/9781920899868>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; INR – international normalised ratio.. 
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13.2 Problems managed with practice nurse 
involvement at encounter 
Practice nurses were involved in management of a wide variety of problems in association 
with the GP encounters. The problems managed most often were immunisation/vaccination 
(29.1% of all problems managed with the involvement of a practice nurse), followed by 
laceration/cut (5.7%), check-ups (4.7%), and chronic skin ulcer (4.1%). Other common 
problems that involved practice nurses at the consultations are listed in Table 13.5. 
Table 13.5: The most common problems managed with involvement of practice nurses 
Problem managed Number 
Per cent of 
problems 
involving practice 
nurse 
(n = 7,826) 
Rate per 100 
encounters with 
recorded practice 
nurse activity(a) 
(n = 7,625) 
95% 
LCL 
95% 
UCL 
Immunisation/vaccination – all* 2,280 29.1 30.7 27.3 34.0 
Laceration/cut 442 5.7 6.0 5.1 6.8 
Check-up – all* 371 4.7 5.0 4.1 5.9 
Chronic ulcer skin (including varicose ulcer) 325 4.1 4.4 3.7 5.1 
Atrial fibrillation/flutter 270 3.4 3.6 2.8 4.4 
Diabetes – all* 257 3.3 3.5 2.6 4.3 
Excessive ear wax 172 2.2 2.3 1.9 2.7 
Malignant neoplasm skin 134 1.7 1.8 1.4 2.2 
Blood test – all* 120 1.5 1.6 1.1 2.1 
Skin infection – post traumatic 119 1.5 1.6 1.2 2.0 
Hypertension* 109 1.4 1.5 1.0 1.9 
Repair/fixation – suture/cast/prosthetic device 
(apply/remove)* 
93 1.2 1.2 0.9 1.6 
Vitamin/nutritional deficiency 90 1.2 1.2 0.9 1.6 
Asthma 87 1.1 1.2 0.8 1.5 
Cystitis/urinary infection 83 1.1 1.1 0.8 1.5 
Other preventive procedures* 76 1.0 1.0 0.6 1.4 
Boil/carbuncle 74 0.9 1.0 0.7 1.3 
Pregnancy* 70 0.9 0.9 0.6 1.3 
Observation/health education/advice/diet – all* 68 0.9 0.9 0.6 1.3 
Burns/scalds 66 0.8 0.9 0.6 1.2 
Subtotal 5,306 67.8% — — — 
Total problems involving practice nurse 7,826 100.0 105.3 104.3 106.3 
(a) Rate of nurse provision of treatment at encounter for selected problem per 100 total encounters in which a practice nurse was involved. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.3, <purl.library.usyd.edu.au/sup/9781920899868>).  
Note: LCL – lower confidence limit; UCL – upper confidence limit.  
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13.3 Discussion 
These results suggest that many GPs are claiming Medicare items for practice nurses to 
provide immunisations and, to a lesser degree, wound treatments, but are infrequently using 
the cervical smear/preventive check and health check practice nurse item numbers.  
The following section extrapolates these results to national estimates and considers them in 
light of Medicare claims data.4  
• Extrapolation of the 7,625 encounters involving a practice nurse (8.0% of all encounters) 
to the 118.1 million GP service items claimed through Medicare in 2010–11 suggests 
there were 9.4 million encounters nationally that involved practice nurses.  
• Extrapolation of the 8,384 activities ascribed to practice nurses in BEACH (8.7 per 
100 encounters) to a national estimate suggests there were 10.3 million such activities 
conducted as part of GP–patient encounters nationally. 
• Extrapolation of the 3,109 practice nurse items claimed (at a rate of 3.2 per 100 BEACH 
encounters) suggests that GPs claimed about 3.8 million practice nurse items for 
activities the nurses undertook in relation to the GP–patient encounters.  
These data suggest that nationally in 2010–11 there were: 
• about 6.5 million practice nurse clinical activities undertaken in association with  
GP–patient encounters that were not claimable or not claimed through Medicare 
(i.e. estimated 10.3 million activities minus estimated 3.8 million claims above). 
• about 2.3 million practice nurse items claimed for practice nurse activities conducted 
independently of direct GP–patient consultations, that is, services provided separately 
from the encounter, and therefore not reported by GPs in BEACH encounter records  
(i.e. 6.1 million Medicare claims from Table 13.2 minus the estimated 3.8 million that 
were for activities associated with the encounters).  
There are no means by which the number of practice nurse clinical activities undertaken 
independently of the GP–patient encounters for which no claim was made can be estimated, 
either because the activity did not qualify for Medicare payment, or because the practice 
simply failed to claim. 
Comparison of the services provided by practice nurses (Table 13.4) with the common 
problems for which these services were provided (Table 13.5) suggests that about 75% of the 
local injections/infiltrations recorded as given by practice nurses were for immunisations, 
and the remaining 25% were for other types of injections, and therefore not eligible to be 
claimed through Medicare.  
Table 13.4 shows that nurses dealt with 1,451 dressing/pressure/compression/tamponades 
in conjunction with the GP encounter, but only 875 claims were made for Medicare payment 
for wound treatment (Table 13.2). This suggests that about 40% of the dressings recorded for 
practice nurses were not claimable under Medicare. Some of these may have been follow-up 
encounters where the follow-up treatment (aftercare) was included in the initial Medicare 
claim (claimed in the past). 
It is clear that practice nurses undertook a wide variety of other activities at the BEACH 
encounters that did not qualify for Medicare reimbursement.  
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13.4 Changes in practice nurse activity, 2005–06 to 
2010–11 
A comparison of practice nurse activity from 2005–06 to 2010–11 is provided in Chapter 13  
of the 10-year summary report A decade of Australian general practice activity 2001–02 to  
2010–11.1 
Changes are summarised below. 
• Encounters involving a practice nurse as a proportion of all encounters more than 
doubled between 2005–06 (4.2%) and 2008–09 (9.0%), but they reverted a little in 2010–11 
to account for 8.0% of all recorded encounters. This suggests that in 2010–11, practice 
nurses were involved in about 10.3 million GP–patient encounters, 6.1 million more than 
in 2005–06.  
• Between 2005–06 and 2008–09 the proportion of encounters with practice nurse activity 
for which a Medicare practice nurse item number was recorded remained constant at  
36–39%. In 2009–10 there was a sudden increase (to 45.5%) that did not quite reach 
statistical significance. In 2010–11 the proportion claimed through Medicare returned to 
its earlier level, at 40.2%.  
• Over the six data years the proportion of Medicare claims accounted for by 
immunisations increased from 63.5% of practice nurse items recorded in 2008–09, to 
74.9% in 2009–10, but this increase was not supported by the 2010–11 data which 
reverted to the 2006–07 level, at 67%. This recent change was also reflected in the 
Medicare claims data which demonstrated a decrease from 5.5 million claims for 
immunisation practice nurse items in 2009–10 to only 3.7 million such claims in 2010–11.  
The transient rise in Medicare claims for practice nurse immunisations in 2009–10 may 
reflect increased immunisations during the H1N1 epidemic. 
• The rate of procedures (including tests) undertaken by practice nurses at  
GP–patient encounters doubled from 4.0 per 100 encounters in 2005–06 to 8.0 per 100 in 
2010–11, the largest portion of this increase occurring between 2008–09 and 2009–10.  
• Provision of clinical treatments (such as advice and health education) by a practice nurse 
at GP encounters remained infrequent, at 0.7 clinical treatments per 100 encounters. This 
was the same rate as in the previous year but had significantly increased from 0.2 per 100 
encounters in 2005–06. There was also a small but significant increase in the proportion 
of clinical treatments that they undertook, from 0.7% clinical treatments in 2005–06 to 
2.0% in 2010–11. 
• Between 2006–07 and 2010–11 there was a significant increase in the practice nurse INR 
testing rate. Between 2005–06 and 2010–11 there were decreases in their rate of dressing 
and of excisions.  
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14 Patient risk factors 
General practice is a useful intervention point for health promotion because the majority of 
the population visit a GP at least once per year – in 2009–10, 83% of Australians visited a GP 
at least once (personal communication DoHA, June 2010). GPs, through ongoing professional 
education, have substantial knowledge of population health, screening programs and other 
interventions. They are therefore in an ideal position to advise patients about the benefits of 
health screening, and to counsel patients individually about their lifestyle choices.  
Since the beginning of the BEACH program (1998), a section on the bottom of each encounter 
form has been used to investigate aspects of patient health or health care delivery not 
covered by general practice consultation-based information. These additional substudies are 
referred to as SAND (Supplementary Analysis of Nominated Data). The SAND methods are 
described in Section 2.6.  
The patient risk factors collected in BEACH include body mass index (BMI) (calculated using 
self-reported height and weight), self-reported alcohol consumption and smoking status. 
Patient risk factors are investigated for a subsample of 40 of the 100 patient encounters 
recorded by each GP. An example of the encounter form with the patient risk factor SAND 
questions is included in Appendix 1. The methods used in the risk factor substudies reported 
in this chapter are described in each section below. 
Data on patient risk factors measured in SAND are reported for each of the ten most recent 
years in the companion report A decade of Australian general practice activity 2001–02 to  
2010–11.1  
Abstracts of results and the research tools used in all SAND substudies from April 1998 to 
March 2011 have been published. Those: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery 
in general practice in Australia22 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: 
abstracts and research tools 1999–200623 
• since August 2006 have been published in each of the general practice activity annual 
reports24-27 
• conducted in the 2010–11 BEACH year are provided in Chapter 15 of this publication. 
14.1 Body mass index 
High body mass was the third highest contributor to the total burden of disease in Australia 
in 2003, accounting for 7.5% of the total burden72, an increase from 4.3% of total burden and 
sixth rank in 1996.73 The 2007–08 National Health Survey (NHS) estimated that, based on 
measured data, 62% of Australians aged 18 years and over were overweight or obese  
(BMI > 25). Men were more likely to be overweight or obese (68%) than women (55%).16  
The 2007–08 NHS also reported that 25% of children aged 5–17 years were classified as 
overweight or obese, with boys and girls having similar rates of overweight/obesity (26% 
and 24% respectively).16 
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Method 
Patient BMI was investigated for a subsample of 40 of the 100 patient encounters. Each GP 
was instructed to ask the patient (or their carer in the case of children): 
• What is your height in centimetres (without shoes)? 
• What is your weight in kilograms (unclothed)? 
Metric conversion tables (feet and inches; stones and pounds) were provided to the GP. 
The BMI for an individual was calculated by dividing weight (kilograms) by height (metres) 
squared. The WHO recommendations74 for BMI groups were used, which specify that an 
adult (18 years and over) with a BMI: 
• less than 18.5 is underweight 
• greater than or equal to 18.5 and less than 25 is normal 
• greater than or equal to 25 and less than 30 is overweight 
• of 30 or more is obese. 
The reported height for adult patients was checked against sex-appropriate upper and lower 
height limits from the Australian Bureau of Statistics (ABS).75 Encounters with adults whose 
reported heights were outside the sex-appropriate limits were excluded from the analysis. 
The standard BMI cut-offs described above are not appropriate in the case of children. 
Cole et al. (2000 & 2007) developed a method that calculates the age–sex-specific BMI cut-off 
levels for underweight, overweight and obesity specific to children aged 2–17 years.76,77 
There are four categories defined for childhood BMI: underweight, normal weight, 
overweight and obese. This method, based on international data from developed Western 
cultures, is applicable in the Australian setting.  
The reported height of children was checked against age–sex-appropriate upper and lower 
height limits from the ABS and Centres for Disease Control (CDC).75,78 Encounters with 
children whose reported heights were outside either of the age–sex-appropriate limits were 
excluded from the analysis. 
The BEACH data on BMI are presented separately for adults (aged 18 years and over) and 
children (aged 2–17 years). The standard BMI cut-offs were applied for the adult sample, and 
the method described by Cole et al. (2000 & 2007) were used for defining underweight, 
overweight and obesity in children (aged 2–17 years).76,77  
Results 
Body mass index of adults 
The sample size was 31,315 patients aged 18 years and over at encounters with 957 GPs. 
• Over half (61.8%) of the patients were overweight (35.1%) or obese (26.7%) (Table 14.1). 
• Only 35.8% of adult patients had a BMI in the normal range and 2.4% were underweight 
(Table 14.1). 
• Males were more likely to be overweight or obese (68.4%, 95% CI: 67.3–69.4) than 
females (57.5%, 95% CI: 56.4–58.5) (results not tabled). 
• Overweight/obesity was most prevalent among male patients aged 65–74 years (76.9%) 
and 45–64 years (75.2%) (Figure 14.1). 
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• Among female patients, overweight/obesity was most prevalent in those aged  
65–74 years (68.1%) and 45–64 years (65.2%) (Figure 14.1). 
• Underweight was most prevalent among patients aged 18–24 years and 75 years and 
over. Of young adults (18–24 years), 7.4% of females and 3.0% of males were 
underweight, and among those aged 75 years and over, 5.3% of women and 1.4% of men 
were underweight (Figure 14.2). 
The overall and sex-specific prevalence estimates from patients at general practice 
encounters (in BEACH: 62% of adults, 68% of males and 58% of females were overweight or 
obese) were consistent with the ABS 2007–08 figures from the National Health Survey (based 
on measured BMI data), which reported that 62% of adults aged 18 and over (68% of men 
and 55% of females) were overweight or obese.16  
Readers interested in prevalence of the three WHO-defined levels of obesity will find more 
information and discussion in Chapter 7 of General practice in Australia, health priorities and 
policies 1998 to 2008.79  
Estimation of body mass index for the adult general practice patient population 
The BEACH study reports data about patient BMI from a sample of the patients attending 
general practice. As older people attend a GP more often than young adults, and females 
attend more often than males, they have a greater chance of being selected in the subsample. 
This leads to a greater proportion of older and female patients in the sample than in the total 
population who attend a GP at least once in a year. The 2010–11 BEACH sample was 
weighted to estimate the BMI of the GP–patient attending population (that is, the 
14.3 million adult patients who attended a GP at least once in 2009–10 (personal 
communication, Department of Health and Ageing (DoHA), June 2010), using the method 
described by Knox et al. (2008).20  
The estimates for the adult GP–patient attending population (after adjusting for age–sex 
attendance patterns) suggest that 26.1% of the adult patient population were obese, 34.6% 
were overweight, 37.0% were normal weight and 2.3% were underweight (Table 14.1).  
Table 14.1: Patient body mass index (aged 18 years and over) 
 Male(a)  Female(a)  Total respondents 
BMI class 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,322) 
Per cent  
in patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 18,741) 
Per cent  
in patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 31,315) 
Per cent  
in patient 
population 
(95% CI)(b) 
Obese 26.1 
(25.2–27.1) 
25.4 
(24.4–26.4)  
27.2 
(26.3–28.1) 
26.7 
(25.8–27.7)  
26.7 
(26.0–27.5) 
26.1 
(25.3–29.9) 
Overweight 42.2 
(41.2–43.2) 
41.0 
(39.9–42.0)  
30.3 
(29.6–31.0) 
29.1 
(28.4–29.9)  
35.1 
(34.4–35.7) 
34.6 
(33..9–35.3) 
Normal 30.6 
(29.5–31.6) 
32.5 
(31.3–33.6)  
39.3 
(38.3–40.3) 
40.9 
(39.9–42.0)  
35.8 
(35.0–36.7) 
37.0 
(36.2–37.9) 
Underweight 1.1 
(0.9–1.3) 
1.2 
(1.0–1.4)  
3.2 
(2.9–3.5) 
3.2 
(2.9–3.5)  
2.4 
(2.2–2.6) 
2.3 
(2.1–2.5) 
(a) Patient sex was not recorded for 252 respondents. 
(b) Estimation of BMI among the total adult general practice patient population (that is, patients aged 18 years and over who attended a GP at 
least once in 2009–10) (n = 14.3 million). 
Note: BMI – body mass index; CI – confidence interval. 
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Figure 14.1: Age–sex-specific rates of overweight/obesity in sampled adults 
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Figure 14.2: Age–sex-specific rates of underweight in sampled adults 
Body mass index of children 
BMI was calculated for 3,008 patients aged 2–17 years at encounters with 788 GPs. 
• Just over one-quarter of children (28.3%, 95% CI: 26.4–30.2) were classed as overweight 
or obese – 10.6% (95% CI: 9.3–12.0) obese and 17.7% (95% CI: 16.2–19.1) overweight 
(results not tabled). 
• There was no difference in the prevalence of overweight/obesity among male (28.6%,  
95% CI: 26.0–31.2) and female children (28.0%, 95% CI: 25.6–30.4) (results not tabled). 
Per cent 
Age group (years) 
Per cent 
Age group (years) 
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• The age-specific rates of obesity followed similar patterns for both sexes 
(figures 14.3 and 14.4). 
Readers interested in further detail and discussion of overweight and obesity in children 
attending general practice will find more information in Cretikos et al. (2008) General practice 
management of overweight and obesity in children and adolescents in Australia.80 
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Figure 14.3: Age-specific rates of obesity, overweight, normal weight and underweight in 
sampled male children 
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Figure 14.4: Age-specific rates of obesity, overweight, normal weight and underweight in 
sampled female children  
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14.2 Smoking (patients aged 18 years and over) 
Tobacco smoking is the leading cause of drug-related death and hospital separations in 
Australia.81 It has been identified as the risk factor associated with the greatest disease 
burden, accounting for 7.8% of the total burden of disease in Australia in 2003,72 a decrease 
from 9.7% of total burden in 1996.73 According to the 2007 National Drug Strategy 
Household Survey (NDSHS), 16.6% of Australians aged 14 years and over smoked daily: 
18.0% of males and 15.2% of females.82 
Method 
GPs were instructed to ask adult patients (18 years and over): 
• What best describes your smoking status?  Smoke daily 
 Smoke occasionally 
 Previous smoker 
 Never smoked 
Results 
The smoking status of 32,160 adult patients was established at encounters with 957 GPs. 
Table 14.2 shows that: 
• 14.8% of adult patients were daily smokers 
• significantly more male (17.8%) than female patients (12.9%) were daily smokers 
• only 2.7% of adult patients were occasional smokers 
• more than a quarter of adults (28.3%) were previous smokers. 
Table 14.2: Patient smoking status (aged 18 years and over) 
 Male(a)  Female(a)  Total respondents 
Smoking status 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,600) 
Per cent in 
patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 19,301) 
Per cent in 
patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 32,160) 
Per cent in 
patient 
population 
(95% CI)(b) 
Daily 17.8 
(16.9–18.7) 
21.6 
(20.6–22.7)  
12.9 
(12.2–13.6) 
14.5 
(13.7–15.3)  
14.8 
(14.2–15.5) 
17.8 
(17.0–18.6) 
Occasional 3.1 
(2.7–3.5) 
4.1 
(3.5–4.6)  
2.4 
(2.2–2.7) 
2.9 
(2.6–3.3)  
2.7 
(2.4–2.9) 
3.5 
(3.1–3.8) 
Previous 36.8 
(35.6–38.0) 
30.0 
(28.9–31.1)  
22.7 
(21.8–23.5) 
21.5 
(20.7–22.4)  
28.3 
(27.5–29.1) 
25.4 
(24.7–26.2) 
Never 42.3 
(41.1–43.5) 
44.3 
(43.0–45.7)  
62.1 
(61.0–63.1) 
61.0 
(60.0–62.1)  
54.2 
(53.3–55.2) 
53.3 
(52.3–54.4) 
(a) Patient sex was not recorded for 259 respondents. 
(b) Estimation of smoking status among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2009–10) (n = 14.3 million). 
Note: CI – confidence interval. 
Daily smoking was most prevalent among younger adult patients aged 18–24 years and  
25–44 years, with 19% and 21% respectively (results not tabled). Almost 60% of male and 
25% of female patients aged 75 years and over were previous smokers, but only 4.8% of 
males and 3.5% of females in this age group were daily smokers (figures 14.5 and 14.6). 
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Figure 14.5: Smoking status – male age-specific rates of sampled patients 
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Figure 14.6: Smoking status – female age-specific rates of sampled patients 
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Estimation of smoking in the adult general practice patient population 
The BEACH study reports data about patient smoking habits from a sample of patients 
attending general practice. As older people attend a GP more often than young adults, and 
females attend more often than males, they have a greater chance of being selected in the 
subsample. This leads to a greater proportion of older and female patients in the subsample 
than in the total population who attend a GP at least once in a year. We weighted the  
2010–11 BEACH smoking substudy to estimate smoking status of the GP–patient attending 
population (that is, the 14.3 million adult patients who attended a GP at least once in 2009–10 
[personal communication, Department of Health and Ageing (DoHA), June 2010]), using the 
method described by Knox et al. (2008).20  
The estimates for the GP–patient population (after adjusting for age–sex attendance patterns) 
suggest that 17.8% of the patient population were daily smokers, 3.5% were occasional 
smokers, 25.4% were previous smokers and 53.3% had never smoked. Male patients in the 
total general practice population were significantly more likely to be daily (21.6%), 
occasional (4.1%) and previous smokers (30.0%) than females patients (14.5%, 2.9% and 
21.5%, respectively) (Table 14.2).  
14.3 Alcohol consumption (patients aged 18 years 
and over) 
In people aged 65 years and over, low to moderate consumption of alcohol has been found to 
have a preventive effect against selected causes of morbidity81 (in particular ischaemic heart 
disease).83 In a review of the evidence, the National Health and Medical Research Council 
(NHMRC) concluded that in young women there was no evidence of any cardiovascular 
mortality benefit from alcohol consumption, and in young men any benefit was outweighed 
by other alcohol-related causes of death.83 In 2003, alcohol consumption accounted for 
3.3% of the total burden of disease in Australia; however, after taking into account the benefit 
derived from low to moderate alcohol consumption, this fell to 2.3%.72 
The 2007–08 NHS classified alcohol use of those aged 15 years or more based on the 
estimated average daily consumption of alcohol during the previous week. They found that 
12.6% drank at levels considered to be risky (14.4% of males and 10.8% of females).16 
The 2007 National Drug Strategy Household Survey (NDSHS) found that 10.3% of people 
aged 14 years and over (10.2% of males and 10.5% of females) drank at levels considered to 
be risky or high-risk for their health in the long term.82 The NDSHS also found that 20.4% of 
people aged 14 years and over (23.7% of males and 17.2% of females) drank alcohol during 
the preceding 12 months at levels that put their health at risk in the short term.82 These 
alcohol consumption risk levels were based on the NHMRC 2001 guidelines.84 
In February 2009 the NHMRC published a revised edition of its evidence-based alcohol 
guidelines, which were significantly different from the rescinded 2001 guidelines, and use 
the concept of progressively increasing risk of harm with the amount of alcohol consumed, 
rather than specifying ‘risky’ and ‘high-risk’ levels of drinking.85 For this reason the 
definitions earlier developed by WHO continue to be applied in this report (see ‘Method’ 
below).86 
 125 
Method 
To measure alcohol consumption, BEACH uses AUDIT-C87 which is the first three items 
from the WHO Alcohol Use Disorders Identification Test (AUDIT),86 with scoring for an 
Australian setting.88 The AUDIT-C has demonstrated validity and internal consistency and 
performs as well as the full AUDIT tool.89 The three AUDIT-C tool is practical and valid in a 
primary care setting to assess ‘at-risk’ alcohol consumption (heavy drinking and/or active 
alcohol dependence).87 The scores for each question range from zero to four. A total (sum of 
all three questions) score of five or more for males or four or more for females suggests that 
the person’s drinking level is placing him or her at risk.88 
GPs were instructed to ask adult patients (18 years and over): 
• How often do you have a drink containing alcohol? Never 
 Monthly or less 
 Once a week/fortnight 
 2–3 times a week 
 4 times a week or more 
• How many standard drinks do you have on a typical day when you are drinking?  
 _______________ 
• How often do you have six or more standard drinks on one occasion?  
 Never 
 Less than monthly 
 Monthly 
 Weekly 
 Daily or almost daily 
A standard drinks chart was provided to each GP to help the patient identify the number of 
standard drinks consumed. 
Results 
Patients’ self-reported alcohol consumption was recorded at 31,190 adult patient (18 years 
and over) encounters with 956 GPs. 
• About one-quarter of adults reported drinking alcohol at at-risk levels (24.8%) 
(Table 14.3). 
• At-risk drinking was more prevalent among male patients (30.0%) than female patients 
(21.4%) (Table 14.3). 
• At-risk drinking was most prevalent in those aged 18–24 years, particularly among men. 
In this age group almost half of the males and one in three of the females reported at-risk 
alcohol consumption (Figure 14.7). 
• The proportion of patients who were at-risk drinkers decreased with age for both males 
and females (Figure 14.7). 
These estimates are not comparable with the 2007–08 NHS16 or the 2007 NDSHS82 as they all 
use different concepts for defining alcohol consumption and risk, and different adult 
populations (patients aged 18 years or more for BEACH, persons aged 15 years or more for 
the NHS, and persons aged 14 years or more for the NDSHS).  
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Readers interested in the relationship between morbidity managed and alcohol consumption 
will find more information in Proude et al. (2006) The relationship between self-reported alcohol 
intake and the morbidities managed by GPs in Australia.90  
Table 14.3: Patient alcohol consumption (aged 18 years and over) 
 Male  Female  Total respondents 
Alcohol 
consumption 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,321) 
Per cent in 
patient 
population 
(95% CI)(a)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 18,869) 
Per cent in 
patient 
population 
(95% CI)(a)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 31,190) 
Per cent in 
patient 
population 
(95% CI)(a) 
At-risk drinker 30.0 
(28.8–31.2) 
34.5 
(33.1–35.9)  
21.4 
(20.5–22.3) 
23.1 
(22.1–24.1)  
24.8 
(23.9–25.7) 
28.3 
(27.3–29.3) 
Responsible drinker 47.7 
(46.5–48.9) 
44.7 
(43.4–45.9)  
41.5 
(40.4–42.6) 
42.4 
(41.2–43.5)  
44.0 
(43.0–44.9) 
43.4 
(42.4–44.4) 
Non-drinker 22.3 
(21.2–23.5) 
20.9 
(19.6–22.1)  
37.1 
(35.7–38.5) 
34.5 
(33.1–35.9)  
31.3 
(30.2–32.4) 
28.2 
(27.1–29.4) 
(a) Estimation of alcohol consumption among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2009–10) (n = 14.3 million). 
Note: CI – confidence interval. 
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Figure 14.7: Age–sex-specific rates of at-risk alcohol consumption in sampled patients 
Estimation of alcohol consumption in the adult general practice patient 
population 
The BEACH study reports data about patient alcohol consumption from a sample of the 
patients attending general practice. As older people attend a GP more often than young 
adults, and females attend more often than males, they have a greater chance of being 
selected in the subsample. This leads to a greater proportion of older and female patients in 
the sample than in the total population who attend a GP at least once in a year. We weighted 
the 2010–11 BEACH sample to estimate alcohol of the GP–patient attending population (that 
is, the 14.3 million adult patients who attended a GP at least once in 2009–10 [personal 
Per cent 
Age group (years) 
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communication, Department of Health and Ageing (DoHA), June 2010]), using the method 
described by Knox et al. (2008).20 
The estimates for the GP–patient population (after adjusting for age–sex attendance patterns) 
suggest that 28.3% of the patient population were at-risk drinkers, 43.4% were responsible 
drinkers and 28.2% were non-drinkers. Male patients in the total general practice population 
were significantly more likely to be at-risk drinkers (34.5%) than female patients (23.1%) 
(Table 14.3).  
14.4 Risk factor profile of adult patients 
All patient risk factor questions (BMI, smoking and alcohol consumption) were asked of the 
same subsample of patients. This allows us to build a risk profile of this sample of adult 
patients. For the purposes of this analysis, being overweight or obese, a daily smoker or an 
at-risk drinker were considered risk factors. A risk factor profile was prepared for the 
30,177 adult patients for whom data were available in all three elements, with 956 GPs. 
(Table 14.4). 
• About half (52.2%) the adult respondents had one risk factor. The most common was 
overweight (23.5% of adults) followed by obesity (18.4%). 
• One in five patients had two risk factors, the most common combinations being: 
– overweight and at-risk alcohol consumption – 6.7% of patients 
– obesity and at-risk alcohol consumption – 4.7% of patients 
– daily smoking and at-risk alcohol consumption – 2.9% of patients. 
• A small group of patients (3.7%) had all three risk factors. 
Table 14.5 shows the number of risk factors by patient sex. 
• Females were significantly more likely to have no risk factors (28.8%) or one risk factor 
(53.1%) than males (19.2% and 50.9% respectively). 
• Almost one-third of males (30.0%) had two or three risk factors compared with about 
one in five (18.1%) females. 
Estimation of the risk profile of the adult general practice patient population 
The 2010–11 BEACH sample was weighted to estimate the risk profile of the GP–patient 
attending population (that is, the 14.3 million adult patients who attended a GP at least once 
in 2009–10 (personal communication, Department of Health and Ageing (DoHA), June 2010), 
using the method described by Knox et al. (2008).20  
The estimates for the GP–patient population (after adjusting for age–sex attendance patterns) 
show that:  
• one-quarter of patients had no risk factors (24.0%) 
• half of the adult patients had one risk factor (50.0%), the most common being overweight 
(21.4% of adults) followed by obesity (16.9%) 
• one in five patients had two risk factors (21.4%), the most common combinations being 
overweight and at-risk alcohol consumption (7.2%), followed by obesity and at-risk 
alcohol consumption (4.9%) 
• 4.7% of patients who attend general practice had three risk factors (Table 14.4). 
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Table 14.4: Risk factor profile of patients (aged 18 years and over) 
Number of risk factors Number 
Per cent in 
BEACH sample  
(n = 30,177) 
95% 
LCL 
95% 
UCL 
 Per cent in 
patient 
population(a) 
95% 
LCL 
95% 
UCL 
No risk factors 7,545 25.0 24.3 25.7  24.0 23.2 24.8 
One risk factor 15,749 52.2 51.5 52.9  50.0 49.2 50.7 
 Overweight only 7,080 23.5 22.9 24.1  21.4 20.8 22.1 
 Obese only 5,549 18.4 17.8 19.0  16.9 16.3 17.5 
 At-risk alcohol level only 2,122 7.0 6.6 7.5  7.9 7.4 8.4 
 Current daily smoker only 998 3.3 3.1 3.5  3.7 3.4 4.0 
Two risk factors 5,774 19.1 18.5 19.8  21.4 20.6 22.1 
 Overweight and at-risk alcohol level 2,014 6.7 6.3 7.0  7.2 6.8 7.6 
 Obese and at-risk alcohol level 1,411 4.7 4.4 5.0  4.9 4.6 5.2 
 Daily smoker and at-risk alcohol level 868 2.9 2.6 3.1  3.7 3.4 4.0 
 Overweight and current daily smoker 804 2.7 2.5 2.9  3.0 2.8 3.3 
 Obese and current daily smoker 677 2.2 2.0 2.4  2.5 2.3 2.8 
Three risk factors 1,109 3.7 3.4 4.0  4.7 4.3 5.0 
 Overweight and current daily smoker 
and at-risk alcohol level 
669 2.2 2.0 2.4  2.9 2.6 3.1 
 Obese and current daily smoker and 
at-risk alcohol level 
440 1.5 1.3 1.6  1.8 1.6 2.0 
(a) Estimation of risk factor profile among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2009–10) (n = 14.3 million). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
Table 14.5: Number of risk factors, by patient sex 
 Male  Female 
Number of risk factors 
Per cent in BEACH 
sample (95% CI) 
(n = 11,955) 
Per cent in patient 
population 
(95% CI)(a)  
Per cent in BEACH 
sample (95% CI) 
(n = 18,222) 
Per cent in patient 
population 
(95% CI)(a) 
No risk factors 19.2 
(18.3–20.0) 
18.2 
(17.2–19.1)  
28.8 
(27.9–29.7) 
28.9 
(28.0–29.9) 
One risk factor 50.9 
(49.8–51.9) 
47.9 
(46.8–49.1)  
53.1 
(52.2–53.9) 
51.7 
(50.8–52.5) 
Two risk factors 24.7 
(23.7–25.6) 
27.3 
(26.2–28.4)  
15.5 
(14.8–16.2) 
16.3 
(15.6–17.1) 
Three risk factors 5.3 
(4.9–5.8) 
6.6 
(6.0–7.2)  
2.6 
(2.3–2.9) 
3.0 
(2.7–3.4) 
(a) Estimation of risk factor profile among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2009–10) (n = 14.3 million). 
Note: CI – confidence interval. 
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14.5 Changes in patient risk factors over the 
decade 2001–02 to 2010–11 
To investigate changes over time in these patient risk factors, results are reported from the 
BEACH sample data for each year from 2001–02 to 2010–11 in the companion report A decade 
of Australian general practice activity 2001–02 to 2010–11.1 
The major changes between 2001–02 and 2010–11 are summarised below. 
• The prevalence of obesity in adults attending general practice increased significantly, 
from 21.5% in 2001–02 to 26.7% in 2010–11, an increase apparent in both male and female 
patients. The prevalence of overweight in adults attending general practice also 
increased significantly, from 33.5% in 2001–02 to 35.1% in 2010–11, but the increase was 
only apparent in female patients. 
• The prevalence of overweight and obesity in children aged 2–17 years remained fairly 
static from 2001–02 to 2010–11, with about 10–11% of children being obese and about 
18% overweight. 
• Prevalence of daily and occasional smoking decreased significantly in adults aged  
18 years and over, from 18.4% and 4.1%, respectively, in 2001–02 to 14.8% and 2.7% in 
2010–11. 
• The prevalence of at-risk alcohol consumption among adults aged 18 years and over 
remained fairly static at about 25–26% between 2001–02 and 2010–11.  
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15 SAND abstracts and research tools 
Since BEACH began in April 1998, a section on the bottom of each encounter form has been 
used to investigate aspects of patient health or health care delivery not covered by general 
practice consultation-based information. These additional substudies are referred to as 
SAND (Supplementary Analysis of Nominated Data). The SAND methods are described in 
Section 2.6. All substudies were approved by the AIHW Ethics Committee (on behalf of the 
AIHW and the University of Sydney). 
The Family Medicine Research Centre (FMRC) and participating stakeholders of the BEACH 
program select topics for investigation in each of the SAND studies. In each BEACH year, up 
to 20 substudies can be conducted in addition to the study of patient risk behaviours (see 
Chapter 14). Topics are often repeated to increase the size of the sample and its statistical 
power. 
This chapter includes the abstracts and research tools for SAND substudies conducted from 
April 2010 to March 2011. The subjects covered in the abstracts in this chapter are listed in 
Table 15.1, with the sample size for each topic. 
Table 15.1: SAND abstracts for 2010–11 and sample size for each  
Abstract 
number Subject 
Number of 
respondents  
Number  
of GPs 
162 Pneumococcal vaccination and middle ear infections 2,920 98 
163 Chronic kidney disease in general practice patients 2,734 91 
164 Type 2 diabetes, weight gain and blood glucose management 2,579 90 
165 Migraine and acute/rescue medication use in general practice patients – 2010 2,856 98 
166 Hypertension, hypercholesterolaemia and diabetes 2,789 95 
167 Management of gout in general practice patients 2,800 95 
168 Management of major depression 2,272 77 
169 Hypertension, comorbidity and blood pressure control 2,350 79 
170 Use of SSRIs and/or SNRIs in general practice patients 2,847 100 
171 Influenza and pneumococcal vaccination among general practice patients 2,946 100 
172 Diabetes management in general practice patients 2,839 72 
173 Type 2 diabetes resource use  4,626 182 
174 Atrial fibrillation/flutter in general practice patients 2,402 83 
175 Pertussis and persistent cough among general practice patients 2,422 82 
176 Comorbidity and management of gout in GP patients 3,094 105 
177 Multiple morbidity and chronic heart failure 2,952 104 
178 Warfarin use in general practice patients 3,075 106 
179 Pneumococcal vaccination and pneumonia in older Australian general practice 
patients(a) 
1,618 102 
(a) Substudy limited to patients aged 50 years and over. 
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SAND abstract number 162: Pneumococcal vaccination and middle 
ear infections  
Organisation supporting this study: GlaxoSmithKline Australia Pty Ltd  
Issues: Pneumococcal vaccination coverage in past five years in patients attending general 
practice; twelve month incidence of middle ear infection; incidence among those vaccinated 
for pneumococcus; incidence in those vaccinated with Pneumovax 23 versus Prevenar; 
treatments and referral rates for middle ear infection. 
Sample: 2,920 patients from 98 GPs; data collection period: 04/05/2010 – 07/06/2010 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>.  
Summary of results  
Sample size and patient demographics: The age and sex distribution of the 2,920 patients 
did not differ from that of patients at all 2009–10 BEACH encounters.  
Pneumoccocal vaccination status was given for 2,918 patients, of whom 918 (31.5%, 95% CI: 
28.0–34.9) had been vaccinated in the past five years (‘vaccinated patients’), 71.4% with 
Pneumovax 23, 24.5% with Prevenar, and for 4.1% the type not known. Vaccination coverage 
was 57.1% among those aged < 15 years and 70.2% among those aged 65+ years. Highest 
vaccination levels among young patients were in 1–4 year olds (83.3%), and < 1 year (61.8%). 
Among older patients, coverage was 74.6% of 75+ year olds and 65.3% of 65–74 year olds. 
Presence/absence of middle ear infection in the previous 12 months (‘period incidence’) was 
recorded for 2,901 patients, 147 (5.1%, 95% CI: 3.8–6.4) of whom had had an infection. 
Incidence was highest among 1–4 (32.9%), < 1 (10.5%) and 5–14 (21.3%), year olds – being  
23.9 for all children aged < 15 years. Incidence was negligible (0.5 %) among patients aged  
65 years and over. Of 137 respondents with a middle ear infection, 58 (42.3%) had been 
vaccinated for pneumococcus prior to the most recent middle ear infection. 
Incidence of middle ear infection among 913 vaccinated respondents was 7.9%  
(95% CI: 5.6–10.1) and did not significantly differ from the overall incidence.  
The vast majority (86.3%) of patients given Pneumovax 23 were aged 65 years or more, in 
line with guidelines for its administration. The period incidence of middle ear infection 
(0.6%) aligned with that found for the total sample of older people.  
The majority (80.3%) of 223 responding patients given Prevenar were aged < 5 years, in line 
with guidelines for its administration. Period incidence of middle ear infection was 28.6% 
compared with the overall incidence in this age group of 25.7%.  
Of 136 respondents who had had middle ear infection, 25 (18.4%) had been referred: mostly 
to ENT specialists (n = 20, 14.7%) and/or audiologists (n = 7, 5.2%). 
Treatments were described for 135 respondents who had had middle ear infection. The 
majority (92.6%) were treated with medication (+/- other treatments). Of 177 medications 
given, 59.3% were antibacterials for systemic use (mostly amoxicillin, 36.7%), followed by 
analgesics (14.1%) (mainly paracetamol 11.9%). Grommets had been inserted for 4 patients.  
The following pages contain the recording form and instructions with which the data in this abstract were collected. 
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SAND abstract number 163: Chronic kidney disease in general 
practice patients 
Organisation supporting this study: FMRC in collaboration with Kidney Health Australia 
Issues: For patients aged 24+ years – the proportion: who had undergone kidney function 
tests in the previous 12 months; with conditions associated with chronic kidney disease 
(CKD); with risk factors for CKD; with drug dosage adjustments due to kidney function (and 
test used); prevalence of CKD; stages of CKD; and underlying causes of CKD. 
Sample: 2,734 patients from 91 GPs; data collection period: 30/03/2010 – 03/05/2010 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>. ‘Heart disease or failure’ was 
defined as: clinical or investigative signs of typical angina; past myocardial infarct; unstable 
angina; past coronary artery bypass graft; past percutaneous coronary intervention; coronary 
artery disease, or congestive cardiac failure. Stages of disease were defined according to 
National Kidney Foundation Guidelines. 
Summary of results  
In the sample, 2,256 patients were 24 years or older, and 2,199 (97.5%) of these responded to 
kidney test questions. Complete kidney function check (both serum creatinine and 
proteinuria/microalbuminuria) was performed for 13.3% (95% CI: 9.3–17.3); 50.2% had a 
serum creatinine test only; 1.2% had a urine test only, and 28.0% had neither test in the 
previous 12 months. Status was not known for 7.4%. At least one test had been performed in 
the previous 12 months for 64.7%.  
Of 2,256 patients, responses to CKD-associated conditions were reported for 2,104 (93.3%). 
Of these, 918 patients (43.6%) had at least one: 33.1% had hypertension; 13.6% had heart 
disease or failure; 13.4% had diabetes; and 3.5% had previous cerebrovascular attack or 
transient ischaemic attack (multiple responses allowed). More than half (56.4%) had none of 
the listed conditions. 
Of the above 918 patients, current risk status was reported for 896 (97.6%), of whom 70.9% 
were taking an ACE Inhibitor or angiotensin II receptor blocker (ARB); 61.5% had total 
cholesterol level of ≥ 4 mmol/L; 53.3% had diabetes and HbA1c ≥ 7%; 49.4% had  
BP ≥ 130/80 mmHg; 21.0% had HbA1c ≥ 7%; and 13.2% had Hb < 120g/L.  
Of the 2,256 patients sampled, responses to medication dose adjustment were reported for 
1,746 (77.4%). For 88 of these (5.0%), medication dosage had been altered because of kidney 
function. Of these, the type of glomerular filtration rate (GFR) used was reported for 68 
patients (77.3%), and the majority (61 patients, 89.7%) reported eGFR automatically 
generated by pathology results. The Cockcroft Gault formula was used for 4 patients (5.9%). 
Of the 2,256 patients originally sampled, responses to diagnosis of CKD were reported for 
1,920 (85.1%). Of these, 207 (10.8%) had diagnosed CKD, and 203 reported the Stage of 
disease. The majority were at Stage 3 (53.2%); 27.1% were at Stage 2; 10.8% were at Stage 4. 
The smallest proportions were at Stage 1 (4.9%) and Stage 5 (3.9%). 
Of the 207 patients with diagnosed CKD, the underlying cause was reported for 200 (96.6%). 
The most common cause was vascular disease (56.5%), 31.5% reported diabetes, 2.5%  
(5 patients) had glomerulonephritis, and for one patient polycystic kidney disease was the 
underlying cause of their CKD. For 28 patients (14.0%) the underlying cause was not known. 
The following pages contain the recording form and instructions with which the data in this abstract were collected.  
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SAND abstract number 164: Type 2 diabetes, weight gain and blood 
glucose management 
Organisation supporting this study: AstraZeneca Pty Ltd (Australia) 
Issues: Prevalence of diagnosed Type 2 diabetes in patients attending general practice. For 
patients with Type 2 diabetes: number of visits to a GP in previous year and number of these 
where diabetes managed; number who have gained weight in previous 12 months; factors 
contributing to weight gain, if medication a factor which medications patients taking; types 
of medication used for management of blood glucose; proportion taking mono, dual, triple 
or quadruple medication therapy for blood glucose; reasons for use of fixed dose 
combination products; reasons for not using these. 
Sample: 2,579 patients from 90 GPs; data collection period: 30/03/2010 – 03/05/2010 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>.  
Summary of results  
The age and sex distribution of the 2,579 respondents did not significantly differ from that of 
patients at all BEACH encounters in 2009–10, 43.9% being male and 35.9% 65 years or more. 
The prevalence of Type 2 diabetes (T2DM) in this sample was estimated as 11.3% (95% CI: 
9.6–13.1) (n = 292). There was no significant difference in prevalence among males and 
females. Prevalence was highest among 65–74 year olds at 21.7%. After adjustment for 
attendance rates by age-sex of patient, we estimated prevalence among the general practice 
attending population as 7.2% (95% CI: 5.8–8.6). 
Data were available on GP visits in the previous 12 months for 278 of the 292 patients with 
T2DM: 17% had visited less than five times, 21% 5–7 times, 21% 8–10 times, 20% 11–15 times 
and 22% more than 15 times. Number of visits in the previous 12 months at which diabetes 
was managed was available for 273 respondents: 8% had 0–1 visits, 52% 2–4, 22% 5–7 and 
18% had 8 or more visits. 
Of 273 respondents to the weight gain question, 79 (28.9%) had gained weight in the 
previous 12 months, lifestyle contributing to 68 (86.8%), medications to 17 (21.5%), and other 
factors contributing to 10 (12.7%) (multiple response allowed). Medication details were given 
for 16 of the 17 patients for whom medications contributed: 9 were on insulin, 4 were on 
metformin, and 2 were on a gliclazide. Three other drugs were listed for 3 individuals.  
Data were available on pharmacological blood glucose management for 276 of the 292 
patients with T2DM: 233 (84.4%) were taking medication for blood glucose management. 
Therapy could be mono, dual or triple, half (51.9%) were on mono-therapy, 36.1% were on 
dual and 12.0% were on triple therapy. Six patients were taking a fixed dose combination. 
Reasons given (multiple response allowed) for the choice of fixed dose combinations centred 
on convenience (n = 5), cost (n = 3) and compliance (n = 2). 
Reasons for not choosing a fixed dose combination were given for 150 of the 227 patients not 
taking a fixed dose combination product. The GP chose: ‘patient has good control’ for 95 
(63.3%); ‘an appropriate drug combination does not exist’ for 28 (18.7%); ‘an appropriate 
dose combination does not exist’ for 10 (6.7%); and ‘other’ for 23 (15.3%) patients. 
The following pages contain the recording form and instructions with which the data in this abstract were collected. 
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SAND abstract number 165: Migraine and acute/rescue medication 
use in general practice patients – 2010 
Organisation supporting this study: Merck Sharp & Dohme (Australia) Pty Ltd 
Issues: The proportion of general practice patients who suffer from migraine attacks. For 
patients who suffer migraine: frequency per month; type and detail of acute/rescue 
medication used at time of attack; current and previous use of triptan medication; 
cardiovascular safety concerns. 
Sample: 2,856 patients from 98 GPs; data collection period: 04/05/2010 – 07/06/2010 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>.  
Summary of results  
The age and sex distribution of the 2,856 respondents did not differ from the distribution for 
all 2009–10 BEACH encounters, with the majority (59.8%) being female. Patients aged less 
than 25 years, 25–44 and 45–64 years accounted for 20.8%, 24.2% and 28.0% of the sample 
respectively.  
Of the 2,856 surveyed patients, 324 (11.3%, 95% CI: 9.5–13.2) suffered from migraine. 
Prevalence of migraine was significantly higher among females (15.5%, 95% CI: 13.0–18.0) 
than males (5.4%, 95% CI: 3.8–6.9), and was highest among patients aged 15–24 years,  
25–44 years and 45–64 years (12.0%, 18.4% and 15.4% respectively). Of 314 patients with 
migraine who reported attack frequency, 55.7% had less than one migraine per month, 
18.5% had one per month, and 25.8% had two or more per month. Reported migraine 
frequency per month did not differ between males and females. 
Of 316 respondents with migraine, 43 (13.6%) currently used no acute/rescue medication at 
the time of an attack, and 273 (86.4%) used prescribed and/or advised over-the-counter 
(OTC) acute/rescue medication. About two-thirds (69.9%) used acute OTC medications, and 
one in four (25.6%) used prescribed medication. For both OTC and prescribed acute 
medication the proportion using medication did not differ by migraine frequency.  
Of the 81 migraine patients currently taking prescribed acute/rescue medication, 80 gave 
details of these medications. About half (52.5%, n = 42) were currently using a triptan, most 
commonly sumatriptan (42.5%, n = 34), followed by zolmitriptan (7.5%, n = 6). Almost half 
(53.8%, n = 43) were currently using other acute/rescue prescribed medications, paracetamol 
combinations being the most commonly listed (n = 25), followed by metoclopramide (n = 11). 
Of the 273 migraine patients currently on acute/rescue medication/s (OTC or prescribed), 
227 gave information about whether they had ever tried a triptan. One-third (31.7%, n = 72) 
had tried a triptan, 146 (64.3%) had never tried a triptan, and the GP indicated ‘Don’t know ’ 
for 9 (4.0%). Of the 72 patients who had tried a triptan, 42 (58.3%) were currently taking a 
triptan. 
Of the 146 migraine patients on current acute/rescue medication who had never tried a 
triptan, 129 gave information on cardiovascular risk concerns related to triptan use. Of the 
129 respondents, only 3 (2.3%) had not tried a triptan due to concerns about cardiovascular 
safety.  
The following pages contain the recording form and instructions with which the data in this abstract were collected. 
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SAND abstract number 166: Hypertension, hypercholesterolaemia 
and diabetes  
Organisation supporting this study: Sanofi-Aventis Australia Pty Ltd  
Issues: The prevalence of hypertension, hypercholesterolaemia, diabetes and high 
cardiovascular risk among patients attending general practice; the prevalence of 
combinations of the morbidities; the types of medications being prescribed for these 
conditions; adjustment of glucose-lowering medication regimen at current encounter. 
Sample: 2,789 respondents from 95 GPs; data collection period: 8/06/2010 – 12/07/2010.  
M ethod: Detailed in the paper entitled SAND Method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>. High cardiovascular risk was 
defined according the PBS, and a card with details of criteria was provided (see below). 
Summary of results  
The age–sex distribution of the respondents did not differ from the distribution at all 
BEACH encounters, with the majority of patients (58.0%) being female and patients aged  
65 years and over accounting for 29.9% of the sample. 
Among the 2,789 patients, prevalence of diagnosed: hypertension was 28.0% (95% CI:  
24.6–31.3); hypercholesterolaemia was 20.0% (95% CI: 17.4–22.6); type 1 diabetes was 0.8%; 
type 2 diabetes was 8.0% (95% CI: 6.5–9.4). The proportion of patients with any of the 
conditions (except Type 1 diabetes) rose significantly through the age groups, with the 
highest rates among patients aged 65 years and over. More than one-third of patients (37.4%, 
95% CI: 33.5–41.3) had at least one of the conditions, and 4.4% of patients (95% CI: 3.3–5.6) 
had hypertension, hypercholesterolaemia and diabetes, including 11.5% of those aged 65–74 
years and 9.6% of those aged 75 or more. There were 12.2% of patients (95% CI: 9.4–15.0) 
who met the PBS criteria for high cardiovascular risk. 
After adjustment for annual attendance patterns by age and sex of patients, prevalence was 
estimated among those who attended at least once in the year as: hypertension – 18.8% (95% 
CI: 16.3–21.4); hypercholesterolaemia – 14.1% (95% CI: 11.9–16.2); type 1 diabetes – 0.8% 
(95% CI: 0.4–1.1); type 2 diabetes – 5.5% (95% CI: 4.3–6.7); and high cardiovascular risk was 
present in 8.1% (95% CI: 6.2–9.9) of the attending population. 
There were 2,730 respondents to the question about BP-lowering and lipid-lowering 
medications, and 869 of them (31.8%) were taking at least one of these medications. Of the 
869 patients taking medication, 39.7% were taking lipid and BP-lowering medications, 16.2% 
were taking lipid medications only, and 44.1% were taking BP-lowering medications only. 
There were 1,599 medications recorded of which lipid-modifying agents accounted for 
31.5%. Of the 1,599 medications, atorvastatin was the most common currently taken, 
accounting for 13.4%, followed by perindopril (8.0%). 
Of the 243 patients with diabetes, 234 gave details about current medication, and 194 (82.9%) 
of these patients were taking a total of 316 glucose-lowering medications. Metformin was the 
most common of these (38.6%), followed by gliclazide (21.8%). There were 172 patients 
taking glucose-lowering medications for whom information was given on adjustment of 
regimen at the current encounter. Of these, 11.0% had medication added, changed or ceased 
at that encounter. 
The following pages contain the recording form and instructions with which the data in this abstract were collected.  
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SAND abstract number 167: Management of gout in general 
practice patients 
Organisation supporting this study: Novartis Pharmaceuticals Australia Pty Ltd 
Issues: The proportion of general practice patients treated for gout; number of gout episodes 
experienced in the previous 12 months; care sought by patients for gout; managements used 
for gout; contraindications in gout management. 
Sample: 2,800 patients from 95 GPs; data collection period: 08/06/2010 – 12/07/2010 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>. 
Summary of results  
The age and sex distribution of the 2,800 respondents did not differ from that of patients at 
all 2009–10 BEACH encounters, with the majority (57.8%) being female. 
Of the 2,800 respondents, 145 (5.2%, 95% CI: 4.0–6.4) had at some time been treated for gout. 
After adjustment for attendance rates by age and sex of patient, we estimated that 3.5%  
(95% CI: 2.5–4.4) of patients who attended the GP once that year had at some time been 
treated for gout. Treatment had most commonly occurred for older patients, with one in ten 
patients in the 65–74 years and 75+ age groups (10.9% and 11.4% respectively) having been 
treated for gout at some time. The sex-specific rate of gout treatment among male patients 
(9.0%, 95% CI: 6.8–11.3) was significantly higher than among females (2.4%, 95% CI: 1.4–3.3). 
Of 136 respondents (of the 145 who had at some time been treated for gout), 39 (28.7%,  
95% CI: 19.5–37.8) had had an episode of gout in the previous 12 months: 19 patients had had 
one episode and 12 had had two episodes. Of 131 respondents (multiple responses allowed), 
34 (26.0%) had used a health service in the previous 12 months for gout management: 33 
(25.2%) had visited a GP, one patient (0.8%) had visited a specialist, two patients (1.5%) had 
required a hospital visit and two visited an emergency department. There were 97 patients 
(74.1%) who had not used a health service for gout management in the previous 12 months. 
Of the 39 patients who had had at least one episode of gout in the previous 12 months, 27 
(69.2%) had used a health service: 26 (66.7%) had visited a GP to have their gout managed, 
one patient (2.6%) had visited a specialist, two patients (5.1%) had required a hospital visit 
and two patients visited an emergency department for their gout. There were 12 patients 
(30.8%) who had an episode of gout in the previous 12 months but not used a health service. 
Of the 145 patients at some time treated for gout, management information was available for 
128. Of these, 104 (81.3%) had received treatment for their most recent episode, and 24 
patients (18.8%) had sought no treatment. Ninety-three patients (72.7%) had used medication 
to treat their most recent episode of gout, and 113 medications were recorded for these 
patients. Colchicine accounted for 32.7% and allopurinol for 28.3% of medications. The most 
common other treatment used for the episode of gout was lifestyle modification (39.1%). 
GPs were asked to record whether the patient was unable to take specified medications for 
gout. Suitability of specified medications for gout was recorded for 159 patients, but the 
response rate varied for each medication. Contraindication or intolerance was indicated for: 
allopurinol for 9.4%; colchicine 10.1%; oral or systemic corticosteroids for 11.5%; and 
NSAIDS for 55.7% of cases. 
The following pages contain the recording form and instructions with which the data in this abstract were collected. 
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SAND abstract number 168: Management of major depression 
Organisation supporting this study: AstraZeneca Pty Ltd (Australia) 
Issues: Prevalence of major depression being managed in general practice patients and first, 
second and third lines of treatment for major depression, duration of and satisfaction with 
each line of treatment; and whether any changes occurred after third line of treatment. 
Sample: 2,272 patients from 77 GPs; data collection period: 13/07/2010 – 16/08/2010 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>.  
Summary of results  
Age and sex were known for 2,255 patients and the age and sex distributions were not 
significantly different from those of patients at all 2009–10 BEACH encounters. 
Of the 2,272 respondents in this sample, 330 patients (14.5%, 95% CI: 12.3–16.7) were 
currently being managed for major depression. Age was known for 327 of these patients. 
Patients aged < 15 years had the lowest prevalence with 0.6% and patients aged 45–64 had 
the highest prevalence with 19.7% (95% CI: 16.2–23.1) currently being managed for major 
depression. Sex was known for 328 patients with major depression. Females accounted for 
71.3% of these patients and major depression was more prevalent among female patients 
(17.1%, 95% CI: 14.5–19.7) than for male patients (10.6%, 95% CI: 7.6–13.6). 
First line treatment was reported for 328 patients: four patients (1.2%) reported the first line 
treatment as ‘None’; 191 patients (58.2%) were managed with counselling by the GP; 256 
(78.1%) were managed with medication (selective serotonin reuptake inhibitors, SSRIs, made 
up 60.4% of these); 77 (23.5%) were managed with a referral (62.8% of which were to a 
psychologist). Duration of first line treatment was given for 208 patients – average duration 
was almost 22 months. Of 291 patients for whom satisfaction with first line treatment was 
recorded, it was satisfactory for 196 (67.4%) and not satisfactory for 95 patients (32.7%). 
Of these 95 patients, 88 responded to the question on second line treatment, of which: 14 
patients (15.9%) were managed with counselling by the GP; 73 (83.0%) were managed with 
medication (SSRIs made up 49.3% of these medications); 35 (39.8%) were managed with a 
referral (71.4% of which were to a psychologist). Duration of second line treatment was given 
for 65 patients – with an average duration of 10 months. Of 72 patients for whom satisfaction 
with second line treatment was recorded, it was satisfactory for 45 (62.5%) and not 
satisfactory for 27 (37.5%). 
Of these 27 patients, 26 responded to the question on third line treatment with: eight patients 
(30.8%) managed with counselling by the GP; 20 (76.9%) managed with medication (‘Other 
antidepressants’ ATC code N06AX, accounted for 48.0% of these medications); 15 (57.7%) 
managed with a referral (68.8% of which were to a psychologist). Duration of third line 
treatment was indicated for 26 patients – with an average duration of 15 months. 
Of the 26 patients on third line treatment, 24 responded to the further change since third line 
treatment question. A further change since the third line of treatment was reported for only 3 
(12.5%) of these patients. 
The following pages contain the recording form and instructions with which the data in this abstract were collected. 
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SAND abstract number 169: Hypertension, comorbidity and blood 
pressure control 
Organisation supporting this study: Merck Sharp & Dohme (Australia) Pty Ltd 
Issues: Prevalence of diagnosed hypertension among patients attending general practice; 
medications taken for hypertension; comorbidities in patients with hypertension; current 
blood pressure (BP) and level of control; management steps if BP was not well-controlled. 
Sample: 2,350 patients from 79 GPs; data collection period: 13/07/2010 – 16/08/2010 
M ethod: Detailed in the paper entitled SAND Method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>. BP levels were defined using the 
National Heart Foundation guidelines available from <www.heartfoundation.org.au/ 
SiteCollectionDocuments/HypertensionGuidelines2008to2010Update.pdf> 
Summary of results  
Sex distribution of patients was no different from the total BEACH sample in 2009–10. 
However, there was a significantly smaller proportion of patients aged 45–64 years (24.5%, 
95% CI: 22.7–26.3) compared with the total sample (28.2%, 95% CI: 27.7–28.8).  
Among the 2,350 respondents, the prevalence of diagnosed hypertension was 28.3% (95% CI: 
24.5–32.0). After adjustment for annual attendance patterns by age-sex of patient, prevalence 
of hypertension among those attending general practice at least once was 18.9% (95% CI: 
16.0–21.8). Among adults in the sample, prevalence rose significantly through the middle age 
groups, and was highest among patients aged 75 years and over (71.1%). More than 70% of 
patients with hypertension were aged 65 years or older. 
Among 655 respondents with hypertension, 93.7% were on at least one medication. A total of 
1,013 medications were listed: ACE inhibitors accounted for 20.4%, and angiotensin II 
antagonists accounted for 17.5% of these medications. At the generic level, perindopril and 
irbesartan were the most commonly recorded.  
Comorbidity was recorded for 610 respondents with hypertension, 500 (82.0%) of whom had 
at least one comorbidity: 26.9% had diabetes; 26.7% had coronary heart disease; 11.5% had 
cerebral vascular disease; 7.4% had peripheral vascular disease; 15.1% had family history of 
coronary artery disease; 48.5% had dyslipidaemia; 1.8% had proteinuria; 9.2% had chronic 
kidney disease. There were 21.8% of patients with an other chronic disease (+/- one or more 
of the above), atrial fibrillation being the most common of these.  
Of 638 patients with hypertension whose BP was recorded on the day of the encounter, 
47.7% had BP levels in the high-normal category, 44.7% had levels that were higher than 
high-normal, and 7.7% had normal BP. 
Level of BP control was given for 625 patients with hypertension. GPs considered 75.5% of 
these patients to have well-controlled BP and 24.5% to have not well-controlled BP. For 
33.1% of 148 respondents, the main reason BP was not well-controlled, was current 
medication not efficacious, followed by patient non-compliance (14.2%). 
Of 153 patients with BP not well-controlled, the next management step was recorded for 144. 
For 25.0% of these patients, no change was planned; for 5.6% the next step was to add a 
diuretic; for 6.9% to add a calcium channel blocker; for 1.4% to add a beta blocker; for 15.3% 
it was dose titration. Other management steps recorded were prompt review of BP, 24 hr BP 
monitor and compliance counselling.  
The following pages contain the recording form and instructions with which the data in this abstract were collected. 
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SAND abstract number 170: Use of SSRIs and/or SNRIs in general 
practice patients 
Organisation supporting this study: Pfizer Australia Pty Ltd 
Issues: Proportion of general practice patients taking selective serotonin reuptake inhibitors 
(SSRIs) and/or selective noradrenaline reuptake inhibitors (SNRIs); current prescribed 
regimens of these medications; conditions being managed with SSRIs/SNRIs; factors 
contributing to initiation of SSRIs/SNRIs; severity of depression and prevalence of recurrent 
depression in patients taking SSRIs/SNRIs. 
Sample: 2,847 patients from 100 GPs; data collection period: 17/08/2010 – 20/09/2010 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>. Severity of depression scale was 
that used by Ellis & Smith (2002). Treating depression: the beyondblue guidelines for treating 
depression in primary care. MJA 176(10 Suppl):S77–S83. Levels defined as: Mild = mild 
depression without complications; Moderate I = moderate depression (including with co-
morbid anxiety) and dysthymia; Moderate II = moderate depression with comorbid 
substance misuse; Severe I = severe depression with melancholia; Severe II = psychotic 
depression, severe depression with risk of suicide, and atypical depression. 
Summary of results  
The age and sex distribution of patients was not significantly different from that of patients 
at all BEACH encounters in 2009–10.  
Of the 2,847 respondents, 227 patients (8.0%) were currently taking an SSRI, 93 (3.3%) were 
currently taking a SNRI and one patient was taking both. In total, 11.3% were taking at least 
one of these medications. Sex specific rates showed a significantly higher proportion of 
females (13.0%, 95% CI: 11.1–14.8) taking SSRIs/SNRIs than males (8.9%, 95% CI: 7.0–11.0). 
There were only 2 patients aged < 15 years taking these medications but there were no 
significant differences in other patient age groups.  
Of 328 medications recorded for 320 respondents, the most commonly recorded was 
sertraline (22.6%), followed by venlafaxine (17.4%). Of 319 respondents, 273 (85.6%) had been 
prescribed the SSRI/SNRI for depression; 82 (25.7%) were prescribed the SSRI/SNRI for 
anxiety, and 11 patients (3.5%) for bipolar disorder. For 18 patients, other conditions were 
listed as the reason for the prescription, most commonly obsessive-compulsive disorder. 
There were 310 respondents who described factors contributing to initiation of SSRI /SNRI: 
GP preference was reported for 47.7%; guideline recommendation for 20.3%; non-response to 
previous medication was reported for 14.2%; patient preference for 7.4%; side-effects of 
previous medication for 7.4%; to avoid potential side-effects for 6.5%; and interaction with 
previous medication had been the reason for initiation for 4 patients (1.3%).  
Of the 273 patients who reported having the SSRI/SNRI prescribed for depression, 263 
responded to the question on severity of depression. The majority (44.1%) had Moderate I 
level; 25.1% had Moderate II level; 13.3% had Mild depression; 12.6% had Severe I level; and 
4.9% had Severe II level depression. 
Of the 273 patients who reported having the SSRI/SNRI prescribed for depression, 225 
responded to the question on recurrent depression. Of these, 69.8% had recurrent 
depression, 20.4% did not have recurrent depression, and 9.8% did not know. 
The following pages contain the recording form and instructions with which the data in this abstract were collected.  
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SAND abstract number 171: Influenza and pneumococcal 
vaccination among general practice patients 
Organisation supporting this study: CSL Ltd 
Issues: The proportion of general practice patients who had discussed influenza vaccination 
with their GP in the past 12 months or pneumococcal vaccination in the past 5 years; who 
initiated the discussion(s); presence of influenza or pneumococcal infection risk factors; 
vaccination status; source of vaccine supply; reason(s) that influenza or pneumococcal 
vaccine was not given in unvaccinated patients.  
Sample: 100 GPs recorded influenza data for 2,946 patients and pneumococcal data for 2,873 
patients; data collection period: 17/08/2010 – 25/10/2010. 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>. M ethod for this study: Risk 
factors for influenza and pneumococcal infection‡ were supplied on a card. 
Summary of results  
The age and sex distributions of the 2,946 patients who responded to the question about 
discussion of influenza vaccination and the 2,873 patients who responded about 
pneumococcal vaccination did not differ from all patients at 2009–10 BEACH encounters. 
Influenza vaccination: GPs discussed influenza vaccination with 1,268 patients (43.0%, 95% 
CI: 38.5–47.6) in the previous 12 months. GPs initiated the discussion in most cases (83.6% of 
1,236 respondents). Influenza infection risk factors were given for 1,203 patients, and at least 
one risk factor was present for 87.2%. Multiple responses were allowed. The most common 
risk factor was being aged 65 years and over (66.3%), followed by chronic heart disease 
(18.5%), diabetes (13.4%), chronic lung disease (11.6%) and other chronic diseases (11.9%).  
Of 1,222 patients who provided vaccination status, 1,116 were vaccinated (91.3%), 105 were 
not (8.6%), and status was not known for 1 patient. Of 1,080 vaccinated respondents, 81.4% 
were supplied the vaccine free of charge (i.e. government supplied), for 5.7% the vaccine was 
PBS subsidised, and for 12.9% it was fully privately funded. Of 100 unvaccinated 
respondents, 54 gave ‘patient objection’ as the reason for not being vaccinated, and 20 
patients were considered ‘not at risk’. 
Pneumococcal vaccination: GPs discussed pneumococcal vaccination with 823 patients 
(28.7%, 95% CI: 24.6–32.7) in the previous 5 years. GPs initiated the discussion in most cases 
(92.5% of 759 respondents). Pneumococcal infection risk factors were given by 802 patients, 
and at least one risk factor was present for 96.0%. Multiple responses were allowed. The 
most common risk factor was being aged 65 years and over (81.9%), followed by chronic 
heart disease (22.1%), diabetes (15.2%), chronic lung disease (12.6%) and other chronic 
diseases (10.1%).  
Of 782 patients who provided vaccination status, 661 were vaccinated (84.5%), 118 were not 
(15.1%), and status was not known for 3. Of 638 vaccinated respondents, 93.0% were 
supplied the vaccine free of charge, for 4.6% the vaccine was PBS subsidised, and for 2.5% it 
was fully privately funded. Of 105 unvaccinated respondents, 59 (56.2%) gave ‘patient 
objection’ as the reason for not being vaccinated, and 16 (15.2%) were considered ‘not at risk’. 
‡ Adapted from National Health and Medical Research Council. Australian Immunisation Handbook 9th Edition 2008. 
The following pages contain the recording form and instructions with which the data in this abstract were collected.  
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SAND abstract number 172: Diabetes management in general 
practice patients  
Organisation supporting this study: Sanofi-Aventis Australia Pty Ltd 
Issues: Prevalence of Type 1 (T1D) and Type 2 diabetes (T2D) among general practice 
patients. For patients with diabetes: the most recent HbA1c and when measured; proportion 
with a self blood glucose monitoring (SBGM) machine; type of machine used; which health 
professional advised purchase and who educated the patient regarding use; proportion of 
patients with diabetes on medication for management of blood glucose; type of medication; 
dose; and frequency of combined therapy.  
Sample: 2,839 patients from 72 GPs; data collection period: 21/09/2010 – 25/10/2010.  
M ethod: Detailed in the paper entitled SAND Method 2010–11 available at:  
<www.fmrc.org.au/publications/SAND_abstracts.htm>.  
Summary of results 
The age distribution of patients differed from the distribution for patients at all BEACH 
encounters 2009–10, with a greater proportion of patients aged 25–44 years. The sex 
distribution did not differ from that of patients at all BEACH encounters, with the majority 
(59.5%) of patients being female. 
Among the 2,839 respondents, 214 had diagnosed diabetes, prevalence being 7.5% (95% CI: 
6.4–8.7). Prevalence of T1D was 1.0% (95% CI: 0.5–1.4) and of T2D was 6.6% (95% CI: 5.4–7.7). 
There was no significant difference in prevalence between the sexes. Prevalence increased 
significantly with age to 18.6% of patients aged 65–74 years and 19.1% in patients aged 75 or 
more.  
Information on most recent HbA1c was known for 189 diabetes patients, and of these, 47.1% 
had HbA1c of less than 7%. Among 188 patients who knew the time since last testing, 46.3% 
had been tested less than three months ago, 38.3% 3–6 months ago and 15.4% more than six 
months ago. 
Of 211 respondents with diabetes, 180 (85.3%) had a self blood glucose monitoring (SBGM) 
machine. Of 179 of those, 30.7% used it 2–3 times daily, and 24.6% used it once daily. Among 
176 respondents with a SBGM machine, the machine was recommended by a GP for 40.3% of 
patients, by a diabetes educator for 35.2% and by an endocrinologist for 10.8% of patients. 
Education about the machine was provided by a diabetes educator for 59.1% of patients, and 
by a GP for 19.9% of patients. 
Medication was reported for 212 respondents with diabetes, 180 (84.9%) were currently 
taking medication for the management of blood glucose and 32 patients (15.1%) were not. 
There were 128 (60.4%) patients currently taking only oral medication for the management of 
their blood glucose, 27 patients (12.7%) were taking only insulin and 25 (11.8%) were taking 
insulin and an oral medication. Of the 180 patients currently taking blood glucose 
management medications, 127 (70.6%) were taking metformin at a median prescribed daily 
dose (PDD) of 1500 mg; and 50 (27.8%) were taking gliclazide at a median PDD of 60 mg. Of 
these 180 patients on blood glucose medications 103 (57.2%) were taking mono therapy, 59 
(32.8%) dual therapy, and 18 (10.0%) triple therapy. 
The following pages contain the recording form and instructions with which the data in this abstract were collected.  
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SAND abstract number 173: Type 2 diabetes resource use 
Organisation supporting this study: Family Medicine Research Centre  
Issues: Prevalence of diagnosed diabetes among patients attending general practice; for 
patients with Type 2 diabetes (T2DM): age and sex, body mass index (BMI), most recent 
HbA1c and time since it was measured, time since diagnosis; number of GP visits and 
number at which T2DM was managed in the previous 12 months; patients’ comorbidities 
and allied health professional (AHP) use; proportion of patients on a MBS incentive scheme. 
Sample: 4,626 patients from 182 GPs; data collection periods: 21/09/2010 – 25/10/2010 and 
18/01/2011 – 21/02/2011. 
M ethod: Detailed in the paper entitled ‘SAND Method 2010–11’ on this website: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>.  
Summary of results  
Age distribution of patients was no different from the total BEACH sample in 2010–11. 
However, there was a significantly smaller proportion of male patients (38.1%, 95% CI:  
35.6–40.5) than in the total BEACH sample (42.9%, 95% CI: 42.0–43.7).  
Among the 4,626 respondents, combined prevalence of diagnosed Type 1 (1.0%, 95% CI:  
0.7–1.4) and T2DM (7.6%, 95% CI: 6.5–8.6) (n = 350) was 8.6%. After adjustment for annual 
attendance patterns by age-sex of patient, prevalence of T2DM among those attending 
general practice at least once in the year was estimated as 5.5% (95% CI: 4.7–6.4). The 
estimated prevalence in the Australian population was 5.1% (95% CI: 4.3–5.8). The highest 
age-specific prevalence of diagnosed T2DM was among patients aged 65–74 years (17.2%), 
and those aged 75 years or more (14.9%) Prevalence was significantly higher among males 
(9.7%; 95% CI: 8.2–11.3) than among females (6.2%; 95% CI: 5.2–7.3). 
The mean BMI of 337 respondents with T2DM was 31.0: 18.1% of patients were in the normal 
BMI range and 81.0% were overweight (BMI 25–< 30) (33.5%), obese (BMI 30–< 35) (23.4%) or 
morbidly obese (BMI > 35) (24.0%). The most recent HbA1c was known for 311 patients, and 
their mean HbA1C was 7.2. However 41.5% of results were between 6 and 6.99, and 28.3% 
were between 7 and 7.99. For 315 respondents, average time since last tested was 4.3 months. 
For 61.0% of 341 respondents, it was more than six years since first being diagnosed with 
T2DM, for 22.3% diagnosis was 3–5 years earlier, and for 11.1% it was 1–2 years earlier.  
Number of GP visits was known for 329 patients, and the mean number of visits to a GP in 
the previous 12 months was 13.5. After adjustment (see above), the estimated average 
number of visits for all general practice patients with T2DM was 8.4 times per year. Among 
306 sampled respondents, T2DM had been managed on average at 5 of their 13.5 GP visits. 
At least one of 12 listed chronic diseases (see recording form) had been diagnosed in 95.1% of 
the sample, and the average number of comorbidities was 3.4 per patient. Hypertension was 
the most common, present among 73.1% of patients with T2DM, followed by dyslipidaemia 
(62.3%), osteoarthritis (40.6%) and ischaemic heart disease (31.7%). 
Of 314 respondents with T2DM: 51.3% had visited a podiatrist, averaging 140 visits per 100 
visiting patient in the year; 29.6% had visited a dentist (67 visits per 100 visiting patients); 
27.1% had visited a diabetes educators (53 visits per 100 visiting patients). Sixty-four per cent 
of patients were currently under a GP management plan, 49.4% were under a team care 
arrangement, and 3.1% were currently under a mental health plan. 
The following page contains the recording form and instructions with which the data in this abstract were collected.
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SAND abstract number 174: Atrial fibrillation/flutter in general 
practice patients 
Organisation supporting this study: Bayer Australia Ltd 
Issues: The proportion of general practice patients with atrial fibrillation or atrial flutter 
(AF/flutter). For patients with AF/flutter: prevalence of diabetes, hypertension, congestive 
heart failure, cerebrovascular accident/transient ischaemic attack (CVA/TIA); CHADS score 
risk of stroke; current AF/flutter medications; warfarin use; INR monitoring. 
Sample: 2,402 patients from 83 GPs; data collection period: 26/10/2010 – 29/11/2010 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>. M ethod for this study: Risk of 
stroke in AF/flutter patients was calculated using the CHADS2 score.‡ 
Summary of results  
The age and sex distribution of the 2,402 respondents did not differ from the distribution for 
all 2009–10 BEACH encounters, with the majority (60.8%) being female.  
Of the 2,402 respondents, 101 (4.2%, 95% CI: 3.2–5.2) had AF/flutter. AF/flutter was rare in 
younger age groups (0.2% in 25–44 and 1.5% in 45–64 age group), but rose significantly to 
7.3% among 65–74 year olds and 18.0% of those aged 75 or more. Males were significantly 
more likely to have AF/flutter (6.2%, 95% CI: 4.5–7.9) than females (3.0%, 95% CI: 2.0–4.0).  
Of 95 AF/flutter patients for whom co-morbidities were reported, 82 (86.3%) had at least one 
of the listed morbidities, 68.4% had hypertension, 29.5% had congestive heart failure, 22.1% 
had diabetes and 19.0% had CVA/TIA. These co-morbidities were used to calculate (a 
CHADS2 score) risk of stroke in AF/flutter patients. Most AF/flutter patients were at 
moderate risk (59.0%, n = 56 of 95) and one-third (35.8%, n = 34) were at high-risk of stroke. 
Details of current AF/flutter medications were available for 99 of the 101 patients with 
AF/flutter. Most (94.9%, n = 94) were on medication, with 40.4% taking one medication, 
39.4% taking two, and 15.2% taking three or more. In total 165 medications were recorded for 
94 medicated AF/flutter patients, the most common being antithrombotic agents (51.5% of 
all medications) comprising warfarin (42.4%) and aspirin (6.1%), followed by cardiac therapy 
(22.4%) comprising digoxin (16.4%), and beta blocking agents (20.0%).  
Among the 99 respondents with AF/flutter, 70 (70.7%) were taking warfarin. Three-quarters 
of these patients had been taking warfarin for more than six months, and for two-thirds 
warfarin was initiated by a cardiologist. For 28 of the 29 patients not on warfarin, reasons for 
not taking the drug were given. The main being patient refusal, followed by bleeding risk. 
Of the 70 AF/flutter patients using warfarin, details of INR monitoring were available for 69. 
The most common timing of INR monitoring was every 28 days/four weeks, accounting for 
30 (44.1%) of AF/flutter patients on warfarin, followed by 17.6% every 15 days/two weeks 
and 11.8% every seven days/one week. For 15 (21.4%) of these patients, a face-to-face contact 
and point of care testing was recorded, and this was the most common combination of 
events per monitoring episode. INR stability information was available for 67 of the 70 
patients. For three-quarters of these patients, less than 25% of their INR results were outside 
the 2–3 range in the past six months. 
‡ Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for 
predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864–70. 
The following pages contain the recording form and instructions with which the data in this abstract were collected. 
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SAND abstract number 175: Pertussis and persistent cough among 
general practice patients  
Organisation supporting this study: GlaxoSmithKline Australia Pty Ltd 
Issues: The vaccination status of general practice patients for pertussis, diphtheria and 
tetanus; whether the patient has close contact with an infant aged less than 6 months and the 
nature of the patient’s relationship with the infant; prevalence of pertussis; prevalence of a 
discreet coughing episode lasting more than 3 weeks (referred to as persistent cough) in the 
previous 12 months; time taken off work or study because the patient or someone in their 
care had pertussis or persistent cough. 
Sample: 2,422 patients from 82 GPs; data collection period: 26/10/2010 – 29/11/2010 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>.  
Summary of results  
The age and sex distributions of the patients who responded to the question about 
vaccination status did not differ from all patients at 2009–10 BEACH encounters. 
Pertussis vaccination status was provided by 2,389 respondents. Of these, 751 patients 
(31.4%, 95% CI: 27.7–35.2) had received a pertussis vaccination in the previous ten years, 
1,393 (58.3%) had not been vaccinated, and 245 (10.3%) did not know if they had been 
vaccinated. Patient age was recorded for 2,376 of these respondents. The proportion 
vaccinated decreased with age: 94.3% of patients aged 0–14 years, 65.6% of those aged 15–24 
years, 29.3% of 25–44 year olds, 15.7% of 45–74 year olds and 11.4% of those aged 75 years 
and over. 
Diphtheria vaccination status was provided for 2,364 patients. Of these, 1,042 patients 
(44.1%, 95% CI: 40.2–47.9) had been vaccinated in the previous ten years, 1,083 (45.8%) had 
not been, and 239 (10.1%) did not know. Tetanus vaccination status was recorded for 2,371 
patients. Of these, 1,149 patients (48.5%, 95% CI: 44.7–52.3) had been vaccinated in the 
previous ten years, 1,000 (42.2%) had not been, and 222 (9.4%) did not know. 
There were 296 patients (12.4% of 2,392 respondents) who had close contact with an infant 
aged < 6 months. Of these, 179 (61.3%) had been vaccinated in the previous decade for 
pertussis. Relationship with the infant was specified for 285 respondents: 85 (29.8%) were 
grandparents, 69 (24.2%) a parent/guardian, 33 (11.6%) siblings, 20 (7.0%) child care 
workers, nine (3.2%) health workers, and 72 (25.3%) had an other relationship with the 
infant. Of the 85 grandparents, 83 provided pertussis vaccination status. Approximately half 
(51.8%) of these were known to be vaccinated. Of the 69 parents, 72.5% had received 
pertussis vaccination, and of the 33 siblings, 32 (97.0%) were vaccinated.  
There were 2,393 respondents to the pertussis diagnosis question. None of the respondents 
had been diagnosed with pertussis in the previous year. However, 65 (2.7%) did not know 
whether they had been diagnosed with pertussis. 
Of 2,334 respondents, 107 patients (4.6%) had had a persistent cough in the previous  
12 months. Of 2,105 respondents, 98.8% had not had time off work or study because the 
patient or someone in their care had pertussis or persistent cough.  
The following pages contain the recording form and instructions with which the data in this abstract were collected. 
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SAND abstract number 176: Comorbidity and management of gout 
in GP patients 
Organisation supporting this study: Novartis Pharmaceuticals Australia Pty Ltd 
Issues: The proportion of general practice patients ever treated for gout; current morbidities; 
number of gout episodes experienced in the previous 12 months; care sought by patients for 
gout; managements used for gout; contraindications in gout management. 
Sample: 3,094 patients from 105 GPs; data collection period: 30/11/2010 – 17/01/2011 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>.  
Summary of results  
The age and sex distribution of the 3,094 respondents did not differ from that of patients at 
all 2009–10 BEACH encounters, with the majority (58.6%) being female.  
Of the 3,094 respondents, 175 (5.7%, 95% CI: 4.5–6.8) had been treated for gout. After 
adjustment for attendance rates by age and sex of patient, we estimated that 4.1% of patients 
who attended the GP once that year had at some time been treated for gout. Treatment was 
most common for older patients, 11.8% of those aged 65–74 years and 11.3% of those aged 
75+ years. The sex-specific rate of gout treatment among male patients (9.8%, 95% CI:  
7.9–11.6) was significantly higher than among females (2.7%, 95% CI: 1.7–3.6). Of 175 patients 
treated for gout, 64.6% had hypertension, 67 (38.3%) had elevated total cholesterol or 
triglycerides, 66 (37.7%) were obese, 65 (37.1%) had osteoarthritis, 41 (23.4%) used a diuretic, 
and 39 (22.3%) had chronic kidney disease. 
Of 169 respondents (of 175 who had been treated for gout), 69 (40.8%, 95% CI: 34.3–47.4) had 
an episode of gout in the previous 12 months: 33 patients had one episode and 20 patients 
had two. Of 160 respondents (multiple responses allowed), 64 (53.3%) used a health service 
in the past 12 months for gout management: 62 (38.8%) visited a GP, three (1.9%) visited a 
specialist, three (1.9%) required a hospital visit and three (1.9%) visited an emergency 
department – 96 patients (60.0%) had not used a health service for management in the 
previous 12 months. 
Of the 68 patients who had had at least one episode of gout in the past 12 months, 55 (80.9%) 
had used a health service: 53 (77.9%) had visited a GP to have their gout managed, three 
(4.4%) had visited a specialist, three (4.4%) had required a hospital visit and one patient 
visited an emergency department for their gout. There were 13 patients (19.1%) who had had 
an episode of gout in the previous 12 months but had not used a health service. 
Of the 175 patients at some time treated for gout, management information was available for 
149. Of these, 131 (87.9%) had received treatment for their most recent episode, and 18 
patients (12.1%) had sought no treatment. Of those treated, 120 (80.5%) had used medication 
to treat their most recent episode, and 145 medications were recorded. Colchicine accounted 
for 37.2% and allopurinol for 22.1% of medications. The most common other treatment used 
for gout was lifestyle modification (51.0%).  
Suitability of specified medications for gout was recorded for 159 patients, while responses 
varied for each medication. Contraindication or intolerance was indicated for: allopurinol 
(4.8%); colchicine (8.3%); oral or systemic corticosteroids (11.5%); and NSAIDS (37.4%). 
The following pages contain the recording form and instructions with which the data in this abstract were collected. 
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SAND abstract number 177: Multiple morbidity and chronic heart 
failure 
Organisation supporting this study: CSL Ltd 
Issues: In patients attending general practice, prevalence of: selected chronic conditions and 
pattern of multiple morbidity; other chronic conditions and pattern of multiple morbidity. 
For patients with chronic heart failure (CHF): patterns of comorbidities; stage of CHF; other 
health professionals involved in management of CHF; proportion currently taking 
medication for CHF; types and prescribed dosage of these medications; whether a beta-
blocker is used in CHF management.  
Sample: 2,952 patients from 104 GPs; data collection period: 30/11/2010 – 17/01/2011 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>. M ethod for this study: Stages of 
heart failure were defined according to the Heart Failure Society of America. A card defining 
the stages of heart failure was provided to assist with the completion of the form.  
Summary of results  
Sex distribution of patients was no different from the total BEACH sample in 2009–10. 
However, there was a significantly smaller proportion of patients aged < 1 year (1.2%,  
95% CI: 0.8–1.6) and 1–4 years (3.1%, 95% CI: 2.2–4.0) compared with the total sample (2.1% 
aged < 1 year, 95% CI: 1.9–2.3, and 4.7% aged 1–4 years, 95% CI: 4.5–5.0).  
Of 2,952 patients, 1,361 (46.1%, 95% CI: 41.7–50.5) had at least one of the ten listed conditions. 
Hypertension was most prevalent (n = 901; 30.5%), followed by chronic arthritic pain 
(12.6%), diabetes (10.8%), chronic back pain (10.3%), chronic obstructive pulmonary disease 
(5.1%), CHF (4.3%), benign prostatic hypertrophy (2.7%), dementia/Alzheimer’s (2.3%), 
psoriasis (1.3%) and chronic cancer pain (1.1%). One–quarter (24.0%; n = 707) had one of the 
listed conditions, 13.4% had two and 8.8% had three or more conditions. There were 1,519 
additional chronic conditions recorded for 804 patients. Circulatory problems accounted for 
19.2% and endocrine/metabolic problems for 18.6%.  
Of the 127 CHF patients, over two-thirds (67.7%) were aged 75 years and over and the sex 
distribution did not differ from all patients in this sample. Of 120 respondents for staged 
CHF, almost half (47.5%) had Mild Stage II CHF, 28.3% had Mild Stage I, and 20.0% had 
Moderate Stage III CHF. Three patients had Severe Stage IV CHF and for two patients, stage 
of CHF was not known. None of the listed morbidities were present in 11.8% of CHF 
patients; 26.8% had one listed comorbidity, 29.1% had two and 32.3% had three or more 
listed comorbidities. The most common combinations of comorbidities were: CHF and 
hypertension (11.8%); CHF and hypertension and diabetes (7.9%); and CHF and 
hypertension and chronic arthritic pain (6.3%). 
Details on current referrals for CHF were available for 101 of the 127 patients with CHF. 
Multiple responses were allowed. Referrals to cardiologists were recorded for 87.1% of 
patients, referrals to general physicians for 12.9% and referrals to geriatricians for 8.9%.  
Of 123 CHF patients with medication details, 118 were currently taking medication for their 
CHF. A total of 315 medications were recorded, with beta-blocking agents being most 
common (n = 74; 23.5%). There were 49 patients who were not taking a beta-blocker, the 
main reason being advanced age (> 70 years), given for 57.1% of these patients. 
The following pages contain the recording form and instructions with which the data in this abstract were collected. 
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SAND abstract number 178: Warfarin use in general practice 
patients 
Organisation supporting this study: Bayer Australia Ltd  
Issues: The prevalence of current or history of atrial fibrillation (AF/past AF), deep vein 
thrombosis (DVT/past DVT), pulmonary embolism (PE/past PE) and heart valve disease 
(HVD/past HVD) in general practice patients; proportion of these patients taking warfarin; 
duration of warfarin use; proportion not taking warfarin; reasons warfarin is not used. For 
AF/past AF patients who take warfarin: frequency of INR testing; which health professional 
orders the INR test; use of health resources for each episode of INR monitoring; number of 
INR results available from the past 6 months; proportion of INR results that reflect 
uncontrolled INR (outside 2.0–3.0 range).  
Sample: 3,075 patients from 106 GPs; data collection period: 18/01/2011 – 21/02/2011 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>.  
Summary of results  
The age distribution of patients did not differ from that of the annual BEACH sample but 
there was a significantly smaller proportion of male patients (38.7%, 95% CI: 35.6–41.8) in 
this sample than in total 2009–10 BEACH encounters (43.1%, 95% CI: 42.3–43.9). 
Among the 3,075 respondents, 92.3% had none of the listed conditions and 237 (7.7%) 
had/had a history of at least one. Multiple listed conditions were allowed for each patient. 
There were 138 (4.5%) AF/past AF patients, 39 (1.3%) DVT/past DVT patients, 29 (0.9%) 
PE/past PE patients and 65 (2.1%) HVD/past HVD patients.  
AF was rare in patients aged less than 45 years. Rates rose significantly through the age 
groups with 63.5% of AF/past AF patients being 75 years and older (95% CI: 53.9–73.1). AF 
was more prevalent in males (6.9%, 95% CI: 5.2–8.6) than in females (3.1%, 95% CI: 2.2–3.9).  
Of 236 respondents with at least one of the listed conditions, more than half (54.7%) were 
currently taking warfarin, 47 (19.9%) had previously taken it and 60 (25.4%) had never taken 
it. Of 43 patients where duration of warfarin use was known, the average was 9.5 months. Of 
107 patients not currently taking warfarin, ‘warfarin not required’ was the reason for 65.9%, 
‘high bleeding risk’ for 15.4%, and ‘patient refusal’ for 3.3%. 
Of 118 AF/past AF respondents, 67 (56.8%) were currently taking warfarin. Of 61 for whom 
duration was known, 53 (86.9%) had taken warfarin for longer than 12 months. Of 64 who 
gave frequency of INR monitoring, every four weeks was the usual (40.6%), followed by 
every two weeks (29.7%). Of 62 who indicated the health professional who ordered INR 
monitoring tests, 90.3% were ordered by a GP, 8.1% by a specialist and 1.6% by an other 
practitioner. Of 67 who provided details on use of health resources for each episode of INR 
monitoring, the most common combination of events was face-to-face contact and point of 
care INR testing (n = 19; 28.4%) followed by phone calls and laboratory INR testing (n = 14; 
20.9%). Of 67 for whom number of INR results in the past six months was known, there were 
an average of 9.7 results. Of respondents to the INR stability questions, 15 (23.4%) had no 
results < 2.0 and 18 (30%) had no results > 3.0 in the past 6 months. Of 58 patients with 
results outside the 2–3 range, 27 (46.6%) had 25–50% of their results reflecting uncontrolled 
INR, 22 of these patients indicated that duration of warfarin use was longer than 12 months. 
The following pages contain the recording form and instructions with which the data in this abstract were collected. 
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SAND abstract number 179: Pneumococcal vaccination and 
pneumonia in older Australian general practice patients 
Organisation supporting this study: Pfizer Australia Pty Ltd 
Issues: For patients aged 50 years and over: proportion of patients who received 
pneumococcal vaccine in the previous 5 years; proportion who received a booster vaccine; 
main reasons for providing pneumococcal vaccine. Proportion of patients diagnosed with 
pneumonia in the previous 12 months; vaccination status of those diagnosed; impact of 
pneumonia on daily life.  
Sample: This SAND was limited to patients aged 50 years and over. There was a total 
sample of 1,618 patients aged 50 years and over from 102 GPs; data collection period: 
22/02/2011 – 28/03/2011. 
M ethod: Detailed in the paper entitled SAND method 2010–11 at: 
<www.fmrc.org.au/publications/SAND_abstracts.htm>.  
Summary of results  
The SAND questions were divided into two parts: part 1 – pneumococcal vaccine and  
part 2 – pneumonia. Of 1,618 patients aged 50 years and over in the sample, 1,565 (96.7%) 
responded to the question on pneumococcal vaccination and 1,513 (93.5%) responded to the 
question on whether they had been diagnosed with pneumonia in the previous 12 months. 
The sex distribution of patients in the sample was not significantly different from that of all 
2009–10 BEACH encounters, with females accounting for 58.7% (95% CI: 55.0–62.4). 
Of 1,565 respondents, 682 (43.6%) received a pneumococcal vaccine in the previous 5 years. 
Of these, 636 patients (93.3%) had received Pneumovax 23, 12 (1.8%) received an other 
pneumococcal vaccine and 35 (5.1%) did not know what vaccine was given. Of 651 
vaccinated respondents, the pneumococcal vaccination was the first adult vaccine for 42.2% 
(n = 275), while for 57.8% (n = 376) it was an adult booster vaccination. 
The main reasons for receiving pneumococcal vaccination were provided for 624 of the 682 
vaccinated patients. Multiple responses were allowed. For 525 patients (84.1%) the main 
reason was being aged 65 years and over. The presence of conditions predisposing the 
patient to pneumococcal infection was the reason for 107 (17.2%) and 155 predisposing 
conditions were recorded. Type 2 diabetes was present in 32.7% of these 107 patients, chronic 
obstructive pulmonary disease for 19.6%, asthma for 14.0% and non-specified risk factor for 
7.5%. For 32 patients (5.1%) being a smoker was a reason for vaccination, while being an 
Indigenous person aged 50 years and over was a reason for 11 (1.8%) patients.  
Of the 1,618 patients aged 50 years and over, 1,513 (93.5%) indicated whether they had been 
diagnosed with pneumonia in the previous 12 months, 37 (2.5%) of these had been. Of 32 
patients who indicated whether they had received a pneumococcal vaccine prior to being 
diagnosed, 22 (68.8%) had been vaccinated before being diagnosed with pneumonia. 
Of 37 patients diagnosed with pneumonia, 33 responded to the question about its impact. Of 
the 33 respondents, 16 (48.5%) said that pneumonia had impacted moderately on their daily 
lives, 11 (33.3%) said it impacted severely and 3 (9.1%) said it impacted very severely. 
Among the 22 patients who had been vaccinated before being diagnosed, 11 (50%) said 
impact of pneumonia on their daily lives was moderate and for 7 (31.8%) it was severe. 
The following pages contain the recording form and instructions with which the data in this abstract were collected. 
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Abbreviations 
ABS Australian Bureau of Statistics 
ACE angiotensin-converting enzyme  
ACRRM Australian College of Rural and Remote Medicine 
AHS allied health service 
AIHW Australian Institute of Health and Welfare 
ASGC Australian Standard Geographical Classification 
ATC Anatomical Therapeutic Chemical (classification) 
BEACH Bettering the Evaluation and Care of Health 
BMI body mass index 
BP blood pressure 
CAPS Coding Atlas for Pharmaceutical Substances 
CI confidence interval (in this report 95% CI is used) 
CT computerised tomography 
DoHA Australian Government Department of Health and Ageing 
DVA Australian Government Department of Veterans’ Affairs 
FACRRM Fellow of the Australian College of Rural and Remote Medicine 
FMRC Family Medicine Research Centre 
FRACGP Fellow of the Royal Australian College of General Practitioners 
FTE full-time equivalent 
GP general practitioner 
HbA1c haemoglobin, type A1c 
HIV human immunodeficiency virus 
ICPC International Classification of Primary Care 
ICPC-2 International Classification of Primary Care – Version 2 
ICPC-2 PLUS a terminology classified according to ICPC-2 
INR international normalised ratio 
LCL lower confidence limit 
MBS Medicare Benefits Schedule 
M,C&S microscopy, culture and sensitivity 
NDSHS National Drug Strategy Household Survey 
NESB non-English-speaking background 
NHMRC National Health and Medical Research Council 
NHS National Health Survey 
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OTC over-the-counter (medications advised for over-the-counter purchase) 
PBS Pharmaceutical Benefits Scheme 
RACGP Royal Australian College of General Practitioners 
RFE reason for encounter 
RRMA Rural, Remote and Metropolitan Area classification 
SAND Supplementary Analysis of Nominated Data 
SAS Statistical Analysis System 
UCL upper confidence limit 
URTI upper respiratory tract infection  
WHO World Health Organization 
Wonca World Organization of Family Doctors 
Symbols 
— not applicable 
< less than 
> more than 
NEC not elsewhere classified 
n number 
NOS not otherwise specified 
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Glossary 
A1 Medicare items: Medicare item numbers 1, 2, 3, 4, 13, 19, 20, 23, 24, 25, 33, 35, 36, 37, 38, 40, 
43, 44, 47, 48, 50, 51, 601, 602. 
Aboriginal: The patient identifies himself or herself as an Aboriginal person. 
Activity level: The number of general practice A1 Medicare items claimed during the previous 
3 months by a participating GP. 
Allied and other health professionals: Those who provide clinical and other specialised services 
in the management of patients, including physiotherapists, occupational therapists, 
dietitians, dentists and pharmacists. 
Chapters (ICPC-2): The main divisions within ICPC-2. There are 17 chapters primarily 
representing the body systems. 
Chronic problem: see Diagnosis/problem: Chronic problem. 
Commonwealth concession card: An entitlement card provided by the Australian Government, 
which entitles the holder to reduced-cost medicines under the Pharmaceutical Benefits 
Scheme and some other concessions from state and local government authorities. 
Complaint: A symptom or disorder expressed by the patient when seeking care. 
Component (ICPC-2): In ICPC-2 there are seven components that act as a second axis across all 
chapters. 
Consultation: See Encounter. 
Diagnosis/problem: A statement of the provider’s understanding of a health problem 
presented by a patient, family or community. GPs are instructed to record at the most 
specific level possible from the information available at the time. It may be limited to the 
level of symptoms. 
• New problem: The first presentation of a problem, including the first presentation of a 
recurrence of a previously resolved problem, but excluding the presentation of a 
problem first assessed by another provider. 
• Old problem: A previously assessed problem that requires ongoing care, including 
follow-up for a problem or an initial presentation of a problem previously assessed by 
another provider. 
• Chronic problem: A medical condition characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern 
of recurrence or deterioration, a poor prognosis, and consequences or sequelae that 
impact on an individual’s quality of life. (Source: O’Halloran J, Miller GC, Britt H 2004. 
Defining chronic conditions for primary care with ICPC-2. Fam Pract 21(4):381–6).  
• Work-related problem: Irrespective of the source of payment for the encounter, it is likely 
in the GP’s view that the problem has resulted from work-related activity or workplace 
exposure, or that a pre-existing condition has been significantly exacerbated by work 
activity or workplace exposure. 
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Encounter (enc): Any professional interchange between a patient and a GP. 
• Indirect: Encounter where there is no face-to-face meeting between the patient and the GP 
but a service is provided (for example, prescription, referral). 
• Direct: Encounter where there is a face-to-face meeting of the patient and the GP. 
Direct encounters can be further divided into: 
– Medicare-claimable 
▪ Surgery consultations: encounters identified by any one of MBS item numbers 3, 23, 
36, 44, 52, 53, 54, 57, 5000, 5020, 5040, 5060, 5200, 5203, 5207, 5208. 
▪ Home or institution visits (excluding residential aged care facilities): encounters 
identified by any one of MBS item numbers 4, 19, 24, 33, 37, 40, 47, 50, 58, 59, 60, 
65, 87, 89, 90, 91, 003, 5023, 5043, 5063, 5220, 5223, 5227, 5228. 
▪ Residential aged care facility: encounters identified by any one of MBS item numbers 
20, 35, 43, 51, 92, 93, 95, 96, 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267. 
▪ Health assessments: encounters identified by any one of MBS item numbers 700, 702, 
704, 706, 708, 709, 710, 712, 713, 714, 717, 718. 
▪ Chronic disease management items: encounters identified by any one of MBS item 
numbers 720, 721, 722, 723, 724, 725, 726, 727, 729, 730, 731. 
▪ Case conferences: encounters identified by any one of MBS item numbers 734, 736, 
738, 740, 742, 744, 762, 765, 773, 775, 778. 
▪ Attendances associated with practice incentive payments: encounters identified by any 
one of MBS item numbers 2497, 2501, 2503, 2504, 2506, 2507, 2509, 2517, 2518, 2521, 
2522, 2525, 2526, 2546, 2547, 2552, 2553, 2558, 2559, 2574, 2575, 2577, 2598, 2600, 
2603, 2606, 2610, 2613, 2616, 2620, 2622, 2624, 2631, 2633, 2635, 2664, 2666, 2668, 
2673, 2675, 2677, 2704, 2705. 
▪ Other MBS encounters: encounters identified by an MBS item number that does not 
identify place of encounter (see A1 Medicare items). 
– Workers compensation: Encounters paid by workers compensation insurance. 
– Other paid: Encounters paid from another source (for example, state). 
General practitioner (GP): A medical practitioner who provides primary comprehensive and 
continuing care to patients and their families within the community (Royal Australian 
College of General Practitioners). 
GP consultation service items: Includes GP services provided under the MBS professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, A19, 
A20, A22 and selected items provided by GPs classified in A11, A15 and A27. 
Medication: Medication that is prescribed, provided by the GP at the encounter or advised for 
over-the-counter purchase. 
Medication rates: The rate of use of all medications, including medications that were 
prescribed, supplied by the GP and advised for over-the-counter purchase. 
Medication status: 
• New: The medication prescribed/provided at the encounter/advised is being used for 
the management of the problem for the first time. 
• Continuation: The medication prescribed/provided at the encounter/advised is a 
continuation or repeat of previous therapy for this problem. 
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• Old: See Continuation. 
Morbidity: Any departure, subjective or objective, from a state of physiological wellbeing. 
In this sense, sickness, illness and morbid conditions are synonymous. 
Patient status: The status of the patient to the practice. 
• New patient: The patient has not been seen before in the practice. 
• Old patient: The patient has attended the practice before. 
Practice nurse involvement: Encounters at which a practice nurse MBS item number and/or 
a treatment (either clinical or procedural) was recorded as done by a practice nurse. 
Prescribed rates: The rate of use of prescribed medications (that is, does not include 
medications that were GP-supplied or advised for over-the-counter purchase). 
Problem managed: See Diagnosis/problem. 
Provider: A person to whom a patient has access when contacting the health care system. 
Reasons for encounter (RFEs): The subjective reasons given by the patient for seeing or 
contacting the general practitioner. These can be expressed in terms of symptoms, diagnoses 
or the need for a service. 
Recognised GP: A medical practitioner who is: 
• vocationally recognised under Section 3F of the Health Insurance Act, or 
• a holder of the Fellowship of the Royal Australian College of General Practitioners who 
participates in, and meets the requirements for, quality assurance and continuing 
medical education as defined in the Royal Australian College of General Practitioners 
(RACGP) Quality Assurance and Continuing Medical Education Program, or 
• undertaking an approved placement in general practice as part of a training program for 
general practice leading to the award of the Fellowship of the Royal Australian College 
of General Practitioners, or undertaking an approved placement in general practice as 
part of some other training program recognised by the RACGP as being of equivalent 
standard. (Source: Commonwealth Department of Health and Aged Care 2001. Medicare 
benefits schedule book. Canberra: DHAC).  
Referral: The process by which the responsibility for part or all of the care of a patient is 
temporarily transferred to another health care provider. Only new referrals to specialists and 
allied health services, and for hospital and residential aged care facility admissions arising at 
a recorded encounter are included. Continuation referrals are not included. Multiple 
referrals can be recorded at any one encounter. 
Repatriation health card: An entitlement card provided by the Department of Veterans’ Affairs 
that entitles the holder to access a range of Repatriation health care benefits, including access 
to prescription and other medications under the Pharmaceutical Benefits Scheme. 
Rubric: The title of an individual code in ICPC-2. 
Significant: This term is used to refer to a statistically significant result. Statistical significance 
is measured at the 95% confidence level in this report.  
Torres Strait Islander: The patient identifies himself or herself as a Torres Strait Islander 
person. 
Work-related problem: See Diagnosis/problem. 
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Appendices 
Appendix 1: Example of a 2010–11 recording form 
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Appendix 2: GP characteristics questionnaire, 
2010–11 
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Appendix 3: Patient information card, 2010–11 
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Appendix 4: Code groups from ICPC-2 and 
ICPC-2 PLUS 
Available at: <purl.library.usyd.edu.au/sup/9781920899868>, see ‘Electronic editions and 
downloads’. 
Table A4.1:  Code groups from ICPC-2 and ICPC-2 PLUS – reasons for encounter  
and problems managed 
Table A4.2: Code groups from ICPC-2 and ICPC-2 PLUS – chronic problems 
Table A4.3: Code groups from ICPC-2 and ICPC-2 PLUS – problems managed by  
practice nurses 
Table A4.4: Code groups from ICPC-2 and ICPC-2 PLUS – clinical treatments 
Table A4.5: Code groups from ICPC-2 and ICPC-2 PLUS – procedures 
Table A4.6: Code groups from ICPC-2 and ICPC-2 PLUS – clinical measurements 
Table A4.7: Code groups from ICPC-2 and ICPC-2 PLUS – referrals 
Table A4.8:  Code groups from ICPC-2 and ICPC-2 PLUS – pathology test orders  
(MBS groups) 
Table A4.9:  Code groups from ICPC-2 and ICPC-2 PLUS – imaging test orders  
(MBS groups) 
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